EP1028955A1 - Pyrimidinone compounds and pharmaceutical compositions containing them - Google Patents

Pyrimidinone compounds and pharmaceutical compositions containing them

Info

Publication number
EP1028955A1
EP1028955A1 EP98954482A EP98954482A EP1028955A1 EP 1028955 A1 EP1028955 A1 EP 1028955A1 EP 98954482 A EP98954482 A EP 98954482A EP 98954482 A EP98954482 A EP 98954482A EP 1028955 A1 EP1028955 A1 EP 1028955A1
Authority
EP
European Patent Office
Prior art keywords
pyrimidin
ylmethyl
thio
pyrimid
fluorobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98954482A
Other languages
German (de)
French (fr)
Other versions
EP1028955B1 (en
Inventor
Deirdre Mary Bernadette Smithkline Hickey
Robert John Smithkline Beecham Ife
Colin Andrew SmithKline Beecham LEACH
Ivan Leo SmithKline Beecham PINTO
Roderick Alan Smithkline Beecham Porter
Stephen Allan SmithKline Beecham SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723358.9A external-priority patent/GB9723358D0/en
Priority claimed from GBGB9723352.2A external-priority patent/GB9723352D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1028955A1 publication Critical patent/EP1028955A1/en
Application granted granted Critical
Publication of EP1028955B1 publication Critical patent/EP1028955B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to certain novel py ⁇ midinone compounds, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy, m particular in the treatment of atherosclerosis
  • WO 95/00649 (SmithKline Beecham pic) describe the phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2), the sequence, isolation and purification thereof, isolated nucleic acids encoding the enzyme, and recombinant host cells transformed with DNA encoding the enzyme Suggested therapeutic uses for inhibitors of the enzyme included atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation A subsequent publication from the same group further describes this enzyme (Tew D et al, Arterioscler Thromb Vas Biol 1996 16;591-9) wherein it is referred to as LDL-PLA2.
  • LDL-PLA2 Lipoprotein Associated Phospholipase A2
  • Lp-PLA2 is responsible for the conversion of phosphatidylcholine to lysophosphatidylcholine, during the conversion of low density lipoprotein (LDL) to its oxidised form
  • the enzyme is known to hydrolyse the sn-2 ester of the oxidised phosphatidylcholine to give lysophosphatidylcholine and an oxidatively modified fatty acid
  • Both products of Lp-PLA2 action are biologically active with lysophosphatidylcholine, a component of oxidised LDL, known to be a potent chemoattractant for circulating monocytes
  • lysophosphatidylcholine is thought play a significant role in atherosclerosis by being responsible for the accumulation of cells loaded with cholesterol ester in the arteries Inhibition of the Lp-PLA2 enzyme would therefore be expected to stop the build up of these macrophage enriched lesions (by inhibition of the formation of lysophosphatidylcholine
  • Lp-PLA2 inhibitors may also have a general application in any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA 2 . Examples of such disorders include psoriasis.
  • Lp-PLA2 inhibitors may also have a general application in any disorder that involves lipid peroxidation in conjunction with Lp-PLA2 activity to produce the two injurious products, lysophosphatidylcholine and oxidatively modified fatty acids.
  • Such conditions include the aforementioned conditions atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).
  • Patent applications WO 96/12963, WO 96/13484, W096/ 19451, WO 97/02242, W097/217675, W097/217676, WO 96/41098, and WO97/41099 disclose ter alia various series of 4-thionyl/sulfinyl/sulfonyl azetidinone compounds which are inhibitors of the enzyme Lp-PLA2- These are irreversible, acylating inhibitors (Tew et al, Biochemistry, 37, 10087, 1998).
  • GB 1 582 527 describes, as compounds of formula (7), a group of pyrimidone compounds of the formula (A):
  • Alk is lower alkyl
  • Het is selected from 2- or 4-imidazolyl, 2-pyridyl, 2-thiazolyl, 3-isothiazolyl, 1.2.5-thiadiazolyl and n is from 1 to 4.
  • Z is a bond and R ⁇ is halogen; or Z is CR 3 R 4 , where R 3 and R 4 are each hydrogen or Cn_4)alkyl, or R ⁇ and R4 together with the intervening carbon atom form a C(3_g)cycloalkyl ring; and
  • R 1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents oxo,
  • X is O or S
  • R 2 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents selected from the substituents hereinbefore defined for R T as well as aryl and arylC ( i_4)alkyl;
  • W is a bond and R ⁇ is hydrogen; or W is S0 or a bond;
  • R ' is RI or a hydrocarbyl group which hydrocarbyl group may be optionally interupted within the carbon chain by a group selected from O, COO, OCO, CO, CONR 8 , NR 8 CO, NR 8 CONR9, NR 8 COO, OCONR 8 , and NR 8 , and which hydrocarbyl group may also be optionally substituted by 1 or 2 substituents selected from mono to perfluoro- C ( ⁇ _4)alkyl.
  • R 5 and R > are independently hydrogen or C(j.20) a ⁇ yl, for instance C(i-4)alkyl (e.g. methyl or ethyl);
  • R 9 and R ⁇ O are independently selected from hydrogen, Cn _20) a lkyl (f° r instance Cn ⁇ alkyl), (which may optionally be fluorinated, including up to perfluorinated on the terminal 1 to 3 carbon atoms), C(i_20 ) alkenyl (preferably c (12-18) alken y 1 ) ' aryl arylC(i_ ⁇ o)alkyl, C( 1 _ 1 o)alkoxyC( 1 .
  • aryloxyC(i.io)alkyl in which an aryl group may have one or two substituents selected from halogen, 0(1.20) ⁇ 1, C i ⁇ O ⁇ koxy, aryloxy and COOCn -20) a lky and
  • RI 1 and R ⁇ 2 are independently selected from one of the values hereinbefore defined for R 8 and R or R ⁇ and R* 2 together with the nitrogen atom to which they are attached form a 5- to 7 membered ring optionally containing one or two further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C ⁇ -4)alkyl, phenyl, or benzyl.
  • Z is CH2-
  • R* when an aryl group include phenyl and naphthyl.
  • Representative examples of R when a heteroaryl group include pyridyl, pyrimidyl, pyrazolyl, furyl, thienyl, thiazolyl, quinolyl, benzothiazolyl, pyridazolyl and pyrazinyl.
  • R ⁇ is a 5- or 6- membered, monocyclic heteroaryl group containing 1 or 2 nitrogen heteroatoms, preferably pyridyl, pyrimidyl or pyrazolyl, more preferably, pyrid- 4-yl or pyrimid-5-yl and optionally substituted by 1 or 2 substituents preferably selected from arylC(i _4)alkyl (e.g. benzyl), C( ) ⁇ g)alkyl (e.g. methyl or ethyl), halogen (e.g. chlorine), oxo, hydroxy, C ( i _4)alkoxy (e.g. methoxy) and arylC ⁇ _4)alkoxy (e.g.
  • arylC(i _4)alkyl e.g. benzyl
  • C( ) ⁇ g)alkyl e.g. methyl or ethyl
  • halogen e.g. chlorine
  • R* is pyrimid-5-yl or a 2-oxo-pyrimid-5-yl group, optionally substituted at N-l by C(i_ ⁇ g ) alkyl (e.g. undecyl, methyl or ethyl), or a 2- C(i_4)alkoxy- or arylC ( i_4)alkoxy-pyrimid-5-yl group.
  • ZR ⁇ is 2-oxo-pyrid-4-ylmethyl, pyrimid-5-ylmethyl or 2-oxo-pyrimid-5- ylmethyl in which the 2-oxo-pyrimid-5-yl moiety is as hereinbefore defined.
  • X is S.
  • Preferred compounds of formula (I) include those in which Y is a bond, i.e. A 1 , A 2 and A 3 each represent a bond.
  • Other preferred examples of the groups A* and A 3 are straight chain Cn .
  • Other preferred examples of Y are (CH.2) ⁇ j and CO(CH 2 )6- Representative examples of R 2 when an aryl group include phenyl and naphthyl.
  • R 2 when a heteroaryl group include pyridyl, pyrimidinyl, pyrazolyl, furanyl, thienyl, thiazolyl, quinolyl,benzothiazolyl, pyridazolyl and pyrazinyl
  • R 2 is phenyl optionally substituted by 1, 2 or 3 substituents selected from halogen (e.g. chlorine or fluorine), C(j.4)alkyl (e.g. methyl or ethyl) or C(i _4)alkoxy (e.g. methoxy).
  • substituents include phenyl and benzyl.
  • R 2 YCH2X include 4-fluorobenzylthiogroup, 4- chlorophenylheptylthio and 4-chlorophenyl-l-oxaheptylthio.
  • R 2 YCH2X is 4-fluorobenzylthio group.
  • W is a bond
  • R ⁇ when a hydrocarbyl group include C ( i_20) a lkyl.
  • W is a bond and R ⁇ is C(i_20)alkyl, especially C(io-20) a ⁇ yl-
  • R ⁇ is also C( i _i ())alkyl, more preferably a C(i _6)alkyl which is substituted by one or two substituents selected from hydroxy, C( i _ ⁇ o) a lkoxy (e.g. methoxy), COOC(i_i())alkyl (e.g.
  • R 8 , R 9 and R ⁇ O is each independently C( ⁇ _20) a lkyl e.g. methyl).
  • substituents include aryl, preferably phenyl which may be optionally substituted by COOC( ⁇ _6)alkyl (e.g methyl) and heteroaryl (for instance pyridyl, imidazolyl, furanyl, thienyl and 2-oxo pyrrolidinyl).
  • Preferred examples of the substituent NRl 1R ⁇ 2 include morpholino, piperidino or 2-oxo-pyrrolidino group.
  • a preferred sub-group of compounds of formula (I) are those in which W is a bond and R is a phenyl or a phenylC ( 1 _g ) alkyl group, for instance benzyl or phenethyl, substituted in the phenyl ring by 1 or 2 substituents selected from C(6-i2) l yl (for instance hexyl and decyl), C( 6 . 12) alkoxy. COOH, COOC (6 . ⁇ 2 )alkyl and C0NHC(6-I2)alkyl.
  • R ⁇ maybe heteroarylC(i_g ) alkyl, preferably heteroarylC(i _3)alkyl in which the heteroaryl ring is monocyclic with 5 to 6 members and one or two heteroatoms selected from nitrogen, oxygen and sulphur, such as pyridyl, furanyl, thienyl and imidazolyl.
  • a further preferred subgroup of compounds of formula (I) are those in which W is a bond and R is a group of the formula (CH2) n BR ⁇ where n is an integer from 1 to 6, preferably 1 to 4, B is selected from NR 14 CO, CONR 14 , NR 14 CONR 15 , NR 15 COO (in which R ⁇ 4 and R ⁇ 5 are independently selected from hydrogen or C(i _6)alkyl, preferably hydrogen) and R ⁇ is C(g_ ⁇ g)alkyl (which may optionally be fluorinated, including up to perfluorinated on the terminal 1 to 3 carbon atoms), and phenylCn _g)alkoxyC(i_6)alkyl in which phenyl may be optionally substituted by halogen or C(i _6)alkyl.
  • C(g. ⁇ g)alkyl are straight chains and include octyl, dodecyl and fatty alkyl groups such as lauryl and stearyl.
  • Preferred values of C(g. ⁇ g)alkenyl include octadec-9-(Z)-en-lyl.
  • Preferred examples of optionally substituted phenylCn_6)alkyl and phenylC(i_g)alkoxyC(i _6)alkyl include 4- fluorophenylhexyl, 4-pentylphenylethyl and 4-fluorophenylhexoxyethyl.
  • Particularly preferred compounds of formula (I) are those in which R ⁇ 2 is C(i2-18) a ⁇ yl or Cr ⁇ 2- 1 g)alkenyl. Such a long, lipophilic substituent is found to be especially beneficial for enzyme inhibition
  • 'alkyl' and similar terms such as 'alkoxy' includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, n- propyl. /w-propyl, rc-butyl, sec-butyl, /_o-butyl, t-butyl, «-pentyl and n-hexyl.
  • hydrocarbyl refers to a group having from 1 to 20 carbon atoms which may be in a straight chain or a branched chain and include a saturated carbocyclic ring having from 3 to 6 carbon atoms and which chain may contain unsaturation (double and/or triple carbon-carbon bonds).
  • 'aryl ' refers to. unless otherwise defined, a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, for instance phenyl or naphthyl.
  • Tieteroaryl' refers to a mono- or bicyclic heteroaromatic ring system comprising up to four, preferably 1 or 2, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms.
  • a bicyclic heteroaromatic ring system may include a carbocyclic ring. Representative examples include pyridyl, pyridyl N-oxide, pyrimidyl, pyrazolyl, furyl, thienyl, thiazolyl, pyridazolyl and pyrazinyl, quinolyl and benzothiazolyl.
  • Tialogen' and Tialo' include fluorine, chlorine, bromine and iodine and fluoro, chloro. bromo and iodo, respectively.
  • Compounds of formula (I) are inhibitors of Lp-PLA2 and as such are expected to be of use in treating atherosclerosis and the other disease conditions noted elsewhere. Such compounds are found to act as inhibitors of Lp-PLA2 in in vitro assays ..
  • Particularly preferred compounds of formula (I) are 2-(4-Fluorobenzylthio)-5-((pyrimid-5-yl)methyl)pyrimidin-4-one; l-Methyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(Tetradec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
  • the compounds of the present invention are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions.
  • the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I).
  • the compounds of the present invention are obtained in crystalline form.
  • solvent of crystallisation may be present in the crystalline product.
  • This invention includes within its scope such solvates.
  • some of the compounds of this invention may be crystallised or recrystalhsed from solvents containing water. In such cases water of hydration may be formed.
  • This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products.
  • This invention includes within its scope all polymorphic forms of the compounds of formula (I).
  • Compounds of the present invention are inhibitors of the enzyme lipoprotein associated phospholipase A2 (Lp-PLA2) and as such are expected to be of use in therapy, in particular in the treatment of atherosclerosis.
  • the present invention provides a compound of formula (I) for use in therapy.
  • the compounds of formula (I) are inhibitors of lysophosphatidylcholine production by Lp-PLA2 and may therefore also have a general application in any disorder that involves endothelial dysfunction, for example atherosclerosis, diabetes, hypertension, angina pectoris and after ischaemia and reperfusion.
  • compounds of formula (I) may have a general application in any disorder that involves lipid peroxidation in conjunction with enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes, other conditions such as rheumatoid arthritis, stroke, inflammatory conditions of the brain such as Alzheimer's Disease, myocardial infarction, reperfusion injury, sepsis, and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).
  • the present invention provides for a method of treating a disease state associated with activity of the enzyme Lp-PLA, which method involves treating a patient in need thereof with a therapeutically effective amount of an inhibitor of the enzyme.
  • the disease state may be associated with the increased involvement of monocytes. macrophages or lymphocytes: with the formation of lysophosphatidylcholine and oxidised free fatty acids: with lipid peroxidation in conjunction with Lp PLA2 activity; or with endothelial dysfunction.
  • Compounds of the present invention may also be of use in treating the above mentioned disease states in combination with anti-hyperlipidaemic or anti-atherosclerotic or anti- diabetic or anti-anginal or anti-inflammatory or anti-hypertension agents.
  • examples of the above include cholesterol synthesis inhibitors such as statins, anti-oxidants such as probucol, insulin sensitisers, calcium channel antagonists, and anti-inflammatory drugs such as NSAIDs.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
  • Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
  • Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
  • Compounds of formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol. polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a typical suppository formulation comprises a compound of formula (I) which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • the composition is in unit dose form such as a tablet or capsule.
  • Each dosage unit for oral administration contains preferably from 1 to 500 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I).
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 1000 mg, preferably between 1 mg and 500 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I), the compound being administered 1 to 4 times per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • Compounds of formula (I) may be conveniently prepared from readily available starting materials by adapting synthetic methodology well known in the art for the preparation and derivatisation of pyrimidones by a process.
  • the present invention provides a process for preparing a compound of formula (I) which process comprises:
  • the reaction of the compounds of formulae (IIA/B) and (III) is advantageously effected in the presence of a base such as sodium ethoxide, potassium carbonate, preferably in a solvent such as ethanol or dimethylformamide, or a base such as di-isopropyl ethylamine, preferably in a solvent such as dichlorome thane.
  • a base such as sodium ethoxide, potassium carbonate
  • a solvent such as ethanol or dimethylformamide
  • a base such as di-isopropyl ethylamine
  • the reaction of the compounds of formulae (IA) and (VI) is advantageously effected at a temperature of 20-100 degrees C, in the presence of sodium hydride in a solvent such as dimethylformamide; or by the compound of formula (IA) being pre-treated with tributyl tin chloride in the presence of di-isopropylethylamine, for example in a dichloromethane solvent at reflux temperature, followed by addition of (VI)
  • the compound of formula (IA) may be treated directly with a compound of formula (VI) and di-isopropylethylamine in a dichloromethane solvent at room temperature.
  • reaction of the compounds of formulae (IA/IB) and (VII) is conveniently effected in the presence of pyridine at an elevated temperature, containing a catalytic amount of 4-dimethylaminopyridine.
  • a compound of formula (I) in which Z is a bond and RI represents halogen may be obtained by treating a compound of formula (VIII):
  • a compound of formula (IIA) may be obtained from a compound of formula (IX):
  • a compound of formula (IIB) may be obtained from a compound of formula (X), in a series of steps.
  • a compound of formula (X) is convened into the corresponding methyl enol ether by treatment with a methylating agent such as dimethyl sulphate in the presence of a base such as potassium carbonate.
  • the corresponding carboxylic acid may then be obtained by conventional hydrolysis, for instance basic hydrolysis, using, for instance aqueous sodium hydroxide.
  • the acid may then be converted into the corresponding acyl chloride, by treatment with oxalyl chloride, and the acyl chloride treated with potassium thiocyanate in a solvent such as acetonitrile, to give an intermediate of the formula (XI):
  • a compound of formula (IV) in which L 2 is N(H)N ⁇ 2 can be conveniently prepared by reacting a compound of formula (X) above with a compound of formula (XIII):
  • reaction in which the reaction is carried out in a conventional manner.
  • a compound of formula (VIII) may be obtained by treating a 3,3-dialkoxypropionic ester of the formula (XIV):
  • R 7 comprises an amide moiety
  • R 7 comprises an amide moiety
  • a precursor comprising an ester, for instance a methyl or ethyl ester by first converting the ester to an acid, by hydrolysis and then treating the acid with an appropriate amine, under amide bond forming conditions.
  • the acid may preferably be converted into an activated derivative, prior to amide bond formation.
  • R 7 comprises a urea moiety
  • R 7 comprises a urea moiety
  • Compounds of formula (I) in which R 7 comprises a urea moiety can be prepared from a precursor comprising an amine moiety, by treating the amine with an isocyanate, under urea forming conditions, well known in the art.
  • Triethylsilane (30.5 g, 260 mmol) was added dropwise to 8-bromo-l-(4- fluorophenyl)octan-l-one (230 ml, 105 mmol) over 20 min, with cooling to keep the temperature at ca 30°C. After 2 hours stirring, a further 3.1 g (27 mmol) triethylsilane was added, and reaction continued for an additional 2 hours. The mixture was poured into ice-water (200 ml) and ether (300 ml), then the organic layer was washed with aqueous sodium hydroxide, dried and evaporated, finally at 65°C/0.01 mm.
  • T cor a mixture of phenol (0.58g) and 1 ,7-dibromoheptane (4.76g) in dimethylformamide (5ml) was added potassium carbonate (4.3g) and the mixture was heated at 80°C for 6h. The mixture was cooled and the solvent was removed under reduced pressure. Toluene ( 10ml) was added and removed under reduced pressure. The residue was chromatographed on silica gel using hexane as eluent. This gave l-bromo-7- phenoxyheptane (1.15g).
  • 9-Bromononanoyl chloride was obtained from the carboxylic acid (reference 12) by treatment with thionyl chloride.
  • 9-Bromo-l-(4-chlorophenyl)nonan-l-one was prepared analogously to intermediate Al.
  • 'H-NMR (CDC1 3 ) ⁇ 1.2-2.0 (12H,m), 2.95 (2H,t), 3.41 (2H.t), 7.44 (2H,m) and 7.90 (2H.m).
  • 6-(4-Chlorobenzoylamino)hexan-l-ol (17.0g) was refluxed in 48% hydrobromic acid (260ml) for 2.5h. The mixture was cooled and added to water (450ml) and diethyl ether (450ml). The organic layer was washed with saturated sodium bicarbonate (450ml) and brine (450ml) and was dried over magnesium sulfate. Evaporation followed by recrystallisation from diethyl ether gave l-bromo-6-(4-chlorobenzoylamino)hexane (8.6g). 'H-NMR (CDC1 3 ) ⁇ 1.3-2.0 (8H,m), 3.35-3.55 (4H,m), 6.15 (lH,bs), 7.40 (2H,m) and 7.70 (2H,m).
  • the appropriate BOC-protected amine was dissolved in neat TFA (ca 5ml/g) at room temperature. After 5min the solution was concentrated to a brown gum and re-evaporated from ethyl acetate.
  • the crude amine salt in dichloromethane (ca 15ml/g) was treated with the isocyanate (1.1 equiv.) in dichloromethane, followed by the addition of triethylamine and the reaction mixture shaken overnight. The reaction mixture was centrifuged to remove any solid material and the supernatent washed with water. The organic layer was dried over anhydrous magnesium sulfate and the solution concentrated. The crude material was then purified by silica gel chromatography.
  • Finely ground cyanamide ( 1.68 g, 0.04 mol) and cyanamide dihydrochloride (2.26 g, 0.02 mol) were treated with 4-phenyl- 1 -butanol (3.24 g, 0.02 mol), occasionally stirring with a glass rod over a 20 day period.
  • the white paste was dissolved in water, extracted with chloroform and the aqueous layer adjusted to pH 13 (cone, sodium hydroxide) with ice cooling.
  • the oil which precipitated was extracted into ethyl acetate, dried (MgS0 4 ) and the solvent evaporated to give the isourea as a clear oil (3.88 g).
  • a portion of this material (2.44 g) was converted to the hydrochloride salt by treatment with

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.

Description

PYR IMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOS ITIONS CONTAINING THEM
The present invention relates to certain novel pyπmidinone compounds, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy, m particular in the treatment of atherosclerosis
WO 95/00649 (SmithKline Beecham pic) describe the phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2), the sequence, isolation and purification thereof, isolated nucleic acids encoding the enzyme, and recombinant host cells transformed with DNA encoding the enzyme Suggested therapeutic uses for inhibitors of the enzyme included atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation A subsequent publication from the same group further describes this enzyme (Tew D et al, Arterioscler Thromb Vas Biol 1996 16;591-9) wherein it is referred to as LDL-PLA2. A later patent application (WO 95/09921, Icos Corporation) and a related publication in Nature (Tjoelker et al, vol 374, 6 April 1995, 549) describe the enzyme PAF-AH which has essentially the same sequence as Lp-PLA2 and suggest that it may have potential as a therapeutic protein for regulating pathological inflammatory events.
It has been shown that Lp-PLA2 is responsible for the conversion of phosphatidylcholine to lysophosphatidylcholine, during the conversion of low density lipoprotein (LDL) to its oxidised form The enzyme is known to hydrolyse the sn-2 ester of the oxidised phosphatidylcholine to give lysophosphatidylcholine and an oxidatively modified fatty acid Both products of Lp-PLA2 action are biologically active with lysophosphatidylcholine, a component of oxidised LDL, known to be a potent chemoattractant for circulating monocytes As such, lysophosphatidylcholine is thought play a significant role in atherosclerosis by being responsible for the accumulation of cells loaded with cholesterol ester in the arteries Inhibition of the Lp-PLA2 enzyme would therefore be expected to stop the build up of these macrophage enriched lesions (by inhibition of the formation of lysophosphatidylcholine and oxidised free fatty acids) and so be useful in the treatment of atherosclerosis
The increased lysophosphatidylcholine content of oxidatively modified LDL is also thought to be responsible for the endothelial dysfunction observed in patients with atherosclerosis Inhibitors of Lp-PLA2 could therefore prove beneficial in the treatment of this phenomenon An Lp-PLA2 inhibitor could also find utility in other disease states that exhibit endothelial dysfunction including diabetes, hypertension, angina pectoπs and after ischaemia and reperfusion In addition, Lp-PLA2 inhibitors may also have a general application in any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA2. Examples of such disorders include psoriasis.
Furthermore, Lp-PLA2 inhibitors may also have a general application in any disorder that involves lipid peroxidation in conjunction with Lp-PLA2 activity to produce the two injurious products, lysophosphatidylcholine and oxidatively modified fatty acids. Such conditions include the aforementioned conditions atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).
Patent applications WO 96/12963, WO 96/13484, W096/ 19451, WO 97/02242, W097/217675, W097/217676, WO 96/41098, and WO97/41099 (SmithKline Beecham pic) disclose ter alia various series of 4-thionyl/sulfinyl/sulfonyl azetidinone compounds which are inhibitors of the enzyme Lp-PLA2- These are irreversible, acylating inhibitors (Tew et al, Biochemistry, 37, 10087, 1998).
GB 1 582 527 describes, as compounds of formula (7), a group of pyrimidone compounds of the formula (A):
in which Alk is lower alkyl, Het is selected from 2- or 4-imidazolyl, 2-pyridyl, 2-thiazolyl, 3-isothiazolyl, 1.2.5-thiadiazolyl and n is from 1 to 4. These compounds are said to be useful as intermediates in the preparation of further compounds which are H2 antagonists.
A new class of pyrimidone compounds has now been identified which are inhibitors of the enzyme Lp-PLA2-
Accordingly, the present invention provides compounds of formula (I):
(I) in which:
Z is a bond and R^ is halogen; or Z is CR3R4, where R3 and R4 are each hydrogen or Cn_4)alkyl, or R^ and R4 together with the intervening carbon atom form a C(3_g)cycloalkyl ring; and
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents oxo,
Cn -4)alkoxy;
X is O or S;
Y is a group of formula -A*-A2~A3- in which A and A^ each represent a bond or a straight chain or branched C(j _ιo)alkylene group and A2 represents a bond or O, S, SO, S02, CO, C=CH2, CH=CH, C≡C, CONH, NHCO, or CR5R6, providing that when A2 is O, S. SO, S02or CONH, A- contains at least two carbon atoms linking the A2 group and the CH2 group in formula (I);
R2 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents selected from the substituents hereinbefore defined for R T as well as aryl and arylC(i_4)alkyl;
W is a bond and R^ is hydrogen; or W is S0 or a bond; and
R ' is RI or a hydrocarbyl group which hydrocarbyl group may be optionally interupted within the carbon chain by a group selected from O, COO, OCO, CO, CONR8, NR8CO, NR8CONR9, NR8COO, OCONR8, and NR8, and which hydrocarbyl group may also be optionally substituted by 1 or 2 substituents selected from mono to perfluoro- C( ι_4)alkyl. OR8, COOR8, CONR8R9, NR8COR9, NR8CONR9R10, NR8COOR9, OCONR8R9, NRi iR^ and R1 :
R5 and R > are independently hydrogen or C(j.20)a^yl, for instance C(i-4)alkyl (e.g. methyl or ethyl);
R8. R9 and R^O are independently selected from hydrogen, Cn _20)alkyl (f°r instance Cn ^alkyl), (which may optionally be fluorinated, including up to perfluorinated on the terminal 1 to 3 carbon atoms), C(i_20)alkenyl (preferably c(12-18)alkeny1)' aryl arylC(i_ιo)alkyl, C(1_1o)alkoxyC(1.1o)alkyl, or aryloxyC(i.io)alkyl and in which an aryl group may have one or two substituents selected from halogen, 0(1.20)^^1, C i^O^koxy, aryloxy and COOCn -20)alky and
RI 1 and R^2 are independently selected from one of the values hereinbefore defined for R8 and R or R^ and R*2 together with the nitrogen atom to which they are attached form a 5- to 7 membered ring optionally containing one or two further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, Cπ -4)alkyl, phenyl, or benzyl.
Preferably, Z is CH2-
Representative examples of R* when an aryl group include phenyl and naphthyl. Representative examples of R when a heteroaryl group include pyridyl, pyrimidyl, pyrazolyl, furyl, thienyl, thiazolyl, quinolyl, benzothiazolyl, pyridazolyl and pyrazinyl.
Preferably R^ is a 5- or 6- membered, monocyclic heteroaryl group containing 1 or 2 nitrogen heteroatoms, preferably pyridyl, pyrimidyl or pyrazolyl, more preferably, pyrid- 4-yl or pyrimid-5-yl and optionally substituted by 1 or 2 substituents preferably selected from arylC(i _4)alkyl (e.g. benzyl), C( ) ιg)alkyl (e.g. methyl or ethyl), halogen (e.g. chlorine), oxo, hydroxy, C( i _4)alkoxy (e.g. methoxy) and arylCπ _4)alkoxy (e.g. benzyloxy). More preferably, R* is pyrimid-5-yl or a 2-oxo-pyrimid-5-yl group, optionally substituted at N-l by C(i_ιg)alkyl (e.g. undecyl, methyl or ethyl), or a 2- C(i_4)alkoxy- or arylC( i_4)alkoxy-pyrimid-5-yl group.
Preferably, ZR^ is 2-oxo-pyrid-4-ylmethyl, pyrimid-5-ylmethyl or 2-oxo-pyrimid-5- ylmethyl in which the 2-oxo-pyrimid-5-yl moiety is as hereinbefore defined.
Preferably X is S.
Preferred compounds of formula (I) include those in which Y is a bond, i.e. A1, A2 and A 3 each represent a bond. Other preferred examples of the groups A* and A 3 are straight chain Cn .[( jalkylene groups. When A2 is other than a bond, A^ is preferably a bond. Preferred examples of A2 when other than a bond include CO, C=CH2 and O, the CO group being especially preferred. Other preferred examples of Y are (CH.2)~j and CO(CH2)6- Representative examples of R2 when an aryl group include phenyl and naphthyl. Representative examples of R2 when a heteroaryl group include pyridyl, pyrimidinyl, pyrazolyl, furanyl, thienyl, thiazolyl, quinolyl,benzothiazolyl, pyridazolyl and pyrazinyl Preferrably, R2 is phenyl optionally substituted by 1, 2 or 3 substituents selected from halogen (e.g. chlorine or fluorine), C(j.4)alkyl (e.g. methyl or ethyl) or C(i _4)alkoxy (e.g. methoxy). Further optional substituents include phenyl and benzyl.
Representative examples of R2YCH2X include 4-fluorobenzylthiogroup, 4- chlorophenylheptylthio and 4-chlorophenyl-l-oxaheptylthio. Preferably, R2YCH2X is 4-fluorobenzylthio group.
Preferably W is a bond.
Representative examples of R^ when a hydrocarbyl group include C(i_20)alkyl. C(2_20)alkenyl, C(2-20)alkynyl' C(3_6)cycloalkyl, C(3_6)cycloalkylC(i_5)alkyl, or C(l-15)alkoxyC(i _i ())alkyl each of which may be optionally substituted by 1 or 2 substituents as hereinbefore defined.
Preferably, W is a bond and R^ is C(i_20)alkyl, especially C(io-20)a^yl- Preferably, R^ is also C( i _i ())alkyl, more preferably a C(i _6)alkyl which is substituted by one or two substituents selected from hydroxy, C( i _ιo)alkoxy (e.g. methoxy), COOC(i_i())alkyl (e.g. COOCH3, COOC2H5), CONR8R9, NR8CONR9R 10, NHCOR8 (in which R8, R9 and R^O is each independently C( ι_20)alkyl e.g. methyl). Further optional substituents include aryl, preferably phenyl which may be optionally substituted by COOC( ι_6)alkyl (e.g methyl) and heteroaryl (for instance pyridyl, imidazolyl, furanyl, thienyl and 2-oxo pyrrolidinyl). Preferred examples of the substituent NRl 1R ^2 include morpholino, piperidino or 2-oxo-pyrrolidino group.
A preferred sub-group of compounds of formula (I) are those in which W is a bond and R is a phenyl or a phenylC( 1 _g)alkyl group, for instance benzyl or phenethyl, substituted in the phenyl ring by 1 or 2 substituents selected from C(6-i2) l yl (for instance hexyl and decyl), C(6.12)alkoxy. COOH, COOC(6.ι 2)alkyl and C0NHC(6-I2)alkyl. Alternatively, R^ maybe heteroarylC(i_g)alkyl, preferably heteroarylC(i _3)alkyl in which the heteroaryl ring is monocyclic with 5 to 6 members and one or two heteroatoms selected from nitrogen, oxygen and sulphur, such as pyridyl, furanyl, thienyl and imidazolyl. A further preferred subgroup of compounds of formula (I) are those in which W is a bond and R is a group of the formula (CH2)nBR^ where n is an integer from 1 to 6, preferably 1 to 4, B is selected from NR14CO, CONR14, NR14CONR15, NR15COO (in which R^4 and R^5 are independently selected from hydrogen or C(i _6)alkyl, preferably hydrogen) and R^ is C(g_ιg)alkyl (which may optionally be fluorinated, including up to perfluorinated on the terminal 1 to 3 carbon atoms), and phenylCn _g)alkoxyC(i_6)alkyl in which phenyl may be optionally substituted by halogen or C(i _6)alkyl. Prefered examples of C(g.ι g)alkyl are straight chains and include octyl, dodecyl and fatty alkyl groups such as lauryl and stearyl. Preferred values of C(g.ι g)alkenyl include octadec-9-(Z)-en-lyl. Preferred examples of optionally substituted phenylCn_6)alkyl and phenylC(i_g)alkoxyC(i _6)alkyl include 4- fluorophenylhexyl, 4-pentylphenylethyl and 4-fluorophenylhexoxyethyl. Particularly preferred compounds of formula (I) are those in which R^2 is C(i2-18)a^yl or Cr\2- 1 g)alkenyl. Such a long, lipophilic substituent is found to be especially beneficial for enzyme inhibition
When used herein, the term 'alkyl' and similar terms such as 'alkoxy' includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, n- propyl. /w-propyl, rc-butyl, sec-butyl, /_o-butyl, t-butyl, «-pentyl and n-hexyl.
When used herein, the term "hydrocarbyl" refers to a group having from 1 to 20 carbon atoms which may be in a straight chain or a branched chain and include a saturated carbocyclic ring having from 3 to 6 carbon atoms and which chain may contain unsaturation (double and/or triple carbon-carbon bonds).
When used herein, the term 'aryl' refers to. unless otherwise defined, a mono- or bicyclic aromatic ring system containing up to 10 carbon atoms in the ring system, for instance phenyl or naphthyl.
When used herein, the term Tieteroaryl' refers to a mono- or bicyclic heteroaromatic ring system comprising up to four, preferably 1 or 2, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms. A bicyclic heteroaromatic ring system may include a carbocyclic ring. Representative examples include pyridyl, pyridyl N-oxide, pyrimidyl, pyrazolyl, furyl, thienyl, thiazolyl, pyridazolyl and pyrazinyl, quinolyl and benzothiazolyl.
When used herein, the terms Tialogen' and Tialo' include fluorine, chlorine, bromine and iodine and fluoro, chloro. bromo and iodo, respectively. Compounds of formula (I) are inhibitors of Lp-PLA2 and as such are expected to be of use in treating atherosclerosis and the other disease conditions noted elsewhere. Such compounds are found to act as inhibitors of Lp-PLA2 in in vitro assays ..
Particularly preferred compounds of formula (I) are 2-(4-Fluorobenzylthio)-5-((pyrimid-5-yl)methyl)pyrimidin-4-one; l-Methyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(Tetradec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(N-(Dodec- 1 -yl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; and
1 -(N-Methyl-N-(dodec- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one.
Since the compounds of the present invention, in particular compounds of formula (I), are intended for use in pharmaceutical compositions, it will be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds of formula (I) may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical, it will be readily understood that the substantially pure form is preferred as for the compounds of formula (I). Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
When some of the compounds of this invention are allowed to crystallise or are recrystalhsed from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or recrystalhsed from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. In addition, different crystallisation conditions may lead to the formation of different polymorphic forms of crystalline products. This invention includes within its scope all polymorphic forms of the compounds of formula (I).
Compounds of the present invention are inhibitors of the enzyme lipoprotein associated phospholipase A2 (Lp-PLA2) and as such are expected to be of use in therapy, in particular in the treatment of atherosclerosis. In a further aspect therefore the present invention provides a compound of formula (I) for use in therapy. The compounds of formula (I) are inhibitors of lysophosphatidylcholine production by Lp-PLA2 and may therefore also have a general application in any disorder that involves endothelial dysfunction, for example atherosclerosis, diabetes, hypertension, angina pectoris and after ischaemia and reperfusion. In addition, compounds of formula (I) may have a general application in any disorder that involves lipid peroxidation in conjunction with enzyme activity, for example in addition to conditions such as atherosclerosis and diabetes, other conditions such as rheumatoid arthritis, stroke, inflammatory conditions of the brain such as Alzheimer's Disease, myocardial infarction, reperfusion injury, sepsis, and acute and chronic inflammation. Further such conditions include various neuropsychiatric disorders such as schizophrenia (see Psychopharmacology Bulletin, 31, 159-165, 1995).
Further applications include any disorder that involves activated monocytes, macrophages or lymphocytes, as all of these cell types express Lp-PLA:. Examples of such disorders include psoriasis.
Accordingly, in a further aspect, the present invention provides for a method of treating a disease state associated with activity of the enzyme Lp-PLA, which method involves treating a patient in need thereof with a therapeutically effective amount of an inhibitor of the enzyme. The disease state may be associated with the increased involvement of monocytes. macrophages or lymphocytes: with the formation of lysophosphatidylcholine and oxidised free fatty acids: with lipid peroxidation in conjunction with Lp PLA2 activity; or with endothelial dysfunction.
Compounds of the present invention may also be of use in treating the above mentioned disease states in combination with anti-hyperlipidaemic or anti-atherosclerotic or anti- diabetic or anti-anginal or anti-inflammatory or anti-hypertension agents. Examples of the above include cholesterol synthesis inhibitors such as statins, anti-oxidants such as probucol, insulin sensitisers, calcium channel antagonists, and anti-inflammatory drugs such as NSAIDs.
In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository.
Suitable pharmaceutical compositions include those which are adapted for oral or parenteral administration or as a suppository. Compounds of formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent. A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate. starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol. polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of formula (I) which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Preferably the composition is in unit dose form such as a tablet or capsule. Each dosage unit for oral administration contains preferably from 1 to 500 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I). The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 1000 mg, preferably between 1 mg and 500 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the formula (I), the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. Compounds of formula (I) may be conveniently prepared from readily available starting materials by adapting synthetic methodology well known in the art for the preparation and derivatisation of pyrimidones by a process.
Accordingly, in a first aspect, the present invention provides a process for preparing a compound of formula (I) which process comprises:
(a) treating a compound of formula (IIA):
O
HN R1
H
(HA) in which R I and Z are as hereinbefore defined; with a compound of formula (III):
R2YCH2L1
(HI) in which Y and R2 are as hereinbefore defined and L^ is a leaving group e.g. bromine or iodine; to give a compound of formula (IA):
(IA) in which Z, Y, R* and R2 are as hereinbefore defined and X is S; or
(b) treating a compound of formula (IV):
H
(IV) in which Z and R* are as hereinbefore defined and L2 is a leaving group, e.g. halogen such as chlorine or bromine, alkylthio such as methylthio.or -NHNO2, with a compound of formula (V):
R2YCH2XH
(V)
in which X, Y and R2 are as hereinbefore defined; advantageously at an elevated temperature, in a solvent such as pyridine, to give a compound of formula (IA); and thereafter, and if so desired;
treating a compound of formula (IA) form (a) or (b) above with a compound of formula
(VI):
R7WL!
(VI) in which L^, W and R' are as hereinbefore defined; to give a compound of formula (IB):
(IB) in which X, Y, Z, R^ and R2 are as hereinbefore defined and WR7 is as hereinbefore defined, other than -H; or
(c) treating a compound of formula (IIB):
(IIB) in which W is a bond. Z and R are as hereinbefore defined and R7 are as hereinbefore defined, other then H, with a compound of formula (III) as hereinbefore defined, to obtain a compound of formula (IB); and, thereafter and if so desired;
treating a compound of formula (IA) or (IB) in which X is S with a compound of formula
(V):
R2YCH2OH " (VII) in which Y and R2 are as hereinbefore defined; to give a corresponding compound of formula (I) in which X is O.
In the above process, the reaction of the compounds of formulae (IIA/B) and (III) is advantageously effected in the presence of a base such as sodium ethoxide, potassium carbonate, preferably in a solvent such as ethanol or dimethylformamide, or a base such as di-isopropyl ethylamine, preferably in a solvent such as dichlorome thane.
In the above process, the reaction of the compounds of formulae (IA) and (VI) is advantageously effected at a temperature of 20-100 degrees C, in the presence of sodium hydride in a solvent such as dimethylformamide; or by the compound of formula (IA) being pre-treated with tributyl tin chloride in the presence of di-isopropylethylamine, for example in a dichloromethane solvent at reflux temperature, followed by addition of (VI) Alternatively, the compound of formula (IA) may be treated directly with a compound of formula (VI) and di-isopropylethylamine in a dichloromethane solvent at room temperature.
In the above processes, the reaction of the compounds of formulae (IA/IB) and (VII) is conveniently effected in the presence of pyridine at an elevated temperature, containing a catalytic amount of 4-dimethylaminopyridine.
A compound of formula (I) in which Z is a bond and RI represents halogen may be obtained by treating a compound of formula (VIII):
(VIII) in which W, Y, R2, and R7 are as hereinbefore defined; with a halogenating agent, preferably with bromine to form a compound of formula (I) in which Z is a bond and R is bromine, the reaction being advantageously effected in a solvent such as dichloromethane.
A compound of formula (IIA) may be obtained from a compound of formula (IX):
(IX) in which L^ is Cn .g^alkyl, for instance methyl, and Z and R^ are as hereinbefore defined; by the initial treatment thereof with a formylating agent such ethyl formate in the presence of a strong base such as potassium t-butoxide or sodium hydride, to give an enolate metal salt compound of formula (X):
CH
MO /
(X) in which LA Z and R* are as hereinbefore defined and M is a metal cation, for instance sodium or potassium. Further treatment of a compound of formula (X) or a salt thereof with thiourea leads to a compound of formula (IIA). The two steps, starting form the compound of formula (IX) may conveniently be carried out as a "one-pot" process.
A compound of formula (IIB) may be obtained from a compound of formula (X), in a series of steps. In a first step, a compound of formula (X) is convened into the corresponding methyl enol ether by treatment with a methylating agent such as dimethyl sulphate in the presence of a base such as potassium carbonate. The corresponding carboxylic acid may then be obtained by conventional hydrolysis, for instance basic hydrolysis, using, for instance aqueous sodium hydroxide. The acid may then be converted into the corresponding acyl chloride, by treatment with oxalyl chloride, and the acyl chloride treated with potassium thiocyanate in a solvent such as acetonitrile, to give an intermediate of the formula (XI):
SCN — CO — C — Z — R1
CH /
CH30 (XI) in which R^ and Z are as hereinbefore defined. Treatment of a compound of formula (XI) with a compound of formula (XII):
R7WNH (XII) in which R ' is as hereinbefore defined and W is a bond, followed by the addition of an organic base such as sodium ethoxide. leads to a compound of formula (IIB).
A compound of formula (IV) in which L2 is N(H)Nθ2 can be conveniently prepared by reacting a compound of formula (X) above with a compound of formula (XIII):
^ NO2 N
/ \
H2N NH2
(XIII)
in which the reaction is carried out in a conventional manner.
A compound of formula (VIII) may be obtained by treating a 3,3-dialkoxypropionic ester of the formula (XIV):
(XIV) in which L3 is as hereinbefore defined; with a thiourea of the formula (XV):
R7NHCSNH2
(xv) in which R7 is as hereinbefore defined; in the presence of sodium hydride followed by aqueous acetic acid.
Compounds of formula (I) in which R7 comprises an amide moiety can be prepared from a precursor comprising an ester, for instance a methyl or ethyl ester, by first converting the ester to an acid, by hydrolysis and then treating the acid with an appropriate amine, under amide bond forming conditions. The acid may preferably be converted into an activated derivative, prior to amide bond formation.
Compounds of formula (I) in which R7 comprises a urea moiety can be prepared from a precursor comprising an amine moiety, by treating the amine with an isocyanate, under urea forming conditions, well known in the art.
The present invention will now be illustrated by the following examples.
Intermediate Al - 8-Bromo-l-(4-chlorophenyl)octan-l-one
To a stirring suspension of aluminium chloride (33.6g) in dry dichloromethane (474ml) was added 8-bromo-n-octanoyl chloride (67.8g) over lOmin. Chlorobenzene (123ml) was then added over lOmin and the mixture allowed to stir at 25°C for 74h and stood for 64h. The mixture was poured into ice/water (540ml) and diethyl ether (1.3L). The organic layer was removed and was washed with water (540ml), saturated sodium hydrogen carbonate (540ml), water (400ml) and brine (400ml) and dried over magnesium sulfate. Removal of the organic layer under reduced pressure and chromatography of the residue on silica gel using 5% ethyl acetate in hexane gave 8-bromo-l-(4-chlorophenyl)octan-l- one (35.5g). Η-NMR (CDC13) δ 1.2-1.6 (6H,m), 1.6-1.95 (4H,m), 2.95 (2H,t), 3.42 (2H,t), 7.43 (2H,m) and 7.90 (2H.m).
Intermediate A2 - 8-Hydroxy-l-(4-chlorophenyl)octan-l-one
To 8-bromo-l-(4-chlorophenyl)octan-l-one (4.0g) in ethanol (170ml) was added 3% aqueous sodium hydroxide (70ml). The mixture was heated at reflux for 3h, cooled and evaporated to one third volume. Water (50ml) and dichloromethane (100ml) were added. The organic layer was separated and the aqueous layer was re-extracted with dichloromethane (2x50ml). The combined extracts were washed with water (30ml) and dried over magnesium sulphate. The solvent was removed under reduced pressure and the residue was crystallised from 40-60°C petroleum ether to give 8-hydroxy-l-(4- chlorophenyl)octan-l-one ( l.Og). Η-NMR (CDC13) δ 1.25-1.9 (10H,m), 2.94 (2H.t), 3.64 (2H.t), 7.43 (2H,m) and 7.89 (2H.m). (El) Found M+=254. C14H19C102 requires 254.
Intermediate A3 - 8-Bromo-l-(4-methoxyphenyl)octan-l-one
Prepared analogously to intermediate Al. Η-NMR (CDC13) δ 1.3-1.95 (10H,m), 2.91 (2H,t). 3.41 (2H,t), 3.87 (3H,s), 6.93 (2H,m) and 7.94 (2H,m).
Intermediate A4 - 8-Bromo-l-(4-bromophenyl)octan-l-one
Prepared analogously to intermediate Al . Η-NMR (CDC13) δ 1.25-1.55 (6H,m), 1.65- 1.95 (4H,m), 2.93 (2H.t), 3.41 (2H.t), 7.60 (2H.m) and 7.83 (2H,t). Intermediate A5 - 8-Bromo-l-(2-thienyl)octan-l-one
Prepared analogously to intermediate Al, except using SnCl4 as catalyst in place of AICI3. Η-NMR (CDCI3) δ 1.3-1.55 (6H,m), 1.65-1.95 (4H.m), 2.90 (2H,t), 3.41 (2H,t), 7.13 (lH,dd), 7.63 (lH,dd and 7.70 (lH,dd).
Intermediate A6 - 8-Bromo-l-(2-furyl)octan-l-one
Prepared analogously to intermediate Al, except using SnCl4 as catalyst in place of AICI3. Η-NMR (CDCI3) δ 1.3-1.55 (6H,m), 1.6-1.95 (4H,m), 2.82 (2H,t), 3.41 (2H,t), 6.53 (lH,m), 7.18 (lH,m) and 7.58 (lH,m).
Intermediate A7 - 8-Bromo-l-(4-methylphenyl)octan-l-one
Prepared analogously to intermediate Al. 'H-NMR (CDC13) δ 1.3-1.55 (6H,m), 1.65- 1.95 (4H,m), 2.41 (3H,s), 2.94 (2H,t), 3.41 (2H,t), 7.25 (2H.m) and 7.86 (2H,m).
Intermediate A8 - 8-Bromo-l-(4-fluorophenyI)octan-l-one
Prepared analogously to intermediate Al. 'H-NMR (CDC13) δ 1.3-1.6 (6H.m), 1.6-1.95 (4H.m), 2.94 (2H.t). 3.41 (2H.t), 7.13 (2H.m) and 7.98 (2H,m).
Intermediate A9 - 8-Bromo-l-(4-methyl-l-naphthyl)octan-l-one
Prepared analogously to intermediate Al . 'H-NMR (CDC13) δ 1.3-1.55 (6H,m), 1.7-1.95 (4H.m). 2.74 (3H,s), 3.03 (2H,t), 3.41 (2H,t), 7.32 ( lH.m), 7.5-7.65 (2H,m), 7.76 (lH,d), 8.0-8.1 (lH,m) and 8.55-8.7 ( lH.m).
Intermediate A10 - l-Bromo-8-(2-thiazolinyl)octane
To a solution of 2-methyl-2-thiazoline ( l.Olg) in dry tetrahydrofuran at -70°C was added a solution of n-butyl lithium in hexanes (2.5M, 4.0ml) dropwise over lOmin. After stirring at -70°C for 2h, 1,7-dibromoheptane ( 12.9g) was added in one portion (temperature increased to -45°C). The mixture was cooled again to -70°C for lh and then allowed to warm to room temperature over lh. The mixture was cooled to 0°C and water (10ml) added, followed by dilute hydrochloric acid (to pH 2). The organic layer was separated and the aqueous layer extracted with diethyl ethyl (2x20ml). The organic layers were combined and washed with water and brine and dried over magnesium sulfate. Evaporation under reduced pressure gave an oil that was chromatographed on silica gel using 40-60°C petroleum ether:ethyl acetate 5: 1 to give l-bromo-8-(2-thiazolinyl)octane (1.06g). 'H-NMR (CDC13) δ 1.2-1.5 (6H,m), 1.5-1.75 (4H,m), 1.75-1.95 (2H,m), 2.50 (2H,t), 3.28 (2H,t), 3.40 (2H,t) and 4.21 (2H,dt).
Intermediate All - l-Bromo-8-(2-pyridyl)octane
Prepared analogously to intermediate A10. Η-NMR (CDC13) δ 1.2-1.55 (8H,m), 1.6- 1.95 (4H,m), 2.76 (2H.t), 3.41 (2H,t), 7.05-7.2 (2H,m), 7.5-7.65 (lH.m) and 8.52 (lH.m).
Intermediate A12 - 8-(3,4-DichlorophenyI)oct-7-yn-l-ol
A mixture of 3,4-dichloroiodobenzene (2.16g), oct-7-yn-l-ol (1.20g), tetrakis (triphenylphosphine)palladium (0) (0.185g), copper (I) iodide (0.046g) and triethylamine (15ml) was stirred at room temperature for 16h. The solid was filtered off and the filtrate evaporated under reduced pressure. The residual oil was dissolved in ethyl acetate (15ml) and washed with water (10ml), 2M hydrochloric acid (2x10ml) and brine (10ml). Drying over magnesium sulfate and removal of the solvent under reduced pressure gave an oil that was purified by flash chromatography on silica gel using dichloromethane as eluent. This gave 8-(3,4-dichlorophenyl)oct-7-yn-l-ol (1.89g). 'H-NMR (CDC13) δ 1.2-1.75 (8H.m), 2.40 (2H,t), 3.66 (2H,t),7.19 ( lH.dd), 7.35 (lH,d) and 7.47 (lH,dd)
Intermediate A13 - 8-(3,4-Dichlorophenyl)octan-l-ol
To a solution of 8-(3,4-dichlorophenyl)-oct-7-yn-l-ol (0.70g) in methanol (20ml) was added platinum dioxide (0.05g) and the mixture reacted under an atmosphere of hydrogen (initial pressure 50 psi). After lh. the catalyst was filtered through Hyflo and washed with methanol. The combined methanol layers were evaporated under reduced pressure to give 8-(3,4-dichlorophenyl)octan-l-ol (0.69g). 'H-NMR (CDC13) δ 1.1-1.8 (12H,m), 2.55 (2H,t), 3.64 (2H.m), 6.99 (lH.dd) and 7.2-7.4 (2H,m) Intermediate A14 - 8-Bromo-l-(3,4-dichlorophenyl)-l-octyne
A solution of 8-(3,4-dichlorophenyl)-oct-7-yn-l-ol (0.52g) in diethyl ether (2.5ml) was treated with phosphorous tribromide (0.23g) at 0°C (ice/salt bath). The solution was stirred at 0-5°C for 2h and allowed to warm to room temperature. Aqueous sodium hydrogen carbonate solution was added. The aqueous layer was extracted with further diethyl ether (2x5ml) and the combined organic layers were washed with brine (5ml) and dried over magnesium sulfate. Removal of the solvent under reduced pressure gave an oil that was chromatographed on silica gel using dichloromethane as eluent. This gave 8- bromo-l-(3,4-dichlorophenyl)-l-octyne (0.25g). ' H-NMR (CDC13) δ 1.35-1.7 (6H,m), 1.75-1.95 (2H,m), 2.33 (2H,t), 3.35 (2H,t), 7.13 (lH,dd), 7.27 (lH,d) and 7.40 (lH,d)
Intermediate A15 - l-Bromo-8-(3,4-dichlorophenyl)octane
A solution of 8-(3,4-dichlorophenyl)octan-l-ol (0.66g) in 48% hydrobromic acid (7ml) was stirred under reflux for 2h. Water (20ml) and diethyl ether (20ml) were added. The organic layer was separated and the aqueous layer reextracted with diethyl ether (10ml). The combined organic extracts were washed with water (10ml), sodium hydrogen carbonate solution (10ml) and brine (10ml) and dried over magnesium sulfate. The solution was treated with charcoal, filtered and evaporated under reduced pressure to give l-bromo-8-(3,4-dichlorophenyl)octane (0.74g). 'H-NMR (CDC13) δ 1.2-1.8 (12H,m), 2.55 (2H,t), 3.41 (2H,t), 7.00 (lH,dd), 7.25 (lH,dd) and 7.33 (lH,d).
Intermediate A16 - 8-(3-Chlorophenyl)oct-7-yn-l-ol
Prepared analogously to intermediate A 12. Η-NMR (CDC13) δ 1.25 (8H,m), 2.41 (2H,t), 3.66 (2H,t), 7.13-7.33 (3H,m) and 7.37 (lH,m)
Intermediate A17 - 8-(3-Chlorophenyl)octan-l-ol
Prepared analogously to intermediate A13. Η-NMR (CDC13) δ 1.1-1.8 (12H,m), 2.57 (2H,t), 3.64 (2H,t), 7.0-7.4 (4H.m)
Intermediate A18 - l-Bromo-8-(3-chlorophenyl)octane
Prepared analogously to intermediate A15. Η-NMR (CDC13) δ 1.05-1.9 (12H,m), 2.50 (2H,t), 3.33 (2H,t) and 6.9-7.25 (4H,m).
Intermediate A19 - 8-(4-Acetylphenyi)octan-l-ol
Prepared analogously to intermediate A13. Η-NMR (CDC13) δ 1.2-1.8 (12H,m), 2.59 (3H,s), 2.68 (2H,t), 3.63 (2H,t)7.25 (2H,m) and 7.88 (2H,m)
Intermediate A20 - l-Bromo-8-(4-acetylphenyl)octane
Prepared analogously to intermediate A15. 'H-NMR (CDC13) δ 1.2-1.75 (10H,m), 1.85 (2H,m). 2.59 (3H,s), 2.67 (2H,m), 3.40 (2H,t), 7.2-7.3 (2H,m) and 7.88 (2H,m).
Intermediate A21 - l-Bromo-8-(4-fiuorophenyl)octane
Triethylsilane (30.5 g, 260 mmol) was added dropwise to 8-bromo-l-(4- fluorophenyl)octan-l-one (230 ml, 105 mmol) over 20 min, with cooling to keep the temperature at ca 30°C. After 2 hours stirring, a further 3.1 g (27 mmol) triethylsilane was added, and reaction continued for an additional 2 hours. The mixture was poured into ice-water (200 ml) and ether (300 ml), then the organic layer was washed with aqueous sodium hydroxide, dried and evaporated, finally at 65°C/0.01 mm. The residue was filtered through silica gel, eluting with petroleum ether, then distilled, collecting the fraction at 122-140°C/0.5 mm (24.2 g). Η-NMR (CDC13) δ 1.2-1.7 (lOH.m), 1.85 (2H.m), 2.57 (2H,t), 3.40 (2H,t), 6.9-7.05 (2H.m) and 7.05-7.2 (2H,m).
Intermediate A22 - l-Bromo-8-(4-methoxyphenyl)octane
Prepared as in reference 1 Intermediate A23 - l-Bromo-8-(4-pyridyl)octane
Prepared analogously to intermediate A10. 'H-NMR (CDC13) δ 1.2-1.95 (12H,m), 2.48 (2H.t), 3.42 (2H,t), 7.1 1 (2H.d) and 8.47 (2H,m).
Intermediate A24 - l-Bromo-8-(4-chlorophenyl)octane
Prepared analogously to intermediate A21. Η-NMR (CDC13) δ 1.2-1.5 (8H,m), 1.5-1.7 (2H.m), 1.75-1.95 (2H,m), 2.56 (2H,t), 3.40 (2H,t), 7.08 (2H,m) and 7.23 (2H,m).
Intermediate A25 - l-Bromo-6-(4-chlorobenzyloxy)hexane
Sodium hydride (60%, 0.39g) was added to a mixture of 6-bromohexanol (1.78g) and 4- chlorobenzyl bromide (2.02g) in dry tetrahydrofuran (150ml). The mixture was stirred at 25°C for 5h and poured into IM hydrochloric acid. Extraction with diethyl ether (3x), and washing the combined extracts with water and brine gave a solution that was dried over magnesium sulfate and evaporated under reduced pressure. The residue so obtained was chromatographed on silica gel using 40-60°C petroleum ether to 10% diethyl ether in 40-60°C petroleum ether as eluents. This gave l-bromo-6-(4-chlorobenzyloxy)hexane (1.7g). 'H-NMR (CDC13) δ 1.3-1.55 (4H,m), 1.55-1.7 (2H,m), 1.75-1.95 (2H,m), 3.35- 3.55 (4H,m), 4.46 (2H,s) and 7.2-7.4 (4H,m).
Intermediate A26 - l-Bromo-6-(4-fluorobenzyloxy)hexane
Prepared analogously to intermediate A25. Η-NMR (CDC13) δ 1.3-1.5 (4H,m), 1.6 (2H.m), 1.9 (2H,m), 3.39 (2H.t), 3.45 (2H,t), 4.44 (2H,s), 7.0-7.1 (2H,m), 7.2-7.4 (2H,m).
Intermediate A27 - l-Bromo-6-benzyloxyhexane
Prepared as in reference 14. Intermediate A28 - l-Bromo-7-phenoxyheptane
T cor a mixture of phenol (0.58g) and 1 ,7-dibromoheptane (4.76g) in dimethylformamide (5ml) was added potassium carbonate (4.3g) and the mixture was heated at 80°C for 6h. The mixture was cooled and the solvent was removed under reduced pressure. Toluene ( 10ml) was added and removed under reduced pressure. The residue was chromatographed on silica gel using hexane as eluent. This gave l-bromo-7- phenoxyheptane (1.15g). Η-NMR (CDC13) δ 1.3-1.7 (6H,m), 1.7-2.1 (4H,m), 3.41 (2H.t), 3.95 (2H,t), 6.8-7.0 (3H.m) and 7.2-7.4 (2H.m)
Intermediate A29 - l-Bromo-7-(4-chlorophenoxy)heptane
Prepared analogously to intermediate A28. Η-NMR (CDC13) δ 1.3-1.6 (6H,m), 1.7-2.0 (4H,m), 3.41 (2H,t), 3.91 (2H,t), 6.75-6.9 (2H,m) and 7.15-7.3 (2H,m). Intermediate A30 - l-Bromo-7-(4-chlorophenylthio)heptane
To 1 ,7-dibromoheptane (23g) and potassium carbonate (lOg) in dry dimethylformamide (100ml) was added 4-chlorothiophenol (4.3g) dropwise with stirring at 25°C. After 6h, the mixture was filtered and the solvent removed under reduced pressure. Chromatography of the residue on silica gel using hexane as eluent gave l-bromo-7-(4- chlorophenylthio)heptane (9.6g). Η-NMR (CDC13) δ 1.2-1.55 (6H,m), 1.55-1.75 (2H,m), 1.8-2.0 (2H,m), 2.89 (2H,t), 3.40 (2H,t) and 7.2-7.4 (4H,m).
Intermediate A31 - l-Bromo-7-(4-chlorophenylsulfinyl)heptane
A solution of l-bromo-7-(4-chlorophenylthio)heptane (0.80g) in dichloromethane (10ml) was cooled to -78°C (cardice/acetone) and a slurry of metachloroperbenzoic acid (60%, 0.72g) in dichloromethane (5ml) was added over 20min. After 40min, the reaction was allowed to warm to room temperature and shaken with aqueous sodium sulfite/sodium hydrogen carbonate solution. The organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was chromatographed on silica gel using dichloromethane to 4% methanol in dichloromethane as eluents to give l-bromo-7-(4- chlorophenylsulfinyDheptane (0.43g). 'H-NMR (CDC13) δ 1.2-2.0 (10H,m), 2.77 (2H,t), 3.39 (2H,t) and 7.4-7.7 (4H,m).
Intermediate A32 - l-Bromo-7-(4-chlorophenylsulfonyl)heptane
To a solution of l-bromo-7-(4-chlorophenylthio)heptane (1.19g) in dichloromethane (20ml) at -20°C was added metachloroperbenzoic acid (60%, 2.23g) portionwise over 15min. The mixture was allowed to warm to room temperature over lh and was shaken with aqueous sodium sulfite/sodium hydrogen carbonate solution. The organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was chromatographed on silica gel using 50:50 hexane: dichloromethane as eluent to give 1- bromo-7-(4-chlorophenylsulfonyl)heptane (1.17g). Η-NMR (CDC13) δ 1.2-2.0 (10H,m), 3.07 (2H,m), 3.38 (2H,t), 7.5-7.6 (2H,m) and 7.8-7.9 (2H,m).
Intermediate A33 - l-Bromo-7-phenylthioheptane
Prepared analogously to intermediate A30. Η-NMR (CDC13) δ 1.2-1.55 (6H,m), 1.6- 1.75 (2H.m). 1.75-1.95 (2H,m), 2.91 (2H,t), 3.40 (2H,t) and 7.1-7.4 (5H,m).
oo Intermediate A34 - l-Bromo-7-phenylsulfinylheptane
Prepared analogously to intermediate A31. Η-NMR (CDC13) δ 1.2-1.95 (10H,m), 2.91 (2H,t), 3.40 (2H,m) and 7.1-7.4 (5H,m).
Intermediate A35 - l-Bromo-7-phenylsulfonylheptane
Prepared analogously to intermediate A32. 'H-NMR (CDC13) δ 1.2-2.0 (lH,m), 3.09 (2H,m), 3.38 (2H,t), 7.5-7.8 (3H,m) and 7.85-8.0 (2H,m).
Intermediate A36 - 8-Bromo-l-(4-chlorophenyl)-l-hydroxyoctane
To a solution of 8-bromo-l-(4-chlorophenyl)octan-l-one (0.95g) in industrial methylated spirit ( 10ml) was added sodium borohydride (0.115g) at -10°C. After stirring for lh, glacial acetic acid (0.2g) was added and the mixture was poured into water (60ml) and extracted with diethyl ether. The diethyl ether layer was washed with brine and dried over magnesium sulfate. Removal of the solvent under reduced pressure gave an oil that was chromatographed on silica gel using dichloromethane as eluent. This gave 8-bromo- l-(4-chlorophenyl)-l-hydroxyoctane (0.70g). Η-NMR (CDC13) δ 1.15-1.95 (12H,m), 3.40 (2H,t), 4.65 (lH,t) and 7.2-7.4 (4H,m).
Intermediate A37 - 9-Bromo-2-(4-fluorophenyl)-l-nonene
To a solution of butyl lithium (2.5M, 3.2ml) in anhydrous tetrahydrofuran (75ml) was added triphenylmethylphosphonium bromide (2.86g) in portions over lOmin. The mixture was stirred at 25°C for 3h and a solution of 8-bromo-l-(4-fluorophenyl)octan-l- one ( 1.20g) in dry tetrahydrofuran ( 15ml) added dropwise over 5min. After stirring at 25°C for lh, the mixture was heated at reflux for 24h. The mixture was evaporated under reduced pressure and partitioned between diethyl ether (70ml) and water (4x30ml). The organic layer was washed with brine and dried over magnesium sulfate. Removal of the solvent under reduced pressure gave an oil that was chromatographed on silica gel using 5% diethyl ether in hexane. This gave 9-bromo-2-(4-fluorophenyl)-l-nonene (0.75g). 'H-NMR (CDC13) δ 1.2-1.55 (8H,m), 1.80 (2H,m), 2.46 (2H,t), 3.39 (2H,t), 5.03 (lH,bs), 5.20 (lH,bs), 7.03 (2H.m) and 7.3-7.45 (2H,m). Intermediate A38 - l-(3-Chlorophenyl)hex-l-yn-6-ol
Prepared analogously to intermediate A12. 'H-NMR (CDC13) δ 1.6-1.85 (4H,m), 2.45 (2H,bt), 3.71 (2H,t), 7.15-7.33 (3H,m) and 7.37 (lH,m)
Intermediate A39 - 6-(3-ChlorophenyI)hexan-l-ol
Prepared analogously to intermediate A13. Η-NMR (CDC13) δ 1.2-1.8 (8H,m), 2.58 (2H,t), 3.64 (2H,t) and 7.0-7.3 (4H,m)
Intermediate A40 - l-Bromo-6-(3-chlorophenyl)hexane
Cl^ ^~^ ^-\ /\ /\ ^Br
Prepared analogously to intermediate A15. Η-NMR (CDCI3) δ 1.2-1.95 (8H,m), 2.59 (2H,t), 3.40 (2H,t) and 7.0-7.3 (4H,m)
Intermediate A41 - 9-Bromo-l-(4-chiorophenyl)nonan-l-one
9-Bromononanoyl chloride was obtained from the carboxylic acid (reference 12) by treatment with thionyl chloride. 9-Bromo-l-(4-chlorophenyl)nonan-l-one was prepared analogously to intermediate Al. 'H-NMR (CDC13) δ 1.2-2.0 (12H,m), 2.95 (2H,t), 3.41 (2H.t), 7.44 (2H,m) and 7.90 (2H.m).
Intermediate A42 - N-(6-(4-Fluorophenyl)hexyI)-2-bromoacetamide
To a solution of 6-(4-fluorophenyl)-l-hexylamine (21.8g) in dry dichloromethane (200ml) at 0°C under an argon atmosphere was added diisopropylethylamine (14.4g) followed by bromoacetyl bromide (22.5g) over 30min whilst maintaining the temperature between 0-5°C. The resulting orange solution was stirred at 0-5°C for 45min and evaporated to dryness. The residue was mixed with diethyl ether and the hydrobromide salt filtered off. The filtrate was evaporated under reduced pressure and the residue was chromatographed on silica gel using 5: 1 to 3:2 40-60°C petroleum ether : ethyl acetate as eluents. This gave a yellow oil that was triturated with 40-60°C petroleum ether, filtered and dried to give N-(l-(4-fluorophenyl)-hexyl) bromoacetamide (24.8g). 'H-NMR (CDCI3) δ 1.25-1.45 (4H.m), 1.45-1.75 (4H,m), 2.57 (2H,t), 3.28 (2H,q), 3.88 (2H,s), 6.5 (lH.bs), 6.85-7.05 (2H.m) and 7.05-7.2 (2H.m). Intermediate A43 - l-Bromo-4-(3-phenylpropyloxy)butane
Prepared as in reference 13. Intermediate A44 - 6-(4-Chlorobenzoylamino)hexan-l-ol
To a solution of 6-amino-l-hexanol (12.9g) and diisopropylethylamine (11.9g) in dry dichloromethane (100ml) at 5°C was added 4-chlorobenzoyl chloride (16. lg) in dry dichloromethane at such a rate to maintain the temperature below 10°C. After stirring for 16h, the mixture was poured into water and filtered. The solid was washed with water, 2M hydrochloric acid (150ml), water, dichloromethane and was dried under reduced pressure to give 6-(4-chlorobenzoylamino) hexan-1-ol (19.2g). Η-NMR (d6-DMSO) δ 1.25-1.65 (8H,m), 3.24 (2H.q), 3.38 (2H,t), 7.52 (2H,m), 7.84 (2H,m) and 8.54 (lH,bt)
Intermediate A45 - l-Bromo-6-(4-chlorobenzoylamino)hexane
6-(4-Chlorobenzoylamino)hexan-l-ol (17.0g) was refluxed in 48% hydrobromic acid (260ml) for 2.5h. The mixture was cooled and added to water (450ml) and diethyl ether (450ml). The organic layer was washed with saturated sodium bicarbonate (450ml) and brine (450ml) and was dried over magnesium sulfate. Evaporation followed by recrystallisation from diethyl ether gave l-bromo-6-(4-chlorobenzoylamino)hexane (8.6g). 'H-NMR (CDC13) δ 1.3-2.0 (8H,m), 3.35-3.55 (4H,m), 6.15 (lH,bs), 7.40 (2H,m) and 7.70 (2H,m).
Intermediate Bl - Ethyl 3-(5-pyrimidinyl)acrylate
A mixture of 5-bromopyrimidine (5.93g), ethyl acrylate (5.08g), palladium acetate (0.112g), triphenyl phosphine (0.23g) and triethylamine (4.5g) was stirred at 150°C in a pressure vessel for 6 hours. After cooling overnight, water (50ml) was added to the dark residue, and the product was extracted into toluene. Drying, charcoaling and evaporation gave a pale oil, which was triturated with pet. ether to obtain ethyl 3-(5- pyrimidyl)acrylate (4.78g). 'H-NMR (CDC13) δ 1.36 (3H,t), 4.27 (2H,q), 6.59 (lH,d), 7.62 (lH,d), 8.88 (2H,s), 9.20 (lH,s).
Intermediate B2 - Ethyl 3-(5-pyrimidyl)propionate
To a solution of ethyl 3-(5-pyrimidyl)acrylate (4.75g) in ethanol (90ml) was added 5% palladium on charcoal (0.2g). The mixture was hydrogenated at an initial pressure of 50 psi, then filtered to remove catalyst and the solvent evaporated. Water was added, and the product extracted into ether. Drying, charcoaling and evaporation gave ethyl 3-(5- pyrimidyl)propionate (2.3g) as a yellow oil. 'H-NMR (CDC13) δ 1.23 (3H,t), 2.69 (2H,t), 2.96 (2H,t), 4.14 (2H,q), 8.635 (2H,s) and 9.09 (lH,s).
Intermediate B3 - Ethyl 2-formyl-3-(5-pyrimidyl)propionate o
BO J HO N
A mixture of ethyl 3-(5-pyrimidyl)propionate (2.28g) and ethyl formate (1.41ml) dissolved in dry dimethoxyethane (5ml) was added dropwise over 30 min to a suspension of sodium hydride (60%, 4.0g) in DME (5 ml) under nitrogen, keeping the temperature below 0°C. Stirring was continued for a further 24h. then the mixture was poured onto ice and washed with ether. The aqueous layer was adjusted to pH 7, then evaporated and the residue extracted with acetone. Filtration and evaporation gave crude product, which was taken up in ethyl acetate, charcoaled, dried and evaporated to give ethyl 2-formyl-3- (5-pyrimidyl)propionate. Like other compounds of this type, this proved difficult to characterise and was used without further purification.
Intermediate B4 - 3-(5-Pyrimidyl)acrylic acid o
HO ' Y '-N
A mixture of 5-bromopyrimidine (lOOg), acrylic acid (48g), triphenylphosphine (2.5g) and palladium II acetate (O. lg) was refluxed in tri-n-butylamine (260ml) with overhead stirring for 4.5h at 145-160°C. The mixture was cooled and a 10% solution of potassium carbonate (2L) added followed by dichloromethane (500mL). The organic layer was separated and the aqueous phase extracted with diethyl ether (3 x 300ml). The aqueous layer was brought to pH 3 with concentrated hydrochloric acid (ice-cooling) and the solid so formed was filtered and dried in vacuo to give 3-(5-pyrimidyl)acrylic acid (35g). Η- NMR (d6-DMSO) δ 6.82(lH,d), 7.60( lH.d) and 9.15(3H, 2xs)
Intermediate B5 - Methyl 3-(5-pyrimidinyl)acrylate
3-(5-Pyrimidyl)acrylic acid ( lOOg) was added to a mixture of dry methanol (2L) and 4M hydrogen chloride in dioxan (445ml) and allowed to stir at 60°C under argon for 18h. The mixture was cooled, and the solvent removed under reduced pressure. The residue was partitioned between dichloromethane (500ml) and was washed with saturated sodium bicarbonate (300ml). The aqueous layer was extracted with dichloromethane and the combined dichloromethane layers were dried over magnesium sulfate and evaporated in vacuo to give methyl 3-(5-pyrimidinyl)acrylate (85g). 'H-NMR (d6-DMSO) δ 3.82(3H,s), 7.03(lH,d), 7.75(lH,d) and 9.28(3H,s)
Intermediate B6 - Methyl 3-(5-pyrimidyl)propionate
To a solution of methyl 3-(5-pyrimidyl)acrylate (85g) in glacial acetic acid was added 10% palladium on charcoal (11.3g) and ammonium formate (74.2g) under argon. The mixture was heated at 110°C for 20min, cooled and the solvent removed in vacuo. The resulting oil was dissolved in dichloromethane (1.5L) and washed with saturated sodium bicarbonate (750ml). The aqueous layer was extracted with further dichloromethane (200ml), the organic layers were combined and dried over magnesium sulfate. Removal of the solvent under reduced pressure gave an oil. This was distilled under reduced pressure to give methyl 3-(5-pyrimidyl)propionate (26g). Η-NMR (CDC13) δ 2.69(2H,t), 2.97(2H.t), 3.70(3H,s), 8.65(2H,s) and 9.12(lH,s)
Intermediate B7 - Methyl 2-(5-pyrimidyl)methyl)-3-methoxyacrylate
0 MeO eO^ N
A mixture of methyl 3-(5-pyrimidyl)propionate (13. lg) and methyl formate (7.1ml) dissolved in dry dimethoxyethane (20ml) was added portionwise to a suspension of sodium hydride (60%, 4.0g) in DME (10ml) under argon. Reaction initiated rapidly and was stirred for a further 2h, diluted with dry diethyl ether (50ml) and filtered. The solid so separated was washed with further diethyl ether (50ml) and was dried in vacuo to give a solid that was dissolved in dry dimethyl formamide (50ml) and potassium carbonate (1 1.3g) added under argon. A solution of dimethyl sulfate (7.0ml) was then added over 1 hour. The mixture was stirred for 18h and the solvent removed in vacuo. The residue was partitioned between ethyl acetate (200ml) and water (100ml). The aqueous layer was re-extracted with ethyl acetate (2 x 100ml) and the combined ethyl acetate layers washed with brine (50ml) and dried over sodium sulfate. The solvent was removed in vacuo to give methyl 2((5-pyrimidyl)methyl)-3-methoxyacrylate (9.1g).
Intermediate B8 - 2-(5-Pyrimidyl)methyl)-3-methoxyacrylic acid
To methyl 2-((5-pyrimidyl)methyl)-3-methoxyacrylate (9.0g) was added, with stirring, a solution of sodium hydroxide (3.5g) in water (43ml) at RT under argon. After 20h, the pH of the solution was brought to 3.5 with concentrated hydrochloric acid. Sonication of the oil so formed gave 2-((5-pyrimidyl)methyl)-3-methoxyacrylic acid (5.4g) as a pale yellow solid.
Intermediate B9 - 5-(Pyrimid-5-ylmethyI)-2-thiouracil
Sodium (0.25 g) was dissolved in ethanol (5 ml), thiourea (0.77 g) added, and the mixture stirred under reflux for 1 hour. A solution of ethyl 2-formyl-3-(5-pyrimidyl)propionate (1.99 g) in ethanol (5 ml) was added slowly, and reflux continued for 18 hours. The solvent was evaporated, and the residue taken up in water and washed with dichloromethane. The aqueous solution was acidified to pH 5, and the precipitate filtered off, washed with water and dried to obtain 5-(pyrimid-5-ylmethyl)-2-thiouracil (0.71 g). 'H-NMR (d6-DMSO) δ 3.58 (2H,s), 7.54 (lH,s), 8.70 (2H,s) and 9.02 (lH,s). MPt 265- 6°C
Intermediate B10 - 5-((l-Benzyl-2-oxo-pyrid-4-yl)methyl)-2-thiouracil
Prepared from methyl 2-(l-benzyl-2-oxo-pyrid-4-yl)methyl)-3-hydroxyacrylate (reference 7) analogously to intermediate B9. Η-NMR (d6-DMSO) δ 5.04 (2H,s), 6.15 (lH,dd), 6.21 (lH.bs), 7.2-7.4 (5H,m), 7.45 (lH,s) and 7.67 (lH,d); (El) M=325. CI7H15N302S requires 325.
Intermediate Bll - 5-((l-Methyl-2-oxo-pyrid-4-yl)methyl)-2-thiouracil
Prepared from methyl 2-( l-methyl-2-oxo-pyrid-4-yl)methyl)-3-hydroxyacrylate (reference 7) analogously to intermediate B9. Η-NMR (CD3OD) δ 3.50,3.51 (5H,2xs), 6.32 (lH.dd), 6.40 (lH,bs), 7.35 (lH.s) and 7.54 (lH,d).
Intermediate B12 - 5-((2,3-Dimethylpyrid-5-yl)methyl)-2-thiouracil
Prepared analogously to intermediate B9. 'H-NMR (d6-DMSO) δ 2.19
(3H,s), 2.35 (3H,s), 7.36 (2H,m) and 8.13 (lH,bs) Intermediate B13 - 5-(Fur-2-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B9. 'H-NMR (d6-DMSO) δ 3.58 (2H, s), 6.11 (IH, m), 6.35 (IH, m), 7.27 (IH, s), 7.52 (IH, m), 12 41 (2H, br.m). Mpt 205-7°C (dec)
Intermediate B14 - 5-(Pyrazin-2-ylmethyl)-2-thiouracil
Prepared from methyl 3-(2-pyrazinyl)propionate (reference 10) analogously to intermediate B9. 'H-NMR (d6-DMSO) δ 3.77 (2H.s), 7.48 (lH,s), 8.46 (lH,d), 8.51 ( lH.t) and 8.59 (lH,d). Mpt 265-7°C (dec)
Intermediate B 15 - 5-(Fur-3-ylmethyl)-2-thiouracil
Prepared from methyl 3-(3-furyl)propionate (reference 9) analogously to intermediate B9. 'H-NMR (d6-DMSO) δ 3.33 (2H, s). 6.38 (IH, m), 7.19 (IH, s), 7.47 (IH, m), 7.56 (IH, m). Mpt 197-9°C (dec)
Intermediate B 16 - 5-(Quinolin-3-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B9. ' H-NMR (d6-DMSO) δ 3.77 (2H, s), 7.54 (2H, m). 7.71 ( IH, m), 7.94 (2H, m), 8.14 (IH, m), 8.84 (IH, m) Mpt 274-9°C
Intermediate B17 - 5-(2-(Pyrid-4-yl)ethyI)-2-thiouracil
Prepared analogously to intermediate B9. • H-NMR (d6-DMSO) δ 2.53 (2H,t), 2.77 (2H,t). 7.20 (3H.m) and 8.45 (2H,m). MPt 265-7°C (dec)
Intermediate B18 - 5-(Pyrid-2-ylmethyl)-2-thiouracil
Prepared as in reference 2. Intermediate B19 - 5-(Pyrid-3-ylmethyl)-2-thiouracil
Prepared as in reference 11.
Intermediate B20 - 5-(Pyrid-4-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B9. Η-NMR (d6-DMSO) δ 3.57 (2H, s), 7.25 (2H, m), 7.47 (IH, s), 8.44 (2H, m), 12.43 (2H, br. m) Mpt >250°C
Intermediate B21 - 5-((2-Methylpyrid-5-yl)methyl)-2-thiouracil
Prepared as in reference 5.
Intermediate B22 - 5-(Thiazol-2-ylmethyl)-2-thiouracil
Prepared as in reference 2.
Intermediate B23 - 5-Benzyl-2-thiouracil
Prepared as in reference 6.
Intermediate B24 - 5-(Pyrid-3-ylmethyl)-2-(nitroamino)pyrimidin-4-one
Prepared as in reference 4. Intermediate B25 - 5-(2-Methoxypyrid-4-ylmethyl)-2-(nitroamino)pyrimidin-4-one
Prepared as in reference 3. Intermediate B26 - 5-(4-Methoxypyrid-2-ylmethyl)-2-(nitroamino)pyrimidin-4-one
0
X -- -- .OMe
02N_ ■■ N-^-'
H H Prepared as in reference 4. Intermediate B27 - 5-((l-Butyl-2-oxo-pyrid-4-yl)methyl)-2-(nitroarnino)pyrimidin- 4-one
Prepared as in reference 7.
Intermediate B28 - 5-((l-Oxo-2-methylpyrid-5-yl)methyl)-2- (nitroamino)pyrimidin-4-one
Prepared as in reference 3.
Intermediate B29 - 5-((2,4-Dimethylpyrid-5-yl)methyl)-2-(nitroamino)pyrimidin-4- one
Prepared as in reference 8. Intermediate B30 - 3-(l-Methylpyrazol-4-yl)acrylic acid
A mixture of l-methylpyrazole-4-carboxaldehyde (made as in reference 15) (18.1 g), malonic acid (17.1 g), pyridine (15 ml) and piperidine (0.2 ml) was heated to 100°C for 1 hour. After cooling, water was added, followed by aqueous ammonia to obtain a clear solution, which was acidified to pH5 with hydrochloric acid. The resulting solid was filtered off. washed with water and dried to obtain 3-(l-methylpyrazol-4-yl)acrylic acid ( 18.9 g). 'H-NMR (d6-DMSO) δ 3.83 (3H,s), 6.18 (lH,d), 7.44 (lH,d), 7.83 (lH,s), 8.07 ( lH.s). (APCI) M+H=153. C7H8N202 requires 152. Intermediate B31 - Methyl 3-(l-methylpyrazol-4-yI)acrylate
N — ^N'
3-(l-Methylpyrazol-4-yl)acrylic acid (18.86 g) was added to a solution of sulphuric acid
( 15 ml) in methanol (150 ml), and the mixture refluxed for 2 hours, cooled, and poured onto ice. The acid was neutralised with solid sodium carbonate and the product extracted into dichloromethane, which was dried and evaporated. Crystallisation from ether/petrol gave methyl 3-(l-methylpyrazol-4-yl)acrylate (16.0 g). Η-NMR (d6-DMSO) δ 3.77
(3H,s), 3.91 (3H,s), 6.16 (lH,d), 7.54 (lH,s), 7.56 (lH,d), 7.69 (lH,s). (APCI)
M+H=167. C8H,oN202 requires 166. Intermediate B32 - Methyl 3-(l-methylpyrazol-4-yl)propionate
Prepared analogously to intermediate B6. 'H-NMR (d6-DMSO) δ 2.56 (2H,t), 2.79 (2H,t), 3.67 (3H,s), 3.85 (3H,s), 7.17 (lH,s), 7.31 (3H,s). (APCI) M+H=169. C8H12N202 requires 168.
Intermediate B33 - Methyl 2-formyl-3-(l-methylpyrazol-4-yl)propionate, sodium salt
Sodium hydride (2.62 g, 60% in oil) was washed with petrol and suspended in dry dimethoxyethane (20 ml). Methyl 3-(l-methylpyrazol-4-yl)propionate (8.8 g) and methyl formate (4.87 ml) were dissolved in DME (20 ml), and a few drops of the mixture added to the sodium hydride suspension, which was warmed briefly to initiate the reaction before continuing dropwise addition at a rate which sustained controlled evolution of hydrogen. The mixture was stirred for a further 16 hours at room temperature, then diluted with ether. The solid was filtered off, washed with ether and immediately dried, and was used promptly without further purification.
Intermediate B34 - 5-((l-Methylpyrazol-4-yl)methyl)-2-thiouracil
Prepared analogously to intermediate B9, except using the preformed sodium salt instead of adding sodium ethoxide. Η-NMR (d6-DMSO) δ 3.33 (3H,s), 3.75 (3H,s), 7.15 (lH,s), 7.23 (lH.s), 7.46 ( lH.s), 12.2 (lH.br s), 12.4 (lH,br s). (APCI) M+H=223. C9H10N4OS requires 222.
Intermediate B35 - Ethyl 3-(2-methoxypyrimidin-5-yl)acrylate
A mixture of 2-methoxy-5-bromopyrimidine (75.43 g, 0.399 mol), ethyl acrylate (47.5 ml, 0.439 mol), palladium (II) acetate ( 1.07 g, 0.0048 mol). tri-o-tolylphosphine (2.92 g, 0.0096 mol) and triethylamine (84 ml) were heated at 135°C with stirring under argon for 12 h. After allowing to cool the solid mass was dissolved in water and ethyl acetate, filtered, and the aqueous phase separated and further extracted with ethyl acetate. The combined extracts were washed with saturated aqueous ammonium chloride, dried
(MgS04) and evaporated. The solid thus obtained was triturated with ether/light petrol (1:3, 350 ml), filtered, washed and dried, yield 52.41 g (63%). Η-NMR (CDC13) δ 1.33 (3H, t), 4.06 (3H, s), 4.28 (2H, q), 6.45 (IH, d), 7.58 (IH, d), 8.67 (2H, s); MS (APCI+) found (M+H) = 209; C10H12N2O3 requires 208.
Intermediate B36 - Ethyl 3-(2-methoxypyrimidin-5-yl)propionate
A suspension of ethyl 3-(2-methoxypyrimidin-5-yl)acrylate (52.4 g, 0.252 mol) in ethanol (400 ml) and triethylamine (50 ml) was treated with 10% palladium on carbon (3 g) and hydrogenated at 50 psi for 1.75 h. The catalyst was filtered off through hyflo and the filtrate evaporated. The residue was dissolved in dichloromethane, washed twice with saturated aqueous ammonium chloride, dried (MgS04) and evaporated to an oil, yield 41.2 g (78%). 'H-NMR (CDC13) δ 1.23 (3H, t), 2.61 (2H, t), 2.87 (2H, t), 3.99 (3H, s), 4.13 (2H, q), 8.39 (2H, s); MS (APCI+) found (M+H) = 211; C10H14N2O3 requires 210.
Intermediate B37 - 2-(Methoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid, mixed methyl/ethyl esters
To a stirring suspension of sodium hydride (0.83 g of a 60% dispersion in oil) in anhydrous 1, 2-dimethoxyethane (6 ml) was added dropwise a solution of methyl formate ( 1.54 ml) and ethyl 3-(2-methoxypyrimid-5-yl)propionate (3.5 g) in anhydrous 1,2- dimethoxyethane (6 ml) at such a rate as to maintain the reaction temperature at 25-30°C. After 1 h. ether was added and the precipitated oil allowed to settle. The solution was decanted off and replaced with fresh ether, and the oil slowly solidified. The solid 2- (hydroxymethylene) derivative was filtered, washed and dried, yield 3.8 g. A 1.33 g portion was suspended in dimethyl formamide ( 10 ml) together with anhydrous potassium carbonate ( 1.15 g), and a solution of dimethyl sulphate (0.48 ml) in dimethylformamide (10 ml) was added dropwise with stirring over 30 min. After 16 h the solvent was evaporated and the residue treated with water and extracted with ethyl acetate. The extracts were washed with water, dried (MgS04) and evaporated to give the product as an oil, yield 0.91 g. 'H-NMR (CDC13) δ 1.23 (3H, t), 3.46 (2H, s), 3.69 (3H, s, methyl ester), 3.88 (3H. s), 3.97 (3H. s), 4.16 (2H. q), 7.39 (IH, s), 8.40 (2H, s). 3:2 ratio of methyhethyl esters. MS (APCI+) found (M+l) = 253, 239 (ethyl and methyl esters); C12H16N204 requires 252. CuH14N204 requires 238.
Intermediate B38 - 2-(Methoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid
A suspension of the mixed esters of intermediate 5 (0.9 g) in 2M aqueous sodium hydroxide (3.6 ml) was stirred at ambient temperature for 16 h to give a clear solution. This was diluted with water, extracted with dichloromethane and evaporated to about half volume, then acidified to pH 3-4 (2M hydrochloric acid) when the product crystallised out. The white solid was filtered, washed with ice-cold water and dried, yield 0.46 g. Η- NMR (CDC13) δ 3.43 (2H, s), 3.91 (3H, s), 3.99 (3H, s,), 7.49 (IH, s), 8.42 (2H, s); MS (APCI+) found (M+l) = 225, C10H12N2O4 requires 224.
Intermediate B39 - 5-(2-Methoxypyrimidin-5-ylmethyl)-2-thiouracil
To an ice cooled solution of potassium t-butoxide (7.83 g, 0.07 mol) in anhydrous THF (60 ml) was added dropwise with stirring under argon over 1 hour to a solution of ethyl 3- (2-methoxypyrimidin-5-yl) propionate (5.87 g, 0.028 mol) and methyl formate (3.6 ml, 0.059 mol) in anhydrous ether (70 ml). After stirring for 16 h, the solvents were evaporated, thiourea (4.25 g, 0.056 mol) and propan-2-ol (80 ml) added and the mixture refluxed for 5 h. The solvent was evaporated and the residue dissolved in water, extracted twice with ether and acidified to pH 4.5 with acetic acid. The solid which precipitated was filtered, washed well with water and dried, yield 5.57 g (80%). Η-NMR (d6-
DMSO) δ 3.47 (2H, s), 3.85 (3H, s), 7.43 (IH, s), 8.48 (2H, s), 12.25 (IH, br s), 12.46 (IH, br s); MS (APCI+) found (M+H) = 251; C10H10N4O2S requires 250.
Intermediate B40 - 5-(2-Benzyloxypyrimid-5-ylmethyl)-2-thiouracil
a solution of benzyl alcohol (20ml) in dry dimethylformamide (20ml) was added sodium hydride ((60% in oil) 2.3g) over 0.5h under argon. A slurry of 2- methoxypyrimidyl thiouracil (3.6g) in dry dimethylformamide (10ml) was added in one portion and the solution heated to 80°C for 2.5h. After cooling, the solvent was removed under reduced pressure and the residue partitioned between diethyl ether and water. The aqueous layer was washed with further diethyl ether and then acidified to pH4 with glacial acetic acid. The solid so formed was filtered, washed with water and diethyl ether and dried in vacuo to give the desired material. ' H-NMR (d6-DMSO) δ 3.49 (2H,s), 5.36 (2H,s), 7.2-7.5 (6H,m), 8.50 (2H.s); MS (APCI+) found (M+l) = 327; C16H14N402S requires 326.
Intermediate B41 - Methyl 2-benzyl-3-methoxyacrylate
Prepared analogously to intermediate B7. Intermediate B42 - 2-Benzyl-3-methoxyacrylic acid
Prepared analogously to intermediate B8.
Intermediate B43 - Methyl 2-(l-methyl-2-oxo-pyrid-4-yl)methyl)-3- methoxyacrylate
Prepared from methyl 3-(l-methyl-2-oxo-pyrid-4-yl)propionate
(reference 7) analogously to intermediate B7.
Intermediate B44 - 2-((l-Methyl-2-oxo-pyrid-4-yl)methyI)-3-methoxyacrylic acid
0 repare ana ogous y to nterme ate
Intermediate B45 - l-(Pyrid-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
2-((5-pyrimidyl)methyl)-3-methoxyacrylic acid (5.5g) was slurried in dry dichloromethane (100ml) and oxalyl chloride (4.3ml) added over 5min. After stirring at RT for 3h. the solvent was removed in vacuo and the residue triturated with toluene. The solvent was removed in vacuo to give a solid that was slurried in dry acetonitrile (100ml) under Ar. Dried powdered potassium thiocyanate (3.25g) was added in one portion at RT and the mixture was stirred for 15h. Removal of the solvent in vacuo gave a solid that was slurried with dry dimethylformamide (90ml). One ninth of the slurry was added to triethylamine (0.42ml) and 2-pyridylmethylamine (0.49g). The mixture was stirred for 19h under argon and a solution of sodium ethoxide (3M) in ethanol (1.5ml) was added in one portion. The mixture was heated on an oil bath (bath temp 101°C) for 2h, cooled and the solvent removed under reduced pressure. The residue was dissolved in water (12ml) and brought to pH 4 with glacial acetic acid. The solid so formed was filtered and dried in vacuo to give l-(pyrid-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil (0.69g). Η- NMR (d6-DMSO) δ 3.63(2H,s), 5.47(2H,s), 7.2-7.4(2H,m), 7.7-7.85(lH,m), 8.04(lH,s), 8.5(lH,m), 8.7(2H,s) and 9.04( lH.s); (APCI) M+H=312. C15H13N5OS requires 311. Intermediate B46 - l-(4-Hydroxycyclohexyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.0-2.0(8H.m), 3.63(2H,s), 8.10(lH,s), 8.72(2H,s) and 9.02(lH.s); (ES-) Found (M-l)=317. C , 5H , 8N402S requires 318.
Intermediate B47 - l-(3-(l-Imidazolyl)prop-l-yl)-5-(pyrimid-5-ylmethyI)-2- thiouracil
Prepared analogously to intermediate B45. ! H-NMR (d6-DMSO) δ 2.22 (2H, m), 3.58 (2H, s), 4.13 (4H, m), 7.12 (IH, m), 7.36 (IH, m), 7.88 (IH, s), 8.08 (IH, s), 8.73 (2H, s), 9.05 (IH, s), 12.68 (IH, br s); (APCI+) Found (M+l) =329. C15H16N6OS requires 328
Intermediate B48 - l-(3-(l-MorphoIino)prop-l-yl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 2.35-2.6(6H+d5-
DMSO.m), 3.4-3.8(6H+HOD.m), 4.19(2H,t), 7.96(lH,s), 8.74(2H,s) and 9.04); (APCI+) Found (M+l)=348. C16H21N502S requires 347.
Intermediate B49 - l-(3-(2-Oxo-l-pyrrolidino)prop-l-yl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 1.91 (4H, m), 2.20 (2H, t), 3.24 (2H. t). 3.37 (2H, t), 3.58 (2H, s), 4.09 (2H, t), 7.97 (IH, s), 8.74 (2H. s). 9.04 (IH, s); (APCI+) Found (M+l) =346. C16H19N502S requires 345 Intermediate B50 - l-(3-Ethoxycarbonylprop-l-yI)-5-(pyrimid-5-ylmethyI)-2- thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 1.17(lH.t), 1.98(2H,m), 2.34(2H.t), 3.59(2H,s), 4.04(2H,q), 4.16(2H,t), 7.90(lH,s), 8.75(2H,s) and 9.03(lH,s); (ES+) Found (M+l)=335. C15H18N403S requires 334.
Intermediate B51 - l-(3-DimethyIaminoprop-l-yl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 2.21(6H,s),
3.60(2H,s), 4.15(2H,t), 7.91(lH,s), 8.72(2H,s), 9.03(lH,s); (APCI+) Found (M+l)=306. C14H19N502S requires 305.
Intermediate B52 - l-(3-Hydroxyprop-l-yl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
HO-^ Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.85(2H,m), 3.45(2H.b), 3.61(2H.s), 4.19(2H.t). 4.65(lH,bs), 7.85-8.0(2H,m), 8.71(2H,s) and 9.04(lH.s); (APCI) M+H=279. C12H14N402S requires 278.
Intermediate B53 - l-(3-Hydroxyprop-l-yl)-5-benzyl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.85(2H,m),
3.46(2H.m), 3.56(2H.s), 4.19(2H,t), 4.65(lH,t), 7.1-7.4(5H,m) and 7.81(lH,s); (FAB) M+H=277. C14H16N202S requires 276.
Intermediate B54 - l-(3-Methoxyprop-l-yl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 1.94(2H,m), 3.21(3H,s), 8.55(2H,s), 4.20(2H,t), 7.88(lH,s), 8.72(2H,s) and 9.03(lH,s); (ES-) Found (M-l)=291. C19H22BrClN202S requires 292.
Intermediate B55 - l-(3-Phenylprop-l-yl)-5-(pyrimid-5-ylmethyI)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 2.04(2H,m),
2.63(2H,t), 3.58(2H.s), 4.18(2H,t), 7.1-7.35(5H,m), 7.92(lH,s), 8.72(2H,s) and
9.03(lH,s); (APCI+) Found (M+l )=339. C18H18N4OS requires 338.
Intermediate B56 - l-(5-Hydroxypent-l-yI)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ (HOAc salt) 1.79(3H,s), 3.59(2H,s), 4.13(2H,t), 7.96(lH,s), 8.72(2H,s) and 9.02(lH,s); (APCI+) Found (M+l)=307. C14H18N402S requires 306.
Intermediate B57 - l-(Pyrid-2-ylmethyl)-5-benzyl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.59(2H,s),
5.49(2H,s), 7.1-7.45(7H,m), 7.79( lH,m), 7.95(lH,s) and 8.51(lH,m); MPt 171-4°C; (El) M=309. C17H15N3OS requires 309.
Intermediate B58 - l-(Pyrid-3-ylmethyl)-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.11 (3H, s), 3.15 (2H, s), 5.21 (2H, s), 5.86 ( IH, m), 5.95 (IH, ), 7.15 (IH, m), 7.34 (IH, m), 7.52 (IH, m), 7.80 (IH, s), 8.26 (IH, m), 8.34 (IH, m), 12.55 (IH, br. s); (APCI+) Found (M+l) 341. C17H16N402S requires 340
Intermediate B59 - l-(Pyrid-3-ylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.49 (2H, s), 5.33 (2H, s), 7.28 (IH, m), 7.64 (IH, m), 7.97 (IH, s), 8.42 (2H, m), 8.59 (2H, s), 8.88 (IH, m), 12.70 (IH, br. s) Mpt >250°C
Intermediate B60 - l-(Pyrid-3-ylmethyl)-5-benzyl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.57(2H,s), 5.46(2H,s), 7.1-7.35(5H.m), 7.40(lH,m), 7.75(lH.s), 8.02(lH,s), 8.51(lH,m) and 8.59(lH,m). MPt 236-8°C; (El) M=309. C17H15N3OS requires 309.
Intermediate B61 - l-(Pyrid-4-ylmethyl)-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.39(3H,s), 5.45(2H,s). 6.1 l(lH,dd), 6.21( lH.m), 7.25(2H.m), 7.58(lH,d), 7.96(lH,s) and 8.54(2H,m). MPt 181-3°C; (El) M=340. C17H16N402S requires 340.
Intermediate B62 - l-(Pyrid-4-ylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.64 (2H, s), 5.45 (2H, s), 7.28 (2H, m), 8.00 (IH, s), 8.55 (2H, m), 8.73 (2H, m), 9.05 (IH, m), 12.85 (IH, br s) Mpt >250°C Intermediate B63 - l-(Pyrid-4-ylmethyl)-5-benzyI-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.58(2H,s), 5.46(2H,s), 7.1-7.4(7H,m), 7.93(lH,s) and 8.54(2H.m); MPt 174-6°C; (El) M=309. C17H15N3OS requires 309.
Intermediate B64 - l-(Pyrid-4-ylmethyl)-2-thiouracil
Prepared from 3-methoxyacrylic acid, analogously to intermediate B45. 'H-NMR (d6- DMSO) δ 5.45(2H,s), 6.03(2H,d), 7.23(2H,m), 7.94(2H,d) and 8.54(2H,m); MPt 267- 70°C; (EI) M=219. C10H9N3OS requires 219.
Intermediate B65 - l-(2-(Pyrid-2-yl)ethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.22(2H,t), 3.51(2H,s), 4.51(2H,t), 7.25(2H.m). 7.7(2H,m), 8.47( lH,m). 8.61(2H,s) and 9.03(lH,s); (APCI+) Found (M+l )=326. C16H15N5OS requires 325.
Intermediate B66 - l-(2-(Pyrid-3-yl)ethyl)-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.08 (2H, t), 3.29 (2H, s), 3.37 (3H, s). 4.38 (2H, t), 5.96 (IH, m), 6.13 (IH, m), 7.34 (IH, m), 7.60 (IH, m), 7.67 (IH, m), 7.71 (IH, s), 8.46 (2H, m), 12.73 (IH, br. s); (APCI+) Found (M+l) 355. C18H18N402S requires 354 Intermediate B67 - l-(2-(Pyrid-3-yl)ethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
HN YN
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.08(2H,t), 3.53(2H,s), 4.36(2H,t), 7.3(lH,m), 7.65(lH,m), 7.78(lH,s), 8.45(2H,bs), 8.65(2H,s) and 9.05(lH,s); (APCI+) Found (M+l )=326. C16H15N5OS requires 325.
Intermediate B68 - l-(2-(Pyrid-4-yI)ethyl)-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.07 (2H, t), 3.30 (2H, s), 3.37 (3H, s), 4.39 (2H, t), 5.94 (IH, m), 6.15 (IH, m), 7.27 (2H, m), 7.56 (IH, m), 7.72 (IH, s), 8.48 (2H, m), 12.72 (IH, br. s); (APCI+) Found (M+l) = 355. C18H18N402S requires 354
Intermediate B69 - l-(2-(Pyrid-4-yl)ethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.16(2H,t),
3.54(2H,s), 4.45(2H,t), 7.48(2H.d), 7.82(lH,s), 8.60(2H,d), 8.67(2H,s) and 9.05(lH,s); (ES+) Found (M+l)=326. C16H15N5OS requires 325.
Intermediate B70 - l-(2-Phenylethyl)-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2- thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 3.04(2H,t), 3.27(3H,s), 4.35(2H,t), 5.93(lH,m), 6.12(lH,bs), 7.1-7.45(5H,m), 7.56(lH,d) and 7.67(lH,s); MPt 230-3°C; (APCI) M+H=354. C19H19N302S requires 353.
Intermediate B71 - Benzyl-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.38(s), 5.44(2H,s), 6.07(lH.m), 6.18(lH,m), 7.1-7.5(5H,m), 7.57(lH,d) and 7.96(lH,s). (El) M=339. C18H,7N302S requires 339.
Intermediate B72 - l,5-Dibenzyl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (CDC13) δ 3.63(2H,s), 5.35(2H,s), 6.84(lH,s) and 7.05-7.45(10H,m). MPt 151-2°C; (El) M=308. C18H16N2OS requires 308.
Intermediate B73 - l-(2-Thienylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 3.60 (2H, s), 5.58 (2H, s), 7.03 (IH, m), 7.26 (IH. m), 7;50 (IH, m), 8.08 (IH, s), 8.69 (2H, s), 9.04 (IH, s), 12.18 (lH, br s) (APCI+) Found (M+l ) =317. C]4H12N4OS, requires 316
Intermediate B74 - l-(2,2-Dimethylprop-l-yl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 0.96(9H,s), 3.62(2H,s), 4.17(2H,s), 7.77(lH,s), 8.73(2H,s) and 9.04(lH,s); (APCI+) Found (M+l)=291. C14H18N4OS requires 290. Intermediate B75 - l-(2-(l-Piperidino)ethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
P 0repared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 1.28-1.72 (6H, m), 2.50 (4H, m), 2.73 (2H, t), 3.61 (2H, s), 4.29(2H, t), 7.80 (IH, s), 8.73 (2H, s), 9.05 (IH, s), 12.71 (IH, br s); (APCI+) Found (M+l) =332. C16H2,N5OS requires 331
Intermediate B76 - l-(2-Acetylaminoethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.75(3H,s), 3.43(2H,m), 3.61(2H,s), 4.18(2H,t), 7.78(lH,s), 8.03(lH,bt), 8.73(2H,s) and 9.03(lH,s); (ES+) Found (M+l )=306. C13H15N502S requires 305.
Intermediate B77 - l-(2-Hydroxyethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.60(2H,s), 3.72(2H,bq), 4.21(2H,t), 4.99(lH,t), 7.83(lH,s), 8.73(2H.s) and 9.03(lH.s); (ES+) Found (M+l)=265. CUH121N402S requires 264.
Intermediate B78 - l-(2-Hydroxyethyl)-5-benzyl-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 3.55(2H,s), 3.71(2H,bm), 4.20(2H,t), 4.99(lH.bs), 7.1-7.45(5H,m) and 7.70(lH,s); MPt 171-3°C; (FAB) M+H=263. C13H14N202S requires 262. Intermediate B79 - l-Dimethylaminocarbonylmethyl-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 2.86 (3H, s), 3.02 (3H, s), 3.61 (2H, s), 5.09 (2H, s), 7.76 (IH, s), 8.71 (2H, s), 9.05 (IH, s); (APCI+) Found (M+l) =306. C13H15N502S requires 305
Intermediate B80 - l-Ethoxycarbonylmethyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 1.19 (3H, t), 3.62 (2H, s), 4.16 (2H, q), 4.94 (2H, s), 7.88 (IH, s), 8.73 (2H, s), 9.06 (IH, s); (APCI+) Found (M+l) =307. C13H14N403S requires 306
Intermediate B81 - l-(Fur-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 3.62 (2H. s), 5.43 (2H, s), 6.47 (2H, m), 7.66 (IH. m), 7.98 ( IH, s), 8.70 (2H. s), 9.04 (IH, s), 12.75 (IH, br s); (APCI+) Found (M+l) =301. C14H12N402S requires 300
Intermediate B82 - l-(Fur-2-ylmethyl)-5-benzyl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.57(2H,s), 5.43(2H.s), 6.45(2H,s), 7.1-7.4(5H,m), 7.66(lH.m) and 7.85(lH,s); MPt 153-5°C; (FAB) M+H=299. C16H14N202S requires 298.
Intermediate B83 - l-Methyl-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.57(3H,s), 6.12(lH,m), 6.20(lH,bs), 7.57(lH,d) and 7.87(lH,s); (El) M=263. C12H,3N302S requires 263.
Intermediate B84 - l-Methyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 3.33(3H,s), 7.93(lH,s) 8.73(2H,s) and 9.02(lH,s); (APCI) M+H=235. C10H10N4OS requires 234.
Intermediate B85 - l-MethvI-5-benzvl-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (CDC13) δ 3.55(2H,s), 3.57(3H.s), 7.1-7.4(5H,m) and 7.84(lH,s); MPt 143-6°C; (El) M=232. C12H12N2OS requires 232.
Intermediate B86 - l-Phenyl-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (CDC13) δ 3.51(3H + MeOH,s), 6.16(lH,m), 6.48(lH.m), 7.1-7.45(4H.m) and 7.45-7.65(3H.m); (El) M=325; C17H15N302S requires 325.
Intermediate B87 - l-(2-Methoxyethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (CDC13) δ 3.26 (3H,s), 3.60 (2H,s), 3.65 (2H.t), 4.33 (2H,t), 7.83 ( lH.s), 8.70 (2H,s), 9.04 (lH,s); (ES+) M+H=279; C12H14N402S requires 278.
Intermediate B88 - l-(2-Methylprop-l-yl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. (APCI) M-H=275. C13H16N4OS requires 276.
Intermediate B89 - l-Ethyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.23 (3H,t), 3.60 (2H,s), 4.19 (2H,q), 7.95(lH,s) 8.73(2H,s) and 9.04(lH,s); (APCI) M-H=247. CπH12N4OS requires 248.
Intermediate B90 - l-(8-Phenyloctyl) -5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.15-1.4(8H,m), 1.45-1.8(4H,m), 2.56(2H,t), 3.6 (2H,s), 4.1 l(2H,t), 7.1-7.35(5H,m), 7.94(lH,s), 8.73(2H,s) and 9.02(lH,s). (APCI) M+H=409. C23H28N4OS requires 408.
Intermediate B91 - l-(9-Phenylnonyl) -5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 1.15-1.4(8H,m). 1.45- 1.8(4H.m), 2.55(2H,t), 3.58 (2H.s), 4.12(2H.t), 7.1-7.35(5H,m), 7.95(lH,s), 8.72(2H,s) and 9.02(lH.s). (APCI) M+H=421. C24H30N4OS requires 422.
Intermediate B92 - l-Undecyl-5-(2-ethoxypyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6 DMSO) δ 0.8-0.95 (3H,m),
1.05-1.5 (19H,m), 1.6-1.8 (2H,m), 3.49 (2H,s), 4.1 1 (2H,t), 4.31 (2H,q), 8.48 (2H,s); MS (APCI+) found (M+l) = 418; C22H34N402S requires 417. Intermediate B93 - l-(2-Phenylethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 3.00-3.10 (2H, t), 3.50 (2H, s), 4.29-4.40 (2H, t), 7.10-7.33 (5H, m), 7.71 (IH, s), 8.68 (2H, s), 9.00 (IH, s), 12.62-12.75 (IH, br.s); MS (APCI-) found (M-1) = 323; C17H16N40S requires 324.
Intermediate B94 - l-Benzyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 3.57 (2H, s), 4.46 (2H, s), 7.10-7.44 (6H, m), 7.91 (IH, s), 8.69 (2H, s), 9.01 (IH, s); MS (APCI+) found (M+l) = 311; C16H14N40S requires 310.
Intermediate B95 - l-Undecyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. 'H-NMR (DMSO) δ 0.79-0.93 (3H, t), 1.12-1.44 (16H, m), 1.60-1.79 (2H, t), 3.59 (2H, s), 4.05-4.20 (2H, t), 7.96 (IH, s), 8.70 (2H. s), 9.01 ( IH, s), 12.61 (IH, s); MS (APCI-) found (M-1) = 373; C20H30N4OS requires 374.
Intermediate B96 - l-Dodecyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. ' H-NMR (DMSO) δ 0.79-0.94 (3H, t), 1.13-1.47 (18H, s), 1.60-1.80 (2H, br.t), 3.59 (2H, s), 4.06-4.20 (2H, t), 7.96 (IH, s), 8.71 (2H, s), 9.03 (IH, s); MS (ES-) found (M-1) = 387; C21H32N4OS requires 388. Intermediate B97 - l-(2-(Thien-2-yl)ethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 3.17-3.47 (2H, t), 3.52 (2H, s), 4.30-4.43 (2H, t), 6.80-7.04 (2H, m), 7.27-7.40 (IH, m), 7.73 (IH, s), 8.62 (2H, s), 9.03 (IH, s) 11.97-12.5 (IH, br.s); MS (APCI-) found (M-1) = 329; C15H14N4OS2 requires 330.
Intermediate B98 - l-(5-Methylfuran-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 2.24 (3H, s), 3.63 (2H, s), 5.37 (2H, s), 6.01-6.08 (IH, d), 6.30-6.38 (IH, d), 7.92 (IH, s), 8.72 (2H, s), 9.04 (IH, s) 12.73 (IH, s), MS (ES-) found (M-1) = 313; C15H14N402S requires 314.
Intermediate B99 - l-(4-Fluorobenzyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 3.60 (2H, s), 5.41 (2H, s), 7.13-7.25 (2H, m), 7.35-7.47 (2H, m), 8.02 (IH, s), 8.70 (2H, s), 9.03 ( IH, s), 12.78 (lH,s); MS found (M-1) = 327; C16H13FN4OS requires 328.
Intermediate B100 - l-(2-(2-Chlorophenyl)ethyI)-5-(Pyrimid-5-ylmethyI)-2- thiouracil
Prepared analogously to intermediate B45. Solid. 'H-NMR (DMSO) δ 3.12-3.22 (2H, t), 3.49 (2H, s), 4.34-4.46 (2H, t), 7.14-7.43 (4H, m), 7.52 (IH, s), 8.57 (2H, s), 9.04 (IH, s), 1 1.40-1 1.85 ( IH, br.s); MS (APCI-) found (M-1) = 357; C17H15C1N40S requires 358. Intermediate B101 - l-(2-Phenoxyethyl)-5-(Pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 3.63 (2H, s), 4.25-4.37 (2H, t), 4.50-4.60 (2H, t), 6.84-7.00 (3H, m), 7.20-7.33 (2H, t), 7.94 (IH, s), 8.71 (2H, s), 9.06 (IH, s), 12.78 (IH, s); MS (ES+) found (M+l) = 341; C17H16N402S requires 340.
Intermediate B102 - l-(5-Ethoxycarbonylpent-l-yl)-5-(Pyrimid-5-ylmethyI)-2- thiouracil
Prepared analogously to intermediate B45. Solid. ' H-NMR (DMSO) δ 1.10-1.20 (3H, t), 1.21-1.39 (2H, m), 1.45-1.80 (4H, m), 2.22-2.38 (2H, m), 3.59 (2H, s), 3.96-4.19 (4H, m), 7.94 (IH, s), 8.70 (2H, s), 9.03 (IH, s), 12.12-12.35 (IH, br.s); MS (ES-) found (M-1) 361; C17H22N403S requires 362.
Intermediate B103 - l-(l-EthoxycarbonylethyI)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Solid. 'H-NMR (DMSO) δ 1.06-1.30 (3H, t), 1.58-1.70 (3H, d), 3.67 (2H. d), 4.02-4.27 (2H, m). 6.02-6.19 (IH, q), 8.05 (IH, s), 8.70 (2H, s), 9.03 (IH, s), 12.80 (IH, s); MS (APCI+) found (M+l) = 321; C14H16N403S requires 320.
Intermediate B104 - l-(l-Methylethyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. 'H-NMR (DMSO) δ 1.26-1.45 (6H, d), 3.65 (2H, s), 5.53-5.74 (IH, m), 8.10 (lh, s), 8.72 (2H, s), 9.02 (IH, s), 12.60 (IH, s); MS (APCI-) found (M+l) = 261 ; C12H14N4OS requires 262. Intermediate B105 - l-Cyclopropyl-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. 'H-NMR (DMSO) δ 0.92-1.10 (4H, m), 3.37-3.43 (IH, m), 3.60 (2H, s), 7.89 (IH, s), 8.71 (2H, s), 9.02 (IH, s), 12.60 (IH, s); MS (APCI-) found (M-1) = 259; C12H12N4OS requires 260.
Intermediate B106 - l-(l-Ethoxycarbonylcycloprop-l-yl)-5-(pyrimid-5-ylmethyI)- 2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 1.05-1.20 (3H, t), 1.40-1.95 (4H, m), 3.61 (2H, s), 4.02-4.18 (2H, q), 7.98 (IH, s), 8.72 (2H, s), 9.04 (IH, s), 12.04 (IH, s); MS (APCI+) found (M+l) = 333; C15H16N4OS requires 332.
Intermediate B107 - l-(4-Ethoxycarbonylbenzyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 1.23-1.38 (3H, t), 3.60 (2H, s), 4.24-4.40 (2H, q), 5.50 (2H. s), 7.35-7.47 (2H, m), 7.86-8.00 (2H, m), 8.04 (IH. s), 8.70 (2H, s), 9.03 (IH, s), 12.07-12.40 (IH. br.s); MS (APCI-) found (M-1) = 381; C19H18N403S requires 382.
Intermediate B108 - l-(4-Methoxycarbonylcyclohex-l-yl)-5-(pyrimid-5-ylmethyl)- 2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 1.32-1.92 (6H, m), 2.10-2.30 (2H, m), 2.67-2.80 ( IH, m), 3.64 (3H, s), 3.69 (2H, s), 5.17-5.34 (IH, br.s), 7.87 (IH, s), 8.70 (2H, s), 9.01 (IH, s), 12.63 (IH, s); MS (APCI-) found (M-1) = 359; C17H20N4O3S requires 360. Intermediate B109 - l-(2-(6-(4-Fluorophenyl)hex-l-yloxy)ethyl)-5-(pyrimid-5- ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Solid. Η-NMR (DMSO) δ 1.14-1.60 (12H, m), 3.60 (2H, s), 3.62-3.70 (2H, t), 4.26-4.35 (2H, t), 7.00-7.12 (2H, t), 7.14-7.24 (2H, m), 7.80 (IH, s), 8.70 (2H, s), 9.00 (IH, s), 12.64-12.77 (IH, br.s); MS (APCI-) found (M-1) = 441; C23H27FN402S requires 442.
Intermediate B110 - l-Undecyl-5-(l-methyl-2-oxopyrid-4-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. IH-NMR (CDC13) δ 0.88 (3H, t), 1.26 (14H, m), 1.32 (2H, t), 1.75 (2H, m), 3.48 (2H, s), 3.52 (3H, s), 4.11 (2H, t), 6.10 (IH, m), 6.40 (IH, s), 7.08 (IH, s), 7.22 (IH, d), 9.56 (IH, bs); MS (APCI+) M+l=404, C22H33N302S requires 403. MPt 137-140°C (cream solid)
Intermediate Bill - l-(3-Ethoxycarbonylpropyl)-5-(l-methyl-2-oxopyrid-4- ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.17 (3H, t), 1.95 (2H, m), 2.35 (2H, m), 3.34 (5H, m), 4.03 (2H, q), 4.17 (2H, m), 6.11 (IH, m), 6.20 (IH, s), 7.57 (IH, d), 7.83 (IH, s), 12.63 (IH, bs); MS (APCI+) M+l=3642, C17H21N304S requires 363. MPt 168-170°C (cream solid).
Intermediate B112 - l-(2-(4-Pent-l-ylphenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 0.85 (3H, m), 1.25 (4H, m), 1.53 (2H, m), 2.52 (2H, m), 2.99 (2H, m), 3.49 (2H, s), 4.33 (2H, m), 7.03-7.24 (4H, m),7.71 (IH, s), 8.59 (2H, s), 9.03 (IH, s), 12.70 (IH, bs); MS (APCI+) M+l=395, C22H26N4OS requires 394. (light brown solid)
Intermediate B113 - l-(2-(4-Pent-2-en-l-ylphenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 0.89 (3H, m), 1.30-
1.60 (2H, m), 2.24 (2H, m), 3.03 (2H, m), 3.51 (2H, s), 4.35 (2H, m), 5.63 (IH, m), 6.33
(IH, s), 7.10-7.33 (4H, m),7.76 (IH, s), 8.61 (2H, s), 9.03 (IH, s), 12.70 (IH, bs); MS
(APCI+) M+l =393, C22H24N4OS requires 392. (light brown solid)
Intermediate B114 - l-(2-(4-Bromophenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. 'H-NMR (d6-DMSO) δ 3.02 (2H,t), 3.53 (2H, s), 4.33 (2H, t), 7.22 (2H, m), 7.49 (2H. m), 7.77 (IH, s), 8.60 (2H, s), 9.02 (IH, s), 12.7 (IH, bs), MS (APCI+) M+l=403, C17H15BrN4OS requires 402
Intermediate B115 - l-(4-Bromobenzyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil SB- 296961 -
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 3.60 (2H,s), 5.39 (2H, s), 7.29 (2H, d), 7.57 (2H, d), 8.01 (IH, s), 8.70 (2H, s), 9.03 (IH, s), 12.75 (IH, bs), MS (APCI+) M+l=389, C16H13BrN4OS requires 388 Intermediate B116 - l-(2-(3-Pent-l-ylphenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (CDC13) δ 0.89 (3H, m), 1.30 (4H, m), 1.55 (2H, m), 2.53 (2H, t), 3.10 (2H, t), 3.42 (2H, s), 4.35 (2H, t), 6.49 (IH, s), 6.91- 7.22 (4H, m), 8.44 (2H, s), 9.1 1 (IH, s), 9.60 (IH. bs) MS(APCI+) M+l=395, C22H26N4OS requires 394. MPt 137.5°C (colourless solid)
Intermediate B117 - l-(2-(2-Pent-l-ylphenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. 'H-NMR (CDC13) δ 0.88 (3H, t), 1.28 (4H, m), 1.49 (2H, m), 2.50 (2H, t), 3.15 (2H, t), 3.42 (2H, s), 4.34 (2H, t), 6.41 (IH, s), 7.03-
7.21 (4H, m), 8.50 (2H, s), 9.12 (IH, s), 9.70 (IH, bs); MS(APCI+) M+l=395,
C22H26N4OS requires 394. MPt 181.6°C (pale orange solid)
Intermediate B118 - l-(3-Ethoxycarbonylphenyl)- 5-(pyrimid-5-ylmethyl) -2- thiouracil
Prepared analogously to intermediate B45. Η NMR (CDC13) δ: 1.41 (t, 3H), 3.70 (s, 2H), 4.41 (q, 2H), 7.30 (s, IH), 7.35 (m, IH), 7.60 (m, 2H), 7.98 (m, IH), 8.15 (d, IH), 8.71 (s. 2H), 9.10 (s, IH). MS (ES+) Found (M+l) = 369; C18H,6N403S requires 368.
Intermediate B119 - l-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η NMR (CDC13) δ: 1.41 (t, 3H), 3.69 (s, 2H), 4.39 (q, 2H), 7.30 (s, IH), 7.46 (d, 2H), 8.21 (d, 2H), 8.72 (s, 2H), 9.10 (s, IH). MS (ES+) Found (M+l) = 369; C18H16N403S requires 368.
Intermediate B120 - l-(5-(Ethoxycarbonyl)fur-2-yI)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η NMR (CDC13) δ: 1.39 (t, 3H), 3.69 (s, 2H), 4.39 (q, 2H), 6.69 (d, IH), 7.28 (d, IH), 7.41 (s, IH), 8.72 (s, 2H), 9.12 (s, IH). MS (APCI+) Found (M+l) = 359; C16H14N404S requires 358. Intermediate B121 - l-Phenyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyI)-2- thiouracil
Prepared analogously to intermediate B45. Η NMR (CDC13) δ: 3.69 (s, 2H), 7.30 (m, 3H), 7.50 (m, 3H), 8.72 (s, 2H), 9.10 (s, IH). MS (ES+) Found (M+l) = 297; C15H12N4OS requires 296.
Intermediate B122 - l-(4-(tert-Butoxycarbonylamino)but-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η NMR (DMSO-d6) δ: 1.37 (s, 9H), 1.4 (m, 2H), 1.65 (m, 2H), 2.93 (m, 2H), 3.59 (s, 2H), 4.13 (t, 2H), 6.81 (br s, IH), 7.94 (s, IH), 8.70 (s. 2H), 9.04 (s, IH), 13.45 (br s, IH). MS (ES+) Found (M+l) = 392; C18H25N503S requires 391. Intermediate B123 - l-(3-(Ethoxycarbonylamino)prop-l-yl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45 as a pale buff solid. Η NMR (DMSO-d6) δ: 1.15 (t, 3H), 1.85 (m, 2H), 3.02 (m, 2H), 3.59 (s, 2H), 4.01 (q, 2H), 4.14 (t, 2H), 7.12 (br s, IH), 7.93 (s, IH), 8.69 (s, 2H), 9.00 (s, IH), 13.55 (br s, IH). MS (APCI+) Found (M+l) = 350; C15H19N503S requires 349.
Intermediate B124 - l-(l-Undecyl)- 5-(2-methoxypyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45, except using sodium methoxide in place of ethoxide. 'H-NMR (CDC13) δ 0.8-0.95 (3H,t), 1.1-1.85 (18H,m), 3.59 (2H, s), 4.01 (3H,s), 4.1 1 (2H,t), 7.04 (lH,s), 8.43 (2H, s); MS (APCI+) found (M+l) = 405; C21H32N402S requires 404.
Intermediate B125 - l-(4-(Dec-l-yl)phenyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. The ethoxide cyclisation step failed to go to completion, but the crude thiouracil was used in the next step without purification.
Intermediate B126 - l-(4-(Non-l-yloxyphenyl))-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B 125 Intermediate B127 - l-(4-(Hex-l-yl)phenyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B125
Intermediate B128 - l-(3-(Non-l-yloxy)phenyI)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B 125
Intermediate B129 - l-(3-(Dec-l-yl)phenyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B 125
Intermediate B 130 - l-(4-Iodophenyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B 125
Intermediate B131 - l-(2-FluorobenzyI)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η NMR (d6-DMSO) δ 3.62 (2H,s), 5.45 (2H, s), 7.1-7.4 (4H, m), 7.98 (IH, s), 8.70 (2H, s), 9.04 ( IH, s), 12.8 (IH, bs), MS (APCI-) M- 1=327, C16H13FN4OS requires 328 Intermediate B132 - (S)-l-(Tetrahydrofur-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η NMR (d6-DMSO) δ 1.5-1.65 (lH,m), 1.75-2.05 (3H,m), 3.62 (2H,s), 3.65 (lH,m), 3.79 (lH,m), 3.95 (lH,m), 4.24 (IH, m), 4.47 (lH,dd), 7.83 (IH, s), 8.70 (2H, s), 9.04 (IH, s), 12.7 (IH, bs), MS (APCI-) M- 1=303, C14H16N402S requires 304
Intermediate B133 - (R)-l-(Tetrahydrofur-2-ylmethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η NMR (d6-DMSO) δ 1.5-1.65 (lH,m),
1.75-2.05 (3H,m), 3.62 (2H,s), 3.65 (lH,m), 3.79 (lH,m), 3.95 (lH,m), 4.24 (IH. m),
4.47 (lH.dd), 7.83 (IH, s), 8.70 (2H, s), 9.04 (IH, s), 12.7 (IH, bs), MS (APCI-) M-
1=303, C14H16N402S requires 304
Intermediate B 134 - l-(2-(4-Methoxyphenyl)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 2.97 (2H,t), 3.51 (2H. s), 3,74 (3H.s), 4.31 (2H, t), 6.85 (2H, m), 7.49 (2H, m), 7.14 (IH, s), 8.59 (2H, s), 9.03 ( IH, s), 12.7 ( IH, bs), MS ( APCI+) M+l=355, C18H18N402S requires 354
Intermediate B135 - l-(Undec-l-yl)-5-(2-methylpyrimid-5-ylmethyI)-2-thiouracil
Prepared analogously to intermediate B45, except using sodium methoxide in place of ethoxide. 'H-NMR (CDC13) δ 0.8-0.9 (3H,t), 1.2- 1.35 (16H,m), 1.75 (2H,m), 2.73 (3H,s), 3.62 (2H, s), 4.11 (2H,t), 7.05 (lH,s), 8.57 (2H, s), 9.7-9.8 (lH,br s); MS (APCI+) found (M+l) = 389; C21H32N4OS requires 388.
Intermediate B136 - l-(4-Acetylphenyl)-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B 125.
Intermediate B137 - l-(trα/i--4-(Methoxycarbonyl)cyclohex-l-ylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)-2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.0-1.4 (4H, m), 1.65 (2H, m), 1.92 (2H,m), 2.15-2.35 (IH, m), 3.58 (3H, s), 3.60 (2H, s), 4.01 (2H,m), 7.88 (IH, s), 8.70 (2H, s), 9.06 (IH, s), 12.6 (IH, br s); MS (APCI-) found (M-1) = 373; C18H22N403S requires 374.
Intermediate B138 - l-(2-(t-Butoxycarbonylamino)ethyl)-5-(pyrimid-5-ylmethyl)-2- thiouracil
Prepared analogously to intermediate B45. ' H-NMR (d6-DMSO) δ 1.34 (9H, s), 3.32
(2H,m), 3.58 (2H,s), 4.19 (2H.m), 6.99 (lH,t), 7.69 (IH, s), 8.71 (2H, s), 9.03 (IH, s),
12.6 ( IH, br s); MS (APCI-) found (M-1) = 362; C16H21N503S requires 363.
Intermediate B139 - l-(3-(5-Phenylpent-l-yloxy)prop-l-yl)-5-(pyrimid-5-ylmethyl)- 2-thiouracil
Prepared analogously to intermediate B45. Η-NMR (d6-DMSO) δ 1.33 (2H, m), 1.4-1.7 (4H. m), 1.95 (2H, m), 2.55 (2H, t), 3.2-3.5 (4H, m), 3.60 (2H, s), 4.18 (2H, t), 7.1-7.3 (5H,m), 7.86 (IH, s), 8.71 (2H, s), 9.03 (IH, s), 12.6 (IH, br s); MS (APCI+) found (M+l) = 425; C23H28N402S requires 424.
General method A: S-Alkylation of thiouracils
Al (Nl -unsubstituted thiouracils). Sodium (2.2 equiv) was dissolved in ethanol to give a ca. 0.5M solution of sodium ethoxide. The appropriate thiouracil (1 equiv) was added, usually giving a clear solution, then the appropriate alkyating agent was added (1.0 - 1.25 equiv were used in various preparations, but no consistent advantage was seen with higher amounts) and the mixture was stirred at room temperature overnight. The ethanol was removed by evaporation, the residue was taken up in water, and the solution adjusted to pH 5 with acetic acid. In many cases the product precipitated, and was filtered off, washed with water and dried. When necessary, the aqueous solution was extracted with ethyl acetate, the organic layers dried and evaporated, and the residue triturated with ether or pet. ether to obtain the product.
A2. A mixture of thiouracil (1 equiv), the appropriate alkylating agent (1 - 1.1 equiv) and diisopropylethylamine (1 - 1.1 equiv) was stirred overnight at room temperature in dichloromethane (12ml/mmol). The solution was diluted with dichloromethane and washed with saturated sodium bicarbonate solution. The organic layer was added directly to a silica gel column. Elution (ethyl acetate to methanohethyl acetate) gave the desired product. A3. A mixture of thiouracil ( 1 equiv), the appropriate alkylating agent (1 - 1.1 equiv) and diisopropylethylamine (1 - 1.1 equiv) was stirred for lh at between 64 and 72°C in 1,2- dichloroethane (12ml/mmol). The solution was diluted with dichloromethane and washed with saturated sodium bicarbonate solution. The organic layer was added directly to a silica gel column. Elution (ethyl acetate to methanol: ethyl acetate) gave the desired product.1
A4. A mixture of the appropriate thiouracil ( 1 equiv), the appropriate alkylating agent (1.1 equiv) and potassium carbonate (2-3 equiv) in dry dimethylformamide (ca 4 ml/mmol) was heated at 65°C for 2.5h. The mixture was cooled, the solvent was removed under reduced pressure and the residue partitioned between dichloromethane (50ml) and 3% aqueous potassium carbonate solution. The organic layer was applied directly to a SepPak cartridge (lOg, Silica) and elution was continued with 2% to 8% methanol in ethyl acetate as eluent. This gave l-(4-hydroxycyclohexyl)-2-(8-(4- chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one (0.18g)
A5. Array synthesis. This proceeded essentially as in method A 1 , except that parallel reactions were carried out in screw-capped polypropylene tubes. The appropriate thiouracil ( 1 equiv) was weighed into each tube, then 0.5M ethanolic sodium ethoxide (2 equiv) and the appropriate alkyl halide ( 1 equiv) as an 0.5M ethanol solution were dispensed in by pipette and the tubes capped and vortexed at room temperature overnight on an orbital shaker. After removal of solvent in a vacuum centrifuge, individual products were worked up in the usual way.
General method B: Displacement of 2-(nitroamino)pyrimidones with thiols
The appropriate 2-(nitroamino)pyrimidone ( 1 equiv) and thiol (2 equiv) in pyridine (ca 2ml per mmol) were stirred at reflux for 2 days, then the pyridine was evaporated.
Trituration with an appropriate solvent, as described in the individual examples, gave the desired product.
General method C: Nl-Alkylation of pyrimidin-4-ones
Cl. To a stirred solution of the pyrimidinone (1 equiv) in dry DMF (20ml) was added sodium hydride (1 equiv). The mixture was stirred at room temperature for 30 min, then the appropriate alkylating agent (1 - 1.1 equiv) was added in portions over 15 min, and the mixture was stirred overnight. Ethyl acetate and dilute hydrochloric acid were added, the organic layer was separated and washed with water and brine, dried and evaporated. Flash chromatography (silica, 1-10% methanol in dichloromethane) gave first a mixture of the 3 -alkyl and 4-alkoxypyrimidine byproducts, then the desired l-alkylpyrimidin-4- one.
C2. A mixture of pyrimidinone (1 equiv), the appropriate alkylating agent (1 - 1.1 equiv) and diisopropylethylamine ( 1 - 1.5 equiv, usually 1.25 - 1.3 equiv) was stirred for between 20 - 72h at room temperature in dichloromethane (12ml/mmol) (if the pyrimidinone was only partially soluble in dichloromethane, dimethylformamide
(2ml/mmol) was also added). The solution was diluted with dichloromethane containing up to 2% methanol (if dimethylformamide was used, the solvent was first removed under reduced pressure) and washed with saturated ammonium chloride solution and sodium bicarbonate solution. The organic layer was separated and added directly to a silica gel column. Elution (ethyl acetate to methanol:dichloromethane:ethyl acetate) gave the desired product.
C3. Similar to method C2. except that the solvent was 1 ,2-dichloroethane in place of dichloromethane, and the pyrimidone was treated with tributyltin chloride (1 equiv) and stirred overnight to form the silyl ether before addition of the alkylating agent.
General method D: Ester hydrolysis
To a solution of the ester ( 1 equiv) in 1 ,4 dioxane (9ml/mmol) under argon was added a solution of sodium hydroxide (0.95-1 equiv) in water (2 - 4.5ml/mmol) whilst keeping the temperature below 25 °C. After stirring for between 2 - 20h at room temperature (the reaction was checked for completion), 75% of the solvent was removed under reduced pressure at <25°C. The residue was diluted with water and brought to pH3 with 5% aqueous sodium bisulphate. The solid so formed was filtered and dried in vacuo to give the desired material. General method E: Amide coupling
To a slurry / solution of the carboxylic acid ( 1 equiv) in dichloromethane (or dimethylformamide) (12ml/mmol) was added hydroxybenzotriazole (0.1 equiv), the amine (1 equiv) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.05eq). After stirring under argon for 24h, (the solvent removed under reduced pressure if dimethylformamide) the mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate. Addition of the organic layer directly to a silica gel column and elution (ethyl acetate to methanol: ethyl acetate) gave the desired product. Alternatively, the crude product could be purified by solid phase extraction on a BondElut SCX cartridge, eluted with dichloromethane/methanol.
General method F: Urea synthesis
The appropriate BOC-protected amine was dissolved in neat TFA (ca 5ml/g) at room temperature. After 5min the solution was concentrated to a brown gum and re-evaporated from ethyl acetate. The crude amine salt in dichloromethane (ca 15ml/g) was treated with the isocyanate (1.1 equiv.) in dichloromethane, followed by the addition of triethylamine and the reaction mixture shaken overnight. The reaction mixture was centrifuged to remove any solid material and the supernatent washed with water. The organic layer was dried over anhydrous magnesium sulfate and the solution concentrated. The crude material was then purified by silica gel chromatography.
Example 1 - 2-(8-Phenyloct-l-yl)thio-5-((l-benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
jjnςuo
Prepared from intermediate BIO by general method Al as a white solid. MPt 124 - 129°C; 'H-NMR (d6 DMSO) δ 1.2-1.5 (8H,m), 1.5-1.8 (4H,m), 2.59 (2H,t), 3.13 (2H,t), 3.54 (2H,s), 5.10 (2H,s), 6.14 (lH,dd), 6.50 (lH,bs), 7.15-7.4 (1 lH,m) and 7.68 (lH,s).
Example 2 - 2-(8-(4-Fluorophenyl)oct-l-yl)thio-5-((l-benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 10 and A21 by general method A5 as a white solid. MPt 147 - 151°C; 'H-NMR (CDC13) δ 1.2-1.5 (8H,m), 1.5-1.8 (4H,m), 2.58 (2H,t), 3.15 (2H.t), 3.55 (2H,s), 5.10 (2H,s), 6.15 (lH,dd), 6.47 (lH,m), 6.95 (2H,t), 7.05-7.2 (3H,m), 7.25-7.45 (5H,m) and 7.67 (lH,s); MS (El) M=531; C31H34FN302S requires 531.
Example 3 - 2-(8-(4-Chlorophenyl)oct-l-yI)thio-5-((l-benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediates B 10 and A24 by general method A5 as a white solid. MPt 160 - 164°C; Η-NMR (CDC13) δ 1.2-1.8 (12H,m). 2.56 (2H,f), 3.13 (2H,t), 3.55 (2H,s), 5.10 (2H,s), 6.15 (IH, m), 6.48 (IH.bs). 7.0-7.45 (10H,m) and 7.67 (lH,s); MS (El) M=547; C31H34C1N302S requires 547.
Example 4 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-((l-benzyI-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediates B 10 and Al by general method A5 as a white solid. MPt 147 - 151°C; 'H-NMR (CDC13) δ 1.2-1.8 (10H,m), 2.93 (2H.t), 3.13 (2H,t), 3.55 (2H,s), 5.10 (2H,s), 6.15 (lH,dd), 6.49 (lH,bs), 7.05-7.5 (8H,m), 7.68 (lH,s) and 7.89 (2H,d); MS (El) M=561; C31H32C1N303S requires 561. Example 5 - 2-(8-(4-Fluorophenyl)-8-oxooct-l-yl)thio-5-((l-benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediates BIO and A8 by general method A5 as a white solid. MPt 125 - 133°C; Η-NMR (CDC13) δ 1.2-1.8 (10H), 2.93 (2H,t), 3.13 (2H,t), 3.55 (2H,s), 5.10 (2H,s), 6.15 (lH,m), 6.48 (lH,bs), 7.05-7.45 (8H,m), 7.68 (lH,s) and 7.97 (2H,m); MS (El) M=545; C31H32FN303S requires 545.
Example 6 - 2-(9-Phenylnon-l-yl)thio-5-((l-benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 10 by general method A5 as a white solid. MPt 127 - 132°C; 'H-NMR (CDC13) δ 1.2-1.9 (14H,m), 2.58 (2H,t), 3.14 (2H,t), 3.55 (2H,s), 5.10 (2H,s), 6.15 (lH,dd), 6.48 (lH,bd), 7.05-7.4 (lOH.m) and 7.67 (lH,s); MS (El) M=527; C32H37N302S requires 527.
Example 7 - 2-(6-Phenylhex-l-yl)thio-5-((l-methyI-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 1 1 by general method A5. 'H-NMR (d6-DMSO) δ 1.3 (4H.m). 1.6 (4H.m). 2.55 (2H.t), 3.08 (2H,t), 3.35 (3H,s), 3.41 (2H,s), 6.10 (lH,dd), 6.16 ( lH.d). 7.1-7.3 (5H,m), 7.55 (lH,d), 7.78 (lH,s).
Example 8 - 2-(7-Phenylhept-l-yl)thio-5-((l-methyI-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 1 1 by general method A5. Η-NMR (d6-DMSO) δ 1.3 (6H.m), 1.6 (4H,m), 2.55 (2H.t). 3.07 (2H,t), 3.35 (3H,s), 3.41 (2H,s), 6.10 (lH,dd), 6.15 (lH,d), 7.1-7.3 (5H,m), 7.55 ( lH.d), 7.77 (lH,s). Example 9 - 2-(8-Phenyloct-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 11 by general method A5. Η-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 2.97 (2H,t), 3.40 (3H,s), 3.42 (2H,s), 6.25 (lH,dd), 6.29 (lH,d), 7.1-7.3 (5H,m), 7.52 (lH,d), 7.58 (lH,s).
Example 10 - 2-(9-Phenylnon-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 11 by general method A5. 'H-NMR (d6-DMSO) δ 1.3 ( lOH.m), 1.6 (4H,m), 2.55 (2H,t), 3.06 (2H,t), 3.34 (3H,s), 6.10 (lH,dd), 6.15 (lH,d), 7.1- 7.3 (5H,m), 7.55 (lH,d), 7.75 (lH,s).
Example 11 - 2-(6-Benzyloxyhex-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediates B 11 and A27 by general method A5. 'H-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 3.08 (2H,t), 3.40 (2H,t), 3.64 (2H,s), 4.43 (2H,s), 6.09 (lH,dd), 6.15 (lH.d), 7.1-7.3 (5H,m), 7.55 (lH,d), 7.75 (lH,s).
Example 12 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediates B 1 1 and Al by general method A5 as a white solid. MPt 125 - 127°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 3.00 (2H,t), 3.08 (2H,t), 3.35 (3H.s), 3.41 (2H,s), 6.10 (lH,m), 6.15 (lH,s), 7.57 (3H,m), 7.79 (lH,s), 7.97 (2H,d).
Example 13 - 2-(8-Phenyloct-l-yl)thio-5-((l-butyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B27 by general method B as a white solid from pet. ether. 'H-NMR (d6-DMSO) δ 0.87 (3H,t), 1.26 (10H,m), 1.5-1.7 (6H,m), 2.55 (2H,t), 3.08 (2H,t), 3.42 (2H,s), 3.79 (2H,t), 6.1 (2H,m), 7.2 (3H,m), 7.3 (2H,m), 7.54 (lH,d), 7.81 (lH,s), 12.8 (lH,br s).
Example 14 - 2-(8-Phenyloct-l-yl)thio-5-((2,3-dimethylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 12 by general method Al as a light brown solid. MPt 1 11 113°C; 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.18 (3H,s), 2.35 (3H,s), 2.51 (2H.t), 3.05 (2H,t), 3.52 (2H,s), 7.1=7.3 (5H,m), 7.34 (lH,d), 7.74 (lH,s), 8.14 (lH,d).
Example 15 - 2-(6-Benzyloxyhex-l-yl)thio-5-((2,3-dimethylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B 12 and A27 by general method Al as a light brown solid. MPt 100 - 102°C; Η-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 2.18 (3H,s), 2.35 (3H,s), 3.06 (2H,t), 3.36 (2H,t), 3.52 (2H,s), 4.43 (2H,s), 7.3 (6H,m), 7.74 (lH,s), 8.14 (lH,d).
Example 16 - 2-(8-Phenyloct-l-yl)thio-5-((2,4-dimethylpyrid-5- yI)methyl)pyrimidin-4-one
Prepared from intermediate B29 by general method B as a beige solid from ether/pet. ether. MPt 73 - 75°C; 'H-NMR (d6-DMSO) δ 1.2 (8H,m), 1.6 (4H,m), 2.21 (3H,s), 2.37 (3H,s), 2.57 (2H,t), 3.06 (2H,t), 3.57 (2H,s), 6.83 (lH,s), 7.1-7.3 (5H,m), 7.51 (lH,s), 8.15 ( lH.s), 12.8 (lH.br s).
Example 17 - 2-(5-Phenylpent-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin- 4-one
Prepared from intermediate B21 by general method Al as a white solid. MPt 113 - 117°C; 'H-NMR (d6-DMSO) δ 1.35 (2H.m), 1.6 (4H,m), 2.40 (3H,s), 2.55 (2H,t), 3.07 (2H,t), 3.57 (2H,s), 7.1-7.3 (6H,m), 7.52 ( lH,dd), 7.78 (lH,s), 8.33 (lH,d). Example 18 - 2-(N-(6-(4-Fluorophenyl)hexyl)carboxamidomethyl)thio-5-((2- methylpyrid-5-yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A42 by general method Al. MPt 159 - 161°C; Η- NMR (d6-DMSO) δ 1.2 (4H,m), 1.4 (2H,m), 1.5 (2H,m), 2.40 (3H,s), 2.52 (2H,t), 3.04 (2H,m), 3.57 (2H.s), 3.81 (2H,s), 7.0-7.2 (5H,m), 7.49 (lH,dd), 7.75 (lH,s), 8.15 (lH,t), 8.33 (lH,dd).
Example 19 - 2-(6-Benzyloxyhex-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A27 by general method Al. MPt 93 - 95°C; Η- NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 2.40 (3H,s), 3.07 (2H,t), 3.40 (2H,t), 3.57 (2H,s), 4.43 (2H,s), 7.13 (lH,d), 7.3 (5H,m), 7.51 (lH,dd), 7.80 (lH,s), 8.34 (lH,d).
Example 20 - 2-(8-Phenyloct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one
Prepared from intermediate B21 by general method A5 as a white solid. MPt 92 - 94°C; 'H-NMR (d6-DMSO) δ 1.3 (8H.m). 1.6 (4H.m), 2.40 (3H.s), 2.55 (2H,t), 3.02 (2H,t). 3.54 (2H.s), 7.1 1 (lH,d), 7.16 (3H,m), 7.25 (2H,m), 7.50 (lH.m), 7.69 (lH,s), 8.33 ( lH,d).
Example 21 - 2-(7-Phenylhept-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin- 4-one
Prepared from intermediate B21 by general method A5 as a white solid. MPt 101 - 103°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 2.40 (3H,s), 2.55 (2H,t), 3.02 (2H,t), 3.54 (2H,s), 7.11 (lH.d), 7.16 (3H,m), 7.25 (2H,m), 7.50 (lH,m), 7.68 (lH,s), 8.33 (lH,d). Example 22 - 2-(6-Phenylhex-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one
Prepared from intermediate B21 by general method Al as a white solid. MPt 104 - 106°C; 'H-NMR (d6-DMSO) δ 1.3 (4H,m), 1.6 (4H,m), 2.40 (3H,s), 2.55 (2H,t), 3.05 (2H,t), 3.57 (2H,s), 7.1-7.3 (6H,m), 7.50 (lH,m), 7.78 (lH,s), 8.33 (lH,d).
Example 23 - 2-(9-Phenylnon-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one
Prepared from intermediate B21 by general method Al as a white solid. MPt 112 -
1 14°C; Η-NMR (d6-DMSO) δ 1.3 (10H,m), 1.6 (4H,m), 2.40 (3H,s), 2.54 (2H,t), 3.05 (2H.t), 3.55 (2H,s), 7.1-7.3 (6H,m), 7.50 (lH,m), 7.88 (lH,s), 8.33 (lH,d).
Example 24 - 2-(6-(4-Chlorobenzyloxy)hex-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A25 by general method Al as a white solid. MPt 93 - 95°C; Η-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 2.51 (3H,s), 3.13 (2H.t), 3.44 (2H.t), 3.70 (2H.s), 4.45 (2H,s), 7.06 (lH,d), 7.3 (3H,m), 7.53 (lH.dd), 7.64 (lH.s), 8.43 (lH,d).
Example 25 - 2-(6-(4-Fluorobenzyloxy)hex-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A26 by general method Al as a white solid. MPt 90 - 92°C; 'H-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H.m), 1.6 (2H,m), 2.51 (3H,s), 3.13 (2H.t), 3.45 (2H,t), 3.70 (2H,s), 4.44 (2H,s), 7.0 (3H,m), 7.3 (2H,m), 7.53 (lH,dd), 7.64 (lH.s), 8.43 (lH,d). Example 26 - 2-(8-(4-Methoxyphenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A3 by general method Al as a white solid. MPt 1 14 - 116°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 2.40 (3H,s), 2.93 (2H.t), 3.08 (2H,t), 3.57 (2H,s), 3.83 (3H,s), 7.02 (2H,d), 7.13 (lH,d), 7.51 (lH,dd), 7.79 (lH,s), 7.93 (2H,d), 8.34 (lH,d), 12.7 (lH.br s).
Example 27 - 2-(8-(4-Methoxyphenyl)oct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A22 by general method Al as a white solid. MPt 103 - 105°C; 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.4-1.7 (4H,m), 2.40 (3H,s), 2.48 (2H,t), 3.07 (2H.t), 3.57 (2H,s), 3.84 (3H,s), 6.82 (2H,d), 7.07 (2H,d), 7.12 (lH,d), 7.51 (lH,dd), 7.78 (lH,s), 8.34 (lH,d), 12.7 (lH,br s).
Example 28 - 2-(8-(4-Fluorophenyl)oct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A21 by general method Al. 'H-NMR (d6-DMSO) δ 1.3 (8H,m). 1.6 (4H.m). 2.40 (3H,s), 2.53 (2H.t), 3.06 (2H,t), 3.56 (2H,s), 7.0-7.2 (5H,m), 7.5 ( lH.m), 7.77 (lH,s), 8.33 ( lH,m).
Example 29 - 2-(8-(4-Fluorophenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A8 by general method Al. 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H.m), 2.40 (3H,s), 3.00 (2H,t), 3.08 (2H,t), 3.57 (2H,s), 7.13 (lH,d), 7.34 (2H,m), 7.51 (lH,dd), 7.80 ( lH,s), 8.04 (2H,m). 8.34 (lH,d), 12.7 (lH,br s). Example 30 - 2-(8-(4-Chlorophenyl)oct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A24 by general method Al as a white solid. MPt 100 - 102°C; 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.40 (3H,s), 2.57 (2H,t), 3.06 (2H,t), 3.56 (2H,s), 7.12 (lH,d), 7.20 (2H,d), 7.31 (2H,d), 7.50 (lH,dd), 7.76 (lH,s), 8.33 (lH,d).
Example 31 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and Al by general method Al as a white solid. MPt 90 - 92°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 2.40 (3H,s), 3.00 (2H,t), 3.07 (2H,t), 3.56 (2H,s), 7.12 (lH,d), 7.51 (lH,dd), 7.58 (2H,d), 7.86 (lH,s), 7.97 (2H,d), 8.34 (lH,d).
Example 32 - 2-(8-Phenyl-8-oxooct-l-yl)thio-5-((2-methylpyrid-5- yl)methyI)pyrimidin-4-one
Prepared from intermediate B21 by general method Al as a white solid. MPt 72 - 74°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m). 1.6 (4H.m), 2.40 (3H,s), 3.00 (2H,t), 3.08 (2H,t), 3.57 (2H,s), 7.13 (lH,m), 7.5 (3H.m). 7.6 (lH,m), 7.80 (lH,s), 7.94 (lH,m), 8.33 (lH.d), 12.6 (lH.br s).
Example 33 - 2-(8-(4-Chlorophenyl)-8-hydroxyoct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A36 by general method Al. ' H-NMR (d6-DMSO) δ 1.3 (8H.m), 1.6 (4H,m), 2.40 (3H.s), 3.08 (2H,t), 3.58 (2H,s), 4.5 (lH,br t), 4.9 (lH.br s), 7.10 (lH,m), 7.31 (4H,m), 7.48 (lH,m), 7.71 (lH,s), 8.32 (lH,m), 12.4 (lH.br s). Example 34 - 2-(8-(4-Methylphenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediates B21 and A7 by general method Al as a white solid. MPt 115 - 116°C; 'H-NMR (CDC13) δ 1.2-1.8 (10H,m), 2.41 (3H,s), 2.51 (3H,s), 2.93 (2H,t), 3.13 (2H,t), 7.06 (lH,m), 7.25 (2H,m), 7.26 (lH,s), 7.54 (lH,m), 7.85 (2H,m) and 8.43 (lH,d); MS (El) M=449; C26H31N302S requires 449.
Example 35 - 2-(4-Phenylbut-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one
Prepared from intermediate B21 by general method Al. Mpt 129-30°C; Η-NMR (d6- DMSO) δ 1.6 (4H,m), 2.40 (3H,s), 2.58 (2H,m), 3.11 (2H,m), 3.57 (2H,s), 7.1-7.3 (6H,m), 7.52 (lH,dd), 7.80 (lH,s), 8.33 (lH,d).
Example 36 - 2-(8-Phenyloct-l-yl)thio-5-((l-oxo-2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediate B28 by general method B. Trituration with ether and recrystallisation from ethyl acetate gave the product as an off-white solid. MPt 93 - 95°C; Η-NMR (d6-DMSO) δ 1.3 (8H.m), 1.6 (4H,m), 2.55 (2H,t), 3.07 (2H,t), 3.56 (2H,s), 7.1- 7.3 (6H.m), 7.52 (lH.dd), 7.78 (lH,s), 8.33 (lH,d).
Example 37 - 2-(8-Phenyloct-l-yl)thio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin- 4-one
Prepared from intermediate B25 by general method B as a beige solid from ethanol. MPt 70 - 72°C; Η-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 3.08 (2H,t), 3.58 (2H.s), 3.80 (3H,s), 6.64 (lH,s), 6.84 (lH,d), 7.1-7.3 (5H,m), 7.80 (lH,s), 8.02 (lH,d). Example 38 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrazin-2- ylmethyl)pyrimidin-4-one
Prepared from intermediates B14 and Al by general method Al as a white solid. MPt 122.5 - 124°C; 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 3.00 (2H,t), 3.10 (2H,t), 3.81 (2H,s), 7.59 (2H.d), 7.8 (lH,bs), 7.97 (2H,d), 8.46 (lH.m), 8.50 (lH.m) and 8.58 (lH,m); MS (FAB) M+l=457; C23H25C1N402S requires 456.
Example 39 - 2-(8-Phenyloct-l-yl)thio-5-(pyrid-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 18 by general method Al. Η-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 3.09 (2H,t), 3.76 (2H,s), 7.1-7.3 (7H,m), 7.67 (lH,m), 7.74 (lH,s), 8.44 (lH,m), 12.7 (lH,br s).
Example 40 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(thiazol-2- ylmethyl)pyrimidin-4-one
Prepared from intermediates B22 and Al by general method Al as a pale buff solid. MPt 112 - 114°C; Η-NMR (CDC13) δ 1.2-1.85 (lOH.m), 2.92 (2H,t), 3.15 (2H,t), 4.17 (2H,s), 7.22 (lH.d), 7.42 (2H,m), 7.69 (lH.d) and 7.8-8.0 (3H.m); MS (El) M=461; C22H24C1N302S2 requires 461.
Example 42 - 2-(6-Phenylhex-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. 'H-NMR (d6-DMSO) δ 1.3 (4H,m), 1.6 (4H.m), 2.55 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.1-7.3 (5H,m), 7.63 (lH.m), 7.81 (lH,s). 8.39 ( lH,m), 8.48 ( lH.d).
Example 43 - 2-(7-Phenylhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 2.55 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.1-7.3 (5H,m), 7.63 (lH,m), 7.82 (lH,s), 8.39 (lH,m), 8.48 (lH,d).
Example 44 - 2-(8-Phenyloct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. Η-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 2.97 (2H,t), 3.62 (2H,s), 7.1-7.3 (5H,m), 7.63 (lH,m), 7.82 (lH,s), 8.39 (lH,m), 8.48 (lH,d).
Example 45 - 2-(9-Phenylnon-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. Η-NMR (d6-DMSO) δ 1.3 ( 10H,m), 1.6 (4H,m), 2.55 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.1-7.3 (5H,m), 7.63 (lH,m), 7.81 (lH,s), 8.39 (lH,m), 8.48 (lH,d).
Example 46 - 2-(6-Benzyloxyhex-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediates B 19 and A27 by general method A5. Η-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m). 3.08 (2H,t), 3.40 (2H,t), 3.62 (2H,s), 4.43 (2H,s), 7.1-7.3 (5H.m), 7.64 (6H,m), 7.82 (lH.s), 8.39 (lH,m), 8.49 (lH,d).
Example 47 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediates B 19 and Al by general method Al as a white solid. MPt 105 - 107°C; 'H-NMR (d6-DMSO) δ 1.3 (6H,m), 1.6 (4H,m), 3.00 (2H,t), 3.08 (2H,t), 3.62 (2H.s), 7.3 (lH,m), 7.58 (2H.d), 7.6 (lH.m), 7.82 (lH,s), 7.97 (2H.d), 8.39 (lH,m), 8.48 (lH,m). Example 48 - 2-(8-(4-Fluorophenyl)non-8-en-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediates B 19 and A37 by general method Al as a white powder. MPt 70 - 75°C; 'H-NMR (d6 DMSO) δ 1.2-1.8 (10H,m), 2.45 (2H,t), 3.06 (2H,m), 3.62 (2H.s), 5.04 (lH,s), 5.26 (lH,s), 7.16 (2H,t), 7.29 (lH,dxd), 7.4-7.55 (2H,m), 7.81 (lH.s), 8.38 (lH,m) and 8.48 (lH,d); MS (El) Found M=437; C25H28FN3OS requires 437.
Example 49 - 2-(6-(4-Chlorobenzoylamino)hex-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A45 by general method Al as a white solid. MPt 135 - 139°C; Η-NMR (d6 DMSO) δ 1.2-1.8 (8H,m), 3.09 (2H,t), 3.23 (2H,q), 3.61 (2H,s), 7.28 (lH,s), 7.51 (2H,m), 7.62 (lH,m), 7.84 (3H,m), 8.38 (lH,m), 8.48 (lH,bs) and 8.53 (lH,bt).
Example 50 - 2-(8-(4-Bromophenyl)-8-oxooct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A4 by general method Al as a white solid. MPt 132 - 137°C; 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H.m), 1.5-1.8 (4H,m), 2.98 (2H,t), 3.08 (2H,t), 3.62 (2H,t), 7.28 (lH,m), 7.5-7.95 (6H,m), 8.38 ( lH,m) and 8.48 (lH,bd).
Example 51 - 2-(7-(4-Chlorophenoxy)hept-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A29 by general method Al . 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H.m), 1.5-1.8 (4H,m), 3.09 (2H.t), 3.62 (2H,s), 3.93 (2H,t), 6.94 (2H,m), 7.29 (2H,m), 7.63 (IH, m), 7.83 (lH,bs), 8.38 (lH.m) and 8.48 (lH,bd).
Example 52 - 2-(7-Phenoxyhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A28 by general method Al . 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 3.09 (2H,t), 3.62 (2H,s), 3.93 (2H,t), 6.90 (3H,m), 7.27 (3H,m), 7.63 (lH,m), 7.82 (lH,s), 8.39 (lH,m) and 8.48 (lH,m).
Example 53 - 2-(7-Phenylthiohept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A33 by general method Al . 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 2.94 (2H,t), 3.06 (2H,t), 3.62 (2H,s), 7.16 (lH,m), 7.20- 7.35 (5H,m), 7.62 (lH,m), 7.81 (lH,s), 8.38 (lH,m) and 8.48 (lH,bs).
Example 54 - 2-(7-(4-Chlorophenylthio)hept-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A30 by general method Al. 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 2.94 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.2-7.5 (5H,m), 7.62 (lH.m), 7.82 (lH,s), 8.38 (lH.m) and 8.48 (lH,bs).
Example 55 - 2-(6-(3-Chlorophenyl)hex-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A40 by general method Al as a white solid. MPt 84 - 85°C; 'H-NMR (CDC13) δ 1.2-1.8 (8H,m), 2.57 (2H,t), 3.13 (2H,t), 3.74 (2H,s), 7.03 ( lH.m), 7.15-7.25 (4H.m), 7.65 (2H.m), 8.47 (lH,m),and 8.56 (lH,d); MS (El) M=413; C22H24C1N30S requires 413.
Example 56 - 2-(7-Phenylsulfmylhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A34 by general method Al . Η-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m). 2.6-3.0 (4H.m). 3.55 (2H,s), 7.25 (lH,m), 7.45-7.7 (7H,m), 8.35 (lH,m) and 8.46 ( lH.m). Example 57 - 2-(7-(4-Chlorophenylsulfmyl)hept-l-yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B19 and A31 by general method Al. ' H-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 2.7-3.2 (4H,m), 3.61 (2H,s), 7.28 (lH,m), 7.55-7.75 (5H,m), 7.80 (lH,s), 8.38 (lH,m) and 8.47 (lH,bs).
Example 58 - 2-(7-Phenylsulfonylhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A35 by general method Al. Η-NMR (d6 DMSO) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 3.05 (2H,t). 3.29 (2H,t), 3.62 (2H,s), 7.29 (lH,m), 7.6- 8.0 (7H,m), 8.44 (lH,m) and 8.49 (lH,m).
Example 59 - 2-(7-(4-Chlorophenylsulfonyl)hept-l-yI)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A32 by general method Al. ' H-NMR (d6 DMSO) δ
1.2-1.5 (6H.m), 1.5-1.8 (4H.m), 3.05 (2H,t), 3.62 (2H.s), 7.28 (lH,m), 7.6-80 (6H,m),
8.44 ( lH.m) and 8.48 (lH.m).
Example 60 - 2-(8-(3-Chlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A18 by general method Al as a white solid. MPt 68 - 70°C: 'H-NMR (CDC13) δ 1.2-1.5 (8H.m), 1.5-1.8 (4H,m), 2.56 (2H,t), 3.13 (2H,t), 3.74 (2H.t), 7.05 (lH.m), 7.15-7.25 (4H.m), 7.65 (2H,m), 8.46 (lH,m) and 8.57 (lH,m); MS (El) M=441 ; C24H28C1N30S requires 441.
Example 61 - 2-(8-(3,4-Dichlorophenyl)oct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A15 by general method Al as a white solid. MPt 96 - 99°C; Η-NMR (CDC13) δ 1.2-1.5 (8H.m), 1.5-1.8 (4H,m), 2.54 (2H,t), 3.13 (2H,t), 3.74 (2H,s), 7.0 (lH,m), 7.2-7.35 (3H,m), 7.65 (2H.m), 8.46 (lH,m) and 8.56 (lH,d); MS (El) M=475; C24H27C12N30 requires 475.
Example 62 - 2-(8-(2-Thienyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A5 by general method Al as a light brown solid. MPt 101 - 102°C; ' H-NMR (d6 DMSO) δ 1.2-1.45 (6H,m), 1.5-1.75 (4H,m), 2.79 (2H,t), 3.07 (2H,t), 3.61 (2H,s), 6.69 (lH.dd), 7.2-7.3 (lH,m), 7.45 (lH,d), 7.6-7.7 (lH,m), 7.81 ( lH.s), 7.97 (lH,s), 8.3-8.4 (lH,m) and 8.47 (lH,d).
Example 63 - 2-(8-(2-Furyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A6 by general method Al as a light brown solid. MPt 104 - 107°C; Η-NMR (d6 DMSO) δ 1.2-1.45 (6H.m) 1.5-1.8 (4H,m), 2.79 (2H,t), 3.07 (2H,t), 3.61 (2H,s), 6.69 (lH.m), 7.28 (lH,m), 7.45 (lH,m), 7.63 (lH,m), 7.81 (lH,m), 7.97 (lH,m),8.38 (lH,m) and 8.48 (lH,m).
Example 64 - 2-(8-(2-Pyridyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and Al 1 by general method Al as a light brown solid. MPt 76 - 79°C; Η-NMR (d6 DMSO) δ 1.2-1.5 (8H,m), 1.55-1.8 (4H,m). 2.69 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.05-7.4 (3H,m), 7.55-7.75 (2H,m), 7.82 (lH,s) and 8.35-8.55 (3H,m).
Example 65 - 2-(9-(4-Chlorophenyl)-9-oxonon-l-yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B 19 and Al by general method Al as a white solid. MPt 112 - 114°C; 'H-NMR (CDC13) δ 1.2-1.8 ( 14H), 2.92 (2H,t), 3.1 1 (2H,t), 3.74 (2H,s), 7.2 (lH,m), 7.42 (2H,d), 7.6-7.75 (2H,m), 7.88 (2H,m), 8.45 (lH,m) and 8.55 (lH,m); MS (El) M=469; C25H28C1N302S requires 469.
Example 66 - 2-(8-(3,4-Dichlorophenyl)oct-7-yn-l-yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B 19 and A 14 by general method Al as a white solid. MPt 92 - 94°C; 'H-NMR (CDC13) δ 1.4-1.9 (8H,m), 2.39 (2H,t), 3.15 (2H,t), 3.74 (2H,s), 7.1-7.4 (5H,m), 7.6-7.75 (2H,m), 8.45 (lH,m) and 8.57 (lH,m); MS (El) M=471; C24H23Cl2N3OS requires 471.
Example 67 - 2-(8-(4-Acetylphenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A20 by general method Al as a white solid. MPt 81 - 84°C; 'H-NMR (CDC13) δ 1.2-1.8 (12H,m), 2.58 (3H,s), 2.65 (2H,t), 3.13 (2H,t), 3.74 (2H,s), 7.1-7.35 (3H,m), 7.6-7.75 (2H,m), 7.87 (2H,d) and 8.3-8.7 (2H,bd); MS (El) M=449; C26H31N302S requires 449.
Example 68 - 2-(8-(4-Methylnaphth-l-yl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B 19 and A9 by general method Al as a white solid. MPt 102 - 104°C; 'H-NMR (CDC13) δ 1.2-1.5 (6H,m), 1.5-1.8 (4H,m), 2.73 (3H,s), 3.02 (2H,t), 3.13 (2H.t), 3.73 (2H,s), 7.25 (lH.m), 7.28 ( lH,d), 7.45-7.75 (4H,m), 7.75 (lH,d), 8.02 (lH,m), 8.45 (lH.m) and 8.5-8.7 (2H,m); MS (El) M=485; C29H31N302S requires 485.
Example 69 - 2-(8-(4-Pyridyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A23 by general method Al as a white solid. MPt 86 - 88°C; 'H-NMR (d6 DMSO) δ 1.2- 1.5 (8H,m), 1.5-1.8 (4H,m), 2.57 (2H,t), 3.07 (2H,t), 3.62 (2H,s), 7.21 (2H,d), 7.25 (lH,m), 7.81 (lH,s) and 8.3-8.6 (4H,m). Example 70 - 2-(8-(4-Chlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from intermediate B 19 and A24 by general method Al. 'H-NMR (d6 DMSO) δ 1.2-1.5 (6H.m), 1.5-1.8 (4H,m), 2.54 (2H,t), 3.07 (2H,t), 3.61 (2H,s), 7.1-7.4 (5H,m), 7.63 (lH,m), 7.80 (lH,s), 8.38 (lH,m) and 8.47 (lH,bs).
Example 71 - 2-(4-(3-Phenylprop-l-yIoxy)but-l-yl)thio-5-(pyrid-3-ylmethyI)- pyrimidin-4-one
Prepared from intermediate B 19 and A43 by general method Al. ' H-NMR (d6-DMSO) δ 1.5-1.9 (6H,m), 2.59 (2H,t), 3.12 (2H,t), 3.3 (4H,m), 3.61 (2H,s), 7.1-7.3 (6H,m), 7.6 (lH,m), 7.81 (lH,s), 8.38 (lH,m), 8.48 (lH,d).
Example 72 - 2-(6-Benzyloxyhex-l-yl)thio-5-(quinolin-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 and A27 by general method Al as a light brown solid. MPt 120 - 122°C; 'H-NMR (d6-DMSO) δ 1.3 (4H.m), 1.5 (2H,m), 1.6 (2H,m), 3.08 (2H,t), 3.39 (2H.t), 3.82 (2H,s), 4.42 (2H,s), 7.3 (5H,m), 7.56 (lH,m), 7.70 (lH,m), 7.9- 8.0 (3H.m), 8.13 (lH,d), 8.85 (lH.d), 12.7 (lH,br s).
Example 73 - 2-(8-Phenyloct-l-yl)thio-5-(quinolin-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 16 by general method Al as a light brown solid. MPt 124 126°C; 'H-NMR (d6-DMSO) δ 7.1-7.3 (5H,m), 7.56 ( lH,m). 7.68 ( lH,m), 7.9-8.0 (3H,m), 8.12 (lH,d), 8.85 (lH,d).
Example 74 - 2-(8-Phenyloct-l-yl)thio-5-((4-methoxypyrid-2-yl)methyl)pyrimidin- 4-one
Prepared from intermediate B26 by general method B as a brown solid after trituration with ether and recrystallisation from ethyl acetate. MPt 58 - 60°C; Η-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 3.07 (2H,t), 3.69 (2H,s), 3.78 (3H,s), 6.8 (2H,m), 7.1-7.3 (5H,m), 7.70 (lH,s), 8.25 (lH,d).
Example 75 - 2-(8-Phenyloct-l-yl)thio-5-(2-oxopyrid-4-ylmethyl)pyrimidin-4-one
A mixture of 2-(8-phenyloct- 1 -yl)thio-5-(2-methoxypyrid-4-ylmethyl)pyrimidin-4-one (0.40 g, 0.9 mmol), chlorotrimethylsilane (0.23 ml, 1.8 mmol) and sodium iodide (0.27 g, 1.8 mmol) in acetonitrile (30 ml) was heated at reflux for 6 hours. The solvent was evaporated, the residue taken up in dichloromethane, and washed with water and aqueous sodium thiosulphate. Evaporation of the solvent and trituration with ether gave 2-(8- phenyloct-l-yl)thio-5-(2-oxopyrid-4-ylmethyl)pyrimidin-4-one as a white solid (0.03 g). 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H.m), 2.55 (2H,t), 3.07 (2H,t), 6.07 (2H,m), 7.1-7.3 (6H,m), 7.77 (lH,s); MPt indeterminate.
Example 76 - 2-(8-Phenyloct-l-yl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one
Prepared from intermediate B20 by general method Al as a beige solid. MPt 124 - 125°C; 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H.m), 2.55 (2H,t), 3.08 (2H,t), 3.63 (2H,s), 7.1-7.3 (7H,m), 7.83 (lH,s), 8.42 (2H,d).
Example 77 - 2-(6-Benzyloxyhex-l-yl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one
Prepared from intermediate B20 and A27 by general method Al as a white solid. MPt 1 11 - 113°C; 'H-NMR (d6-DMSO) δ 7.23 (2H,d), 7.3 (5H,m), 7.83 (lH,s), 8.43 (2H,d), 1.28 (lH,br s).
Example 78 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B9 and Al by general method Al as a white solid. MPt 129 - 130°C; 'H-NMR (CDC13) δ 1.2-1.5 (6H.m), 1.5-1.8 (4H,m), 2.93 (2H,t), 3.15 (2H,t), 3.71 (2H,s), 7.43 (2H,d), 7.78 (lH.s), 7.89 (2H,d), 8.72 (2H,s) and 9.07 (lH,s); MS (El) M=456; C23H25C1N402S requires 456. Example 79 - 2-(8-Phenyloct-l-yl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 13 by general method Al as a light brown solid. MPt 79 81°C; 'H-NMR (d6-DMSO) δ 1.3 (8H,m), 1.6 (4H,m), 2.55 (2H,t), 3.07 (2H,t), 3.64 (2H,s), 6.08 (lH,m), 6.34 (lH,m), 7.1-7.3 (5H,m), 7.51 (lH,m), 7.67 (lH,s).
Example 80 - 2-(6-Benzyloxyhex-l-yl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 13 and A27 by general method Al as a brown solid. MPt 63 - 65°C; Η-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 3.08 (2H,t), 3.40 (2H,t). 3.64 (2H.s), 4.43 (2H,s), 6.08 (lH,m), 6.34 (lH,m), 7.3 (5H,m), 7.51 (lH.m), 7.68 (lH,s).
Example 81 - 2-(6-Benzyloxyhex-l-yl)thio-5-(fur-3-ylmethyl)pyrimidin-4-one
Prepared from intermediatee B 15 and A27 by general method Al as a white solid. MPt 58 - 60°C; Η-NMR (d6-DMSO) δ 1.3 (4H,m), 1.5 (2H,m), 1.6 (2H,m), 3.08 (2H,t), 3.4 (4H,m), 4.43 (2H,s), 6.37 (IH, m), 7.3 (5H,m), 7.44 (lH,m), 7.55 (lH,m), 7.68 (lH,s).
Example 82 - 2-(8-Phenyloct-l-yl)thio-5-(fur-3-ylmethyl)pyrimidin-4-one
Prepared from intermediatee B 15 by general method Al as a white solid. MPt 78 - 80°C; 'H-NMR (d6-DMSO) δ 6.37 (lH,s), 7.1-7.3 (5H,m), 7.44 (lH,m), 7.55 (lH,m), 7.65 (lH,s).
Example 83 - 2-Benzylthio-5-((l-methyI-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B 11 by general method Al as a white solid. MPt 194 - 196°C; 'H-NMR (d6-DMSO) δ 3.35 (3H,s), 3.44 (2H,s), 4.39 (2H,s), 6.10 (lH,m), 6.16 (lH,s), 7.56 (lH,d), 7.86 (lH,s), 12.8 (lH,br s). Example 84 - 2-Benzylthio-5-(fur-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 13 by general method A5. Η-NMR (d6-DMSO) δ .366 (2H,s), 4.38 (2H,s), 6.09 (lH,m), 6.35 (lH,m), 7.2-7.4 (5H,m), 7.52 (lH,m), 7.74 (lH,s).
Example 85 - 2-(3-Chlorobenzyl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 13 by general method A5. Η-NMR (d6-DMSO) δ 3.66 (2H,s), 4.39 (2H,s), 6.09 (lH,m), 6.35 (lH,m), 7.3-7.4 (5H,m), 7.50 (lH,m), 7.74 (lH,s).
Example 86 - 2-(4-Chlorobenzyl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 13 by general method A5. ' H-NMR (d6-DMSO) δ 3.63
(2H,s), 4.33 (2H,s), 6.07 (lH.m), 6.34 (lH,m), 7.35 (2H,d), 7.42 (2H,d), 7.50 (lH,m), 7.64 (lH,s).
Example 87 - 2-Benzylthio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one
Prepared from intermediate B21 by general method Al as a white solid. MPt 226 - 228°C; 'H-NMR (d6-DMSO) δ 2.40 (3H,s), 3.59 (2H,s), 4.38 (2H.s), 7.14 (lH,d), 7.2-7.5 (5H,m), 7.52 (lH.dd), 7.84 (lH,s), 8.34 (lH,d).
Example 88 - 2-Benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B25 by general method B as a white solid. MPt 193-5°C; Η- NMR (d6-DMSO) δ 3.60 (2H, s), 3.81 (3H, s), 4.39 (2H, s), 6.65 (IH, s), 6.85 (IH, m), 7.25-7.42 (5H, m), 7.87 ( IH, s), 8.03 (IH, m). Example 89 - 2-Benzylthio-5-(pyrazin-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 14 by general method Al as a white solid. MPt 174 - 175°C; 'H-NMR (d6 DMSO) δ 3.84 (2H,s), 4.40 (2H,s), 7.1-7.5 (5H,m), 7.89 (IH.bs), 8.47 (lH,d), 8.51 (lH,t) and 8.59 (lH.d); MS (FAB) M+l=311; C16H14N4OS requires 310.
Example 90 - 2-Benzylthio-5-(thiazol-2-ylmethyl)pyrimidin-4-one
Prepared from intermediate B22 by general method Al as light brown crystals; ' H-NMR (d6 DMSO) 4.02 (2H,s), 4.41 (2H,s), 7.2-7.45 (6H,m), 7.55 (lH,d), 7.67 (lH,d) and 7.95 (IH.bs); MS (El) M=315; C15H13N3OS2 requires 315.
Example 91 - 2-(4-Chlorobenzyl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. ' H-NMR (d6-DMSO) δ 3.59 (2H,s), 4.30 (2H,s), 7.26 (lH,m), 7.31 (2H,d), 7.41 (2H,d), 7.63 (lH,m), 7.72 (lH,s), 8.37 (lH,m), 8.47 (lH,m).
Example 92 - 2-Benzylthio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. 'H-NMR (d6-DMSO) δ 3.61 (2H,s), 4.33 (2H,s), 7.2-7.4 (5H,m), 7.64 ( lH.m), 7.78 (lH,s), 8.38 (lH,m), 8.49 (lH,m).
Example 93 - 2-(3,4-Dichlorobenzyl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 19 by general method A5. Η-NMR (d6-DMSO) δ 3.60 (2H,s), 4.31 (2H,s), 7.26 (lH,m), 7.39 (lH.m), 7.53 (lH,d), 7.65 (lH,m), 7.75 (lH,s), 8.37 (lH,m), 8.48 (lH.m). Example 94 - 2-Benzylthio-5-(pyrid-4-ylmethyl)pyrimidin-4-one
Prepared from intermediate B20 by general method Al as a white solid. MPt 183 - 185°C; 'H-NMR (d6-DMSO) δ 3.64 (2H,s), 4.39 (2H,s), 7.24 (2H,d), 7.3-7.4 (5H,m), 7.89 (lH,s), 8.43 (2H,d).
Example 95 - 2-(4-Chlorobenzyl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one
Prepared from intermediate B20 by general method A5. Η-NMR (d6-DMSO) δ 3.65
(2H.s), 4.38 (2H,s), 7.24 (2H.d). 7.37 (2H,d), 7.44 (2H,d), 7.88 (lH,s), 8.43 (2H,d).
Example 96 - 2-(3,4-Dichlorobenzyl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one
Prepared from intermediate B20 by general method A5. Η-NMR (d6-DMSO) δ 3.66 (2H,s), 4.39 (2H,s), 7.25 (2H.d), 7.42 (lH.dd), 7.57 (lH.d), 7.69 (lH,d), 7.89 (lH,s), 8.44 (2H,d).
Example 97 - 2-Benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B9 by general method Al as a white solid. MPt 239 - 241°C; 'H-NMR (d6-DMSO) δ 3.65 (2H,s), 4.39 (2H,s), 7.1-7.5 (5H,m), 7.95 (lH,bs), 8.71 (2H.s) and 9.02 (lH,s); MS (El) M=310; C16H14N4OS requires 310.
Example 98 - 2-Benzylthio-5-(2-(pyrid-4-yl)ethyl)pyrimidin-4-one
Prepared from intermediate B17 by general method Al as a white solid. MPt 209 - 2105°C; 'H-NMR (d6-DMSO) δ 2.61 (2H,t), 2.81 (2H,t), 4.36 (2H,s), 7.1-7.5 (7H,m), 7.69 (lH,s) and 8.45 (2H,d); MS (FAB) M+l=324; C18H17N3OS requires 323. Example 99 - 2-Benzylthio-5-benzylpyrimidin-4-one
Prepared from intermediate B23 by general method Al as a brown solid. MPt 156 - 158°C: 'H-NMR (d6-DMSO) δ 3.62 (2H,s), 4.38 (2H,s), 7.1-7.5 (10H,m), 7.8 (lH,s), 12. ( lH,br s).
Example 100 - 2-(8-Phenyloct-l-yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4-one
A mixture of 8-phenyl-l-octanol (1.5g), 2-nitroamino-5-(pyrid-3-ylmethyl)pyrimidin-4- one (l.Og) and pyridine (5ml) was stirred at reflux for 24 hours, then the pyridine was removed by evaporation. Water was added, and the product extracted into dichloromethane, which was dried and evaporated. The residue was purified by chromatography (silica, 0-5% methanol in dichloromethane) and recrystallisation from ether to give 2-(8-phenyloct-l-yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4-one as a pale buff solid (O. lg). MPt 53 - 55°C; 'H-NMR (CDC13) δ 1.32 (8H,m), 1.60 (2H,m), 1.74 (2H,m), 2.58 (2H,t), 3.72 (2H,t), 4.31 (2H.t), 7.1-7.3 (6H,m), 7.54 (lH,m), 7.63 (lH,m), 8.45 (lH,m) and 8.55 (lH,d); MS (El) Found M=391; C24H29N302 requires 391.
Example 101 - 2-(8-(4-Chlorophenyl)-8-oxooct-l-yI)oxy-5-(pyrid-3-ylmethyl)- pyrimidin-4-one
Prepared from intermediates B24 and A2 analogously to example 100. Recrystallisation from acetonitrile/ether gave the product as an off-white solid. MPt 116-7°C; ' H-NMR (CDC13) δ 1.39 (6H.m), 1.74 (4H,m), 2.93 (2H,t), 3.72 (2H,t), 4.31 (2H,t), 7.2 (lH,m), 7.42 (2H,d), 7.55 (lH,s), 7.62 (lH,d), 7.88 (2H,d), 8.45 (lH,m) and 8.54 (lH,d); MS (FAB) M+l =440; C24H26C1N302 requires 439.
Example 102 - 2-(4-PhenyIbut-l-yl)oxy-5-((2-methylpyrid-5-yl)methyl)pyrimidin- 4-one
Finely ground cyanamide ( 1.68 g, 0.04 mol) and cyanamide dihydrochloride (2.26 g, 0.02 mol) were treated with 4-phenyl- 1 -butanol (3.24 g, 0.02 mol), occasionally stirring with a glass rod over a 20 day period. The white paste was dissolved in water, extracted with chloroform and the aqueous layer adjusted to pH 13 (cone, sodium hydroxide) with ice cooling. The oil which precipitated was extracted into ethyl acetate, dried (MgS04) and the solvent evaporated to give the isourea as a clear oil (3.88 g). A portion of this material (2.44 g) was converted to the hydrochloride salt by treatment with
HCl/ethanol/ether, the solvents evaporated and the residue washed several times with ether and dried under high vacuum to yield 1.47 g. This material (1.47 g, 0.00646 mol) was dissolved in ethanol (40 ml) together with ethyl 2-formyl-3-(6-methylpyrid-3-yl)propionate (0.95 g, 0.00431 mol) and triethylamine and heated under reflux for 6 h. The solvent was evaporated and the residue treated with water and extracted with ethyl acetate, dried (MgS04) and evaporated to an oil. Purification by chromatography (silica, methanol/chloroform) followed by crystallisation from ethyl acetate-petrol gave 2-(4-phenylbut-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)- pyrimidin-4-one, yield 0.09 g (6%). MPt 88-90°C; Η-NMR (CDC13) δ 1.75 (4H, m), 2.49 (3H, s), 2.65 (2H, t), 3.64 (2H,s), 4.32 (2H, t), 6.90-7.60 (8H, m), 8.38 (IH, m).
Example 103 - 2-(2-Phenylethyl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one
Prepared from intermediate B21 by general method B as white crystals; MPt 158 - 160°C. 'H-NMR (d6-DMSO) δ 2.41 (3H,s), 2.93 (2H,t), 3.3 (2H+H20, t), 3.58 (2H,s), 7.14 (lH,d), 7.2-7.3 (5H,m), 7.52 (lH,dd), 7.83 (lH,s), 8.34 (lH,d), 12.7 (lH,br s).
Example 104 - 2-(2-Phenylethyl)thio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4- one
Prepared from intermediate B25 by general method B as white crystals; MPt 139 - 140°C. 'H-NMR (d6-DMSO) δ 2.94 (2H.t), 3.3 (2H+H20, t), 3.59 (2H,s), 3.81 (3H,s), 6.65 ( lH,s), 6.86 (lH,dd), 7.2-7.3 (5H,m), 7.85 (lH.br s), 8.03 (lH,d)
Example 105 - 2-Benzylthio-5-((l-methylpyrazol-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B34 by general method Al as a white crystalline solid. Η- NMR (d6-DMSO) δ 3.37 (2H,s), 3.71 (3H,s), 4.33 (2H,s), 7.2-7.4 (6H,m), 7.41 (lH,s), 7.67 (lH,br s), 12.7 (lH.br s); (APCI) M+H=313. C16H16N4OS requires 312.
Example 106 - 2-(4-Fluorobenzylthio)-5-((pyrimid-5-yl)methyl)pyrimidin-4-one
Prepared from intermediate B9 by general method A4. Η-NMR (d6-DMSO) δ 3.65 (2H,s), 4.38 (2H,s), 7.05-7.2 (2H,m), 7.35-7.5 (2H,m), 7.94 (lH,bs), 8.71 (2H,s), 9.06 (lH,s); MS (APCI-) found (M-1 ) = 327; C16H13FN4OS requires 328.
Example 107 - 2-(3,4-Difluorobenzylthio)-5-((2-methoxypyrimid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediate B39 by general method A4. ' H-NMR (d6-DMSO) δ 3.57 (2H, s), 3.87 (3H, s), 4.37 (2H, s), 7.24-7.53 (3H, m). 7.88 (IH, br.s), 8.49 (2H, s), 12.88 (IH, br s); MS (APCI+) found (M+l) = 377; C17H20F2N4O2S requires 376.
Example 108 - 2-(4-Fluorobenzylthio)-5-((2-methoxypyrimid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediate B39 by general method A4. 'H-NMR (d6 DMSO) δ 3.55 (2H,s), 3.85 (3H,s), 4.36 (2H,s), 7.0-7.2 (2H,m), 7.35-7.5 (2H,m), 7.86 (lH,bs), 8.48 (2H,s) 12.81 (lH,b); MS (APCI+) found (M+l) = 359; C17H15FN402S requires 358.
Example 109 - 2-(4-Fluorobenzylthio)-5-((2-benzyloxypyrimid-5- yl)methyl)pyrimidin-4-one
Prepared from intermediate B40 by general method A4. 'H-NMR (d6-DMSO) δ 3.57 (2H,s), 4.38 (2H,s), 5.35 (2H,s), 7.0-7.2 (2H,m), 7.25-7.5 (7H,m), 7.87 (lH,bs), 8.51 (2H,s); MS (APCI+) found (M+l ) = 435; C23H19FN402S requires 434.
Example 110 - l-(4-Hydroxycyclohexyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B46 and Al by general method A4. 'H-NMR (CDC13) δ l. l-2.3(18H.m), 2.94(2H,t), 3.24(2H,t), 3.6-3.8(3H,m). 4.2(lH.m), 7.12( lH,s), 7.45(2H,m), 7.90(2H,m), 8.71(2H,s) and 9.09(lH,s); MS (APCI+) found (M+l)=555; C29H35C1N403S requires 554.
Example 111 - l-(2-Methoxyethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B87 by general method A4. Η-NMR (CDC13) δ 1.25- 1.85(10H,m), 2.93(2H,t), 3.26(2H,t), 3.32(3H,s), 3.62(2H,t), 3.69(2H,s), 3.98(2H,t), 7.08(lH,s), 7.43(2H,m), 7.90(2H,m), 8.70(2H,s) and 9.09(lH,s); MS (APCI+) found (M+l)=515; C26H31C1N403S requires 514.
Example 112 - l-(3-(l-Imidazolyl)prop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B47 and Al by general method A4, as a yellow oil. ' H-NMR (CDC13) δ 1.38 (6H, m), 1.70 (4H, m), 2.25 (2H, m), 2.91 (2H, t), 3.25 (2H, t), 3.69 (2H, s), 3.77 (2H, t), 4.07 (2H, t), 6.81 (IH, s), 6.92 (IH, s), 7 13 (IH, s), 7.43 (2H, d), 7.50 (IH, s), 7.89 (2H, d), 8.70 (2H, s), 9.10 (IH, s); MS APCI+) found (M+l) =565; C29H33C1N602S requires 564.
Example 113 - l-(3-(l-Morpholino)prop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B48 and Al by general method A4, as a thick gum. ' H-NMR (CDCI3) δ 1.2-1.8(10H,m), 1.93(2H,m), 2.25-2.5(6H,m), 2.93(2H,f), 3.25(2H,t), 3.55- 3.8(6H.m), 3.90(2H,t), 7.07(lH,s), 7.45(2H,m), 7.90(2H.m), 8.72(2H,s) and 9.12(lH,s); MS (APCI+) found (M+l)=584; C30H38ClN5O3S requires 583. Example 114 - l-(3-(2-Oxo-l-pyrrolidino)prop-l-yl)-2-(8-(4-chlorophenyl)-8- oxooct-l-yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B49 and Al by general method A4, as a yellow oil. 'H-NMR (CDCI3) δ 1.38 (6H, m), 1.74 ( 4H, m), 1.98 (2H, m), 2.10 (2H, m), 2.43 (2H, t), 2.93 (2H, m), 3.25 (2H, t), 3.34 (2H, t), 3.41 (2H, t), 3.70 (2H, s), 3.82 (2H, t), 7.43 (2H, m), 7.54 (IH, s), 7.89 (2H, m), 8.74 (2H, s), 9.07 (IH, s); MS APCI+) found (M+l) =582; C30H36ClN5O3S requires 581.
Example 115 - l-(3-Dimethylaminoprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l- y l)thio-5-(py rimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B51 and Al by general method A4. as a thick gum. 'H-NMR (CDC13) δ 1.2-1.8(10H,m), 1.8-2.05(4H,m), 2.14(3H,s), 2.19(3H,s), 2.93(2H,t), 3.24(2H,t), 3.70(2H,s), 7.42(2H,m), 7.88(2H,m) 8.72(2H,s) and 9.09(lH,s); MS (APCI+) found (M+l)=542; C28H36C1N502S requires 541.
Example 116 - l-(3-Hydroxyprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B52 and Al by general method A4. 'H-NMR (CDC13) δ 1.3- 1.55 (6H,m), 1.6-1.85 (4H), 1.95-2. l(2H,m), 2.93(2H,t), 3.25(2H,t), 3.6-3.8 (4H,m),
4.01(2H,t), 7.1 l(lH,s) 7.45(2H,d). 7.89(2H,d), 8.70(2H,m) and 9.08(lH,s); MS (APCI+) found (M+l )=515; C26H31C1N403S requires 514.
Example 117 - l-(3-Hydroxyprop-l-yl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- benzylpyrimidin-4-one
Prepared from intermediate B52and A24 by general method A4, as a colourless powder. MPt 76 - 77°C; Η-NMR (CDC13) δ 1.2-2.0(14H,m), 2.56(2H,t), 3.25(2H,t), 3.61(2H,t), 3.73(2H,s), 3.88(2H,t), 6.76(lH,s), 7.09(lH,d) and 7.15-7.4(7H,m); MS (FAB) found M+H=499; C28H35C1N202S requires 498.
Example 118 - l-(3-Methoxyprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B54 and Al by general method A4. Η-NMR (CDC13) δ 1.2- 1.85(10H,m), 2.00(2H,m), 2.94(2H,t), 3.2-3.4(7H,m), 3.70(2H,s), 3.92(2H,t), 6.99(lH,s), 7.44(2H.m), 7.90(2H,m), 8.71(2H,s) and 9.10(lH,s); MS (APCI+) found (M+l)=529; C27H33C1N403S requires 528.
Example 119 - l-(3-Phenylprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B55 and Al by general method A4. Η-NMR (CDC13) δ 1.2- 1.85(10H.m). 2.1 l(2H,quintet), 2.69(2H.t), 2.93(2H.t), 3.24(2H,t), 3.67(2H,s), 3.78(2H,t), 6.84(lH.s), 7.1-7.5(7H.m), 7.90(2H,m), 8.70(2H,s) and 9.10(lH,s); MS (APCI+) found (M+l)=575; C32H35C1N402S requires 574.
Example 120 - l-(5-Hydroxypent-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B56 and Al by general method A4. Η-NMR (CDC13) δ 1.3- 1.9(16H.m), 2.94(2H,t), 3.25(2H.t), 3.6-3.75(4H.m). 3.80(2H,t), 6.96(lH,m), 7.44(2H.m), 7.90(2H.m), 8.71(2H.s) and 9.09(lH,s); MS (APCI+) found (M+l)=543; C28H35C1N403S requires 542. Example 121 - l-(Pyrid-2-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B45 and Al by general method A4, as a white solid. Η- NMR (CDCI3) δ 1.3-1.5 (6H,m), 1.6-1.8(4H,m), 2.92(2H,t), 3.25(2H,t), 3.71(2H,s), 5.06(2H,s), 7.2-7.35(3H,m), 7.6-7.8(lH,m), 8.5-8.6(lH,m), 8.70(2H,s) and 9.10(lH,s); MS (APCI+) found (M+l)=548; C29H30ClN5O2S requires 547.
Example 122 - l-(Pyrid-2-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- benzylpyrimidin-4-one
Prepared from intermediate B57 and A24 by general method A4, as a pale brown oil. H- NMR (CDCI3) δ 1.2-1.5(8H.m), 1.5-1.85(4H,m), 2.55(2H,t), 3.24(2H,t), 3.77(2H,s), 5.00(2H,s), 6.88(lH,s), 7.09(2H,d), 7.25-7.4(9H,m), 7.68(lH.m) and 8.57(lH,m); MS (El) found M=531; C31H34C1N30S requires 531.
Example 123 - l-(Pyrid-3-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-((l- methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B58 and Al by general method A4, as a buff coloured solid. MPt 105 - 106°C; Η-NMR (CDC13) δ 1.36 (6H, m), 1.71 (4H, m), 2.96 (2H, t), 3.26 (2H, t), 3.49 (3H, s), 3.53 (2H, s), 5.02 (2H, s), 6.14 (IH, m), 6.34 (IH, s), 6.99 (IH, s), 7.17 (IH, m), 7.25-7.55 (4H, m), 7.91 (2H, d), 8.52 (IH, s), 8.64 ( IH, m); MS (APCI+) found (M+l) = 577; C31H33C1N403S requires 576.
Example 124 - l-(Pyrid-3-ylmethyI)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B59 and Al by general method A4, as a white solid. MPt 80 - 83°C; 'H-NMR (CDC13) δ 1.40 (6H, m), 1.69 (4H, m), 2.93 (2H, t), 3.26 (2H, t), 3.69 (2H, s), 5.04 (2H, s), 7.04 (IH, s), 7.30-7.56 (4H, m), 7.91 (2H, d), 8.55 (IH, m), 8.68 (3H, m), 9.10 (IH, s); MS (APCI+) found (M+l) = 548; C29H30ClN5O2S requires 547.
Example 125 - l-(Pyrid-3-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- benzylpyrimidin-4-one
Prepared from intermediate B60 and A24 by general method A4, as a pale brown oil. Η- NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.85(4H,m), 2.56(2H,t), 3.26(2H,t), 3.75(2H,s), 4.92(2H,s), 6.66(lH,s), 7.09(lH,d), 7.15-7.5(9H,m), 8.45(lH,m) and 8.59(lH,m); MS (El) found 531 ; C31H34C1N30S requires 531. •
Example 126 - l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yI)thio-5-((l- methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B61 and A24 by general method A4, as an orange gum. Η- NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.75(4H,m), 2.55(2H,t), 3.24(2H,t), 3.49(3H,s), 3.55(2H,s), 5.01(2H,s), 6.16(lH,m), 6.35(lH,bs), 6.9-7.35(8H,m) and 8.63(2H,m); MS (FAB) M+l=563; C31H35C1N402S requires 562.
Example 127 - l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-((l- methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B61 and Al by general method A4, as an off-white solid. MPt 113 - 1 14°C; Η-NMR (CDC13) δ 1.29 (6H, m), 1.63 (4H, m), 2.86 (2H, t), 3.19 (2H, t), 3.43 (3H, s), 3.49 (2H, s), 4.95 (2H, s), 6.09 (IH, m), 6.29 (IH, m), 6.89 (IH, s), 6.99 (2H, m), 7.12 (IH, d), 7.36 (2H, d), 7.83 (2H, d). 8.58 (2H, m). Example 128 - l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B62 and Al by general method A4, as a buff coloured solid. MPt 75 - 77°C; Η-NMR (CDC13) δ 1.35 (6H, m), 1.67 (4H, m), 2.92 (2H, t), 3.27 (2H, t), 3.72 (2H, s), 5.02 (2H, s), 6.99 (IH, s), 7.05 (2H, m), 7.43 (2H, d), 7.89 (2H, d), 8.64 (4H, m), 9.09 (IH, s); MS (APCI+) found (M+l) = 548; C29H30C1N5OS requires 547.
Example 129 - l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- benzylpyrimidin-4-one
Prepared from intermediate B63 and A24 by general method A4, as a buff powder. MPt 108 - 1 10°C; 'H-NMR (CDC13) δ 1.2-1.8(12H.m), 2.55(2H,t), 3.25(2H,t), 3.77(2H,s), 4.91(2H,s), 6.62(lH,s), 6.68(2H,d), 7.08(2H,d), 7.15-7.4(7H,m) and 8.5-8.7(2H,m); MS (El) found M=531 ; C3 !H34C1N30S requires 531.
Example 130 - l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thiopyrimidin-4- one
Prepared from intermediate B64 and A24 by general method A4, as a brown gum. Η- NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.55(2H,t), 3.24(2H,t), 5.04(2H,s), 6.11(lH,d), 7.0-7.4(7H,m) and 8.65(2H,m); MS (El) M=441; C24H28C1N30S requires 441.
Example 131 - l-(2-(Pyrid-2-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B65 and Al by general method A4. Η-NMR (CDC13) δ 1.2- 1.8(10H.m). 2.94(2H.t), 3.2-3.35(4H.m), 3.53(2H.s), 4.32(2H,t), 6.74(lH,s), 7.04(lH,m), 7.20(lH,m), 7.43(2H,m), 7.57(lH.m), 7.88(2H.m), 8.4-8.55(3H,m) and 9.09(lH,s); MS (APCI+) found (M+l)=562; C30H32ClN5O2S requires 561.
Example 132 - l-(2-(Pyrid-3-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- ((l-methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B66 and Al by general method A4, as a cream coloured crystalline solid. MPt 121 - 123°C; Η-NMR (CDC13) δ 1.42 (6H, m), 1.7 (4H, m), 2.94 (2H, t), 3.07 (2H. t), 3.29 (2H, t), 3.45 (2H, s), 3.51 (3H, s), 4.01 (2H, t), 6.05 (IH, m), 6.28 (IH, m), 6.64 (IH, s), 7.16 (IH. d), 7.26 (IH, m), 7.45 (3H, m), 7.89 (2H, d), 8.45 ( IH, m), 8.54 (IH, m); MS (APCI+) found (M+l) = 591; C32H35C1N403S requires 590.
Example 133 - l-(2-(Pyrid-3-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B67 and Al by general method A4. Η-NMR (CDC13) δ 1.3- 1.9 (10H,m), 2.94 (2H,t), 3.08 (2H.t), 3.58(2H.s). 4.03(2H,t), 6.57 (lH,s), 7.43 (2H,m), 7.90 (2H,m), 8.44 (lH,m), 8.55 (3H.m) and 9.09 ( lH,m); MS (APCI+) found (M+l)=562; C30H32ClN5O2S requires 561.
Example 134 - l-(2-(Pyrid-4-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- ((l-methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B68 and Al by general method A4, as a cream coloured crystalline solid. MPt 129 - 130°C: Η-NMR (CDC13) δ 1.40 (6H, m), 1.70 (4H, m), 2.95 (2H,t), 3.06 (2H, t), 3.30 (2H, t), 3.44 (2H, s), 3.51 (3H, s), 4.04 (2H, t), 5.95 (IH, m), 6.29 (IH, m), 6.56 (IH, s), 7.08 (2H, m), 7.17 (IH, d), 7.44 (2H,d), 7.90 (2H, d), 8.53 (2H, m); MS (APCI+) found (M+l) = 591 ; C32H35C1N403S requires 590. Example 135 - l-(2-(Pyrid-4-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B69 and Al by general method A4. ' H-NMR (CDC13) δ 1.25-1.9(10H.m), 2.91(2H,t), 3.06(2H,t), 3.29(2H,t), 3.59(2H,s), 4.04(2H,t), 6.62(lH,s), 7.07(2H,m), 7.43(2H,m), 7.90(2H,m), 8.45-8.7(4H,m) and 9.10(lH,s); MS (APCI+) found (M+l)=562; C30H32ClN5O2S requires 561.
Example 136 - l-(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-((l-methyI-2- oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B70 and A24 by general method A4, as a pale brown gum. 'H-NMR (d6-DMSO) δ 1.2-1.5(8H.m), 1.5-1.8(4H,m), 2.54(2H,t), 3.01(2H,t), 3.11(2H,t), 3.26(2H,s). 3.35(3H+HOD), 4.09(2H.t), 5.94(lH,dd), 6.10(lH,d), 7.1-7.4(9H,m) and 7.54(2H.m).
Example 137 - l-(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from Example 70 by general method Cl, as a brown/green gum. Η-NMR (CDC13) δ 1.2-1.8( 12H,m), 2.56(2H.t), 3.01(2H,t), 3.26(2H,t), 3.51(2H,t), 3.97(2H,t), 6.27(lH,s), 7.0-7.5(1 lH.m), 8.30( lH,m) and 8.46(lH,m); MS (FAB) M+l=546; C32H36C1N30S requires 545. Example 138 - l-(2-Methylprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B88 and Al by general method A4. Η-NMR (d6-DMSO) δ 0.88 (6H,d), 1.2-1.4 (6H,m), 2.5-2.7 (4H,m), 2.08 (lH,m), 3.00 (2H,t). 3.11 (2H,t), 3.57 (2H,s), 3.69 (2H,d), 7.58 (2H,d), 7.82 (lH,s), 7.97 (2H,d), 8.70 (2H,s), 9.01 (lH,s); MS (APCI) M=513; C27H33C1N402S requires 513.
Example 139 - l-PhenylsulfonyI-2-(8-(4-chlorophenyl)oct-l-yI)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Benzenesulfonyl chloride (41mg) was added to a solution of 2-(8-(4-chlorophenyl)oct-l- yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one (103mg) in pyridine (0.5ml), and the mixture stirred overnight. Evaporation of the pyridine followed by chromatography (silica, 0-2% methanol in dichloromethane) gave l-phenylsulfonyl-2-(8-(4- chlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one (25mg). Η-NMR
(CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.56(2H,t), 2.92(2H,t), 3.87(2H,s), 7.08(2H,d), 7.15-7.8(7H,m). 7.95(2H,m), 8.29(lH,s) and 8.35-8.7(2H,bm).
Example 140 - l-Benzyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-((l-methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B71 and A24 by general method A4, as a yellow/orange gum. 'H-NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2,56(2H,t), 3.25(2H,t), 3.49(3H,s), 3.52(2H,s), 4.99(2H,s), 6.16(lH.dd). 6.34(lH,m), 6.95(lH,s) and 7.0-7.5(10H.m); MS (El) M=561 ; C32H36C1N302S requires 561. Example 141 - l-Benzyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-((l-methyl-2- oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B71 and Al by general method A4, as a pale brown solid. 'H-NMR (CDCI3) δ 1.38 (6H, m), 1.73 (4H, m), 2.93 (2H, t), 3.26 (2H, t), 3.49 (3H, s), 3.52 (2H, s), 4.99 (2H, s), 6.16 (IH, m), 6.33 (IH, m), 6.96 (IH, s), 7.16 (3H, m), 7.27- 7.45 (5H, m), 7.90 (2H, d).
Example 142 - l-BenzyI-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from Example 30 by general method Cl, as a pale yellow gum. 'H-NMR (CDCI3) δ 1.2-1.8(12H,m), 2.5-2.65(5H,m), 3.25(2H,t), 3.68(2H,s), 4.95(2H.s), 6.78(lH.s), 7.0-7.6(1 lH,m) and 8.31(lH,d); MS (El) found M=546; C32H36C1N30S requires 546.
Example 143 - l-BenzyI-2-(8-phenyloct-l-yl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one
Prepared from Example 21 by general method Cl, as a pale yellow oil. Η-NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.53(3H,s), 2.59(2H,t), 3.24(2H,t), 3.68(2H,s), 4.95(2H,s), 6.78(lH,s), 7.0-7.5(1 lH.m), 7.52(lH,m) and 8.31(lH,bs); MS (FAB) M+l=512; C32H37N3OS requires 51 1.
Example 144 - l-Benzyl-2-(8-phenyloct-l-yl)thio-5-((2-methoxypyrid-4- yl)methyl)pyrimidin-4-one
Prepared from Example 37 by general method Cl, as a thick gum. 'H-NMR (CDC13) δ 1.2-1.8(10H.m), 2.59(2H,t), 3.26(2H,t), 3.66(2H,s), 3.91(3H,s), 4.95(2H,s), 6.56(lH,bs), 6.73(lH,m), 6.78(lH,s), 7.05-7.45(10H,m) and 8.03(lH,m); MS (APCI+) Found (M+l)=528. C32H37N302S requires 527.
Example 145 - l-Benzyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from Example 47 by general method Cl, as a colourless oil. Η-NMR (CDC13) δ 1.25-1.5(6H,m), 1.5-1.85(4H,m), 2.93(2H,t), 3.25(2H,t), 3.71(2H,s), 4.96(2H,s), 6.83(lH,s), 7.05-7.5(8H,m), 7.60(lH,txd), 7.88(2H,d) and 8.4-8.55(2H,m); MS (El) found M=545; C31H37C1N302S requires 545.
Example 147 - l-(2-Thienylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B73 and Al by general method A4. as a white crystalline solid. MPt 68 - 70°C; Η-NMR (CDC13) δ 1.38 (6H, m), 1.69 (4H, m), 2.93 (2H, t), 3.29 (2H, t), 3.67 (2H, s), 5.14 (2H, s), 7.04 (3H, m). 7.37 (IH, m), 7.43 (2H, m), 7.90 (2H, m), 8.67 (2H, s), 9.01 (IH, s); MS APCI+) found (M+l) =553; C28H29C1N402S2 requires
552.
Example 148 - l-(2,2-Dimethylprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B74 and Al by general method A4. ' H-NMR (CDC13) δ 0.98(9H,s), 1.2-1.85(10H.m), 2.93(2H,t), 3.24(2H,t), 3.65(2H,s), 3.70(2H,s), 6.89(lH,s), 7.43(2H.m), 7.90(2H,m), 8.69(2H,s) and 9.09(lH.s); MS (APCI+) found (M+l)=527; C28H 5C1N402S requires 526. Example 149 - l-(2-(l-Piperidino)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B75 and Al by general method A4, as a yellow oil. Η- NMR (CDC13) δ 1.34-1.90 (16H, m), 2.30-2.55 (6H, m), 2.93 (2H, t), 3.25 (2H, t), 3.71 (2H, s), 4.40 (2H, m), 7.02 (IH, s), 7.42 (2H, m), 7.89 (2H, m), 8.70 (2H, s), 9.09 (IH, s); MS APCI+) found (M+l) =568; C30H38ClN5O2S requires 567.
Example 150 - l-(2-Hydroxyethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B77 and Al by general method A4. Η-NMR (CDC13) δ 1.3-1.8(10H.m), 2.93(2H.t), 3.25(2H,t), 3.66(2H,s), 3.99(4H,m), 7.20(lH,s), 7.43(2H,m), 7.89(2H,m), 8.68(2H.s) and 9.05(lH.s); MS (APCI+) found (M+l)=501; C25H29C1N403S requires 500.
Example 151 - l-(2-Hydroxyethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- benzylpyrimidin-4-one
Prepared from intermediates B78 and A24 by general method A4, as a colourless gum. 'H-NMR (CDC13) δ 1.2-1.5(8H.m), 1.5-1.8(4H,m), 2.54(2H.t), 3.21(2H,t), 3.64(2H,s), 3.8-4.15(4H,m), 5.23(lH,bs), 6.97(lH,s), 7.08(2H,d) and 7.1-7.45(7H,m).
Example 152 - l-Ethyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediates B89 and Al by general method A4. Η-NMR (d6-DMSO) δ 1.2-1.4 (9H.m), 2.5-2.7 (4H.m). 2.84 (2H,t). 3.1 1 (2H,t), 3.56 (2H,s), 3.89 (2H,q), 7.58 (2H.d), 7.85 (lH,s), 7.97 (2H,d), 8.70 (2H,s), 9.01 (lH,s); MS (APCI) M=485; C25H29C1N402S requires 485.
Example 153 - l-(Fur-2-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B81 and Al by general method A4, as a light brown oil. Η- NMR (CDC13) δ 1.38 (6H, m), 1.70 (4H, m), 2.93 (2H, t), 3.27 (2H, t), 3.69 (2H, s), 4.94 (2H, s), 6.40 (2H, m), 7.06 (IH, s), 7.44 (3H, m), 7.90 (2H, m), 8.68 (2H, s), 9.09 (IH, s); MS APCI+) found (M+l) =537; C28H29C1N403S requires 536.
Example 154 - l-(Fur-2-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yI)thio-5- benzylpyrimidin-4-one
Prepared from intermediates B82 and A24 by general method A4, as a pale brown gum. 'H-NMR (CDCI3) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.56(2H,t), 3.27(2H,t), 3.73(2H,s), 4.85(2H,s), 6.33(2H,s), 6.73(lH,s), 7.09(2H,d) and 7.2-7.5(8H,m); MS (FAB) M+l=521; C30H33ClN2O2S requires 520.
Example 155 - l-Methyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- bromopyrimidin-4-one
l-Methyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thiopyrimidin-4-one was prepared from 1- methyl-2-thiouracil by general method A4. A solution of bromine (0.05ml) in dichloromethane (1ml) was added to a slurry of l-methyl-2-(8-(4-chlorophenyl)-8- oxooct-l-yl)thiopyrimidin-4-one (0.38g) in dichloromethane (20ml), and the mixture was stirred for 24 hours. The solution was washed with aqueous sodium carbonate, dried and evaporated. Chromatography (silica, 1-4% methanol in dichloromethane) gave 1-methyl- 2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-bromopyrimidin-4-one (0.18g), as a white solid. 'H-NMR (CDCI3) δ 1.3-1.5 (6H,m), 1.65-1.8 (4H,m), 2.94 (2H,t), 3.26(2H, t), 3.56(3H,s), 7.45(2H,d), 7.56(lH.s) and 7.90(2H,d); MS (APCI+) found (M+l)=459; C19H22BrClN202S requires 458. Example 156 - l-Methyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-((l-methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediates B83 and A24 by general method A4, as a colourless solid. 'H-NMR (CDCI3) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.56(2H,t), 3.25(2H,t), 3.49(3H,s), 3.51(3H,s), 3.54(2H,s), 6.19(lH,m), 6.38(lH,m), 6.93(lH,s) and 7.0-7.35(5H,m); MS (El) M=485; C26H32C1N302S requires 485.
Example 157 - l-Methyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-((l-methyl-2- oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediates B83 and Al by general method A4, as a cream coloured crystalline solid. MPt 90-5°C; 'H-NMR (CDC13) δ 1.38 (6H, m), 1.72 (4H, m), 2.91 (2H, t), 3.26 (2H.t), 3.49 (3H, s), 3.51 (3H, s), 3.54 (2H, s), 6.19 (IH, m), 6.38 (IH, s), 6.93 (IH, s), 7.19 (IH, m), 7.43 (2H, d), 7.90 (2H, d); MS (APCI+) Found (M+l) = 500; C26H30N3O3S requires 499.
Example 158 - l-Methyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from Example 70 by general method Cl, as a pale yellow oil. ' H-NMR (CDC13) δ 1.2-1.8(12H.m), 2.56(2H,t), 3.22(2H,t), 3.46(3H,s), 3.74(2H,s), 6.77(lH,s), 7.08(2H,d), 7.15-7.35(4H,m), 7.66( lH,txd) and 8.49(2H,bs); MS (El) found M=455; C25H30C1N3OS requires 455.
Example 159 - l-Methyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediates B84 and Al by general method A4, as a white solid. Η- NMR (CDC13) δ 1.3-1.55(6H.m), 1.6-1.85(4H,m), 2.93(2H,t), 3.26(2H,t), 3.51(3H,s), 3.70(2H,s). 6.94(lH,s), 7.45(2H,d), 7.89(2H,d), 8.70(2H,s) and 9.1(lH,s); MS (APCI+) found (M+l)=471; C24H27C1N402S requires 470. Example 160 - l-Methyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-benzylpyrimidin-4- one
Prepared from intermediates B85 and A24 by general method A4, as a colourless powder. MPt 92 - 93°C; Η-NMR (CDC13) δ 1.2-1.8(12H,m), 2.56(2H,t), 3.26(2H,t), 3.40(3H,s), 3.76(2H,s), 6.59(lH,s), 7.09(2H,d) and 7.15-7.45(7H,m); MS (El) found M=454; C26H31C1N20S requires 454.
Example 161 - l-Phenyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-((l-methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediates B86 and A24 by general method A4, as a yellow/orange solid. 'H-NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.54(2H,t), 3.14(2H,t), 3.49(3H,s), 3.57(2H,s), 6.22(lH,m), 6.38(lH,m), 7.00(lH,s), 7.08(2H,d), 7.15-7.4(5H,m) and 7.5-7.6(3H,m); MS (El) M=547; C31H34C1N302S requires 547.
Example 162 - l-MethylsulfonyI-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one
Prepared from Example 70, analogously to example 139. 'H-NMR (CDC13) δ 1.2- 1.8(12H,m), 2.56(2H,t), 3.10(2H,t), 3.55(3H,s), 4.03(2H,s), 7.09(2H,m), 7.15-7.3(2H,m), 7.61(lH,m), 7.96(lH.m), 8.45(lH,s) and 8.60(2H.m).
Example 163 - l-Benzyl-2-(8-phenyloct-l-yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4- one
Prepared from Example 100 by general method Cl, as a pale buff solid. MPt 74 - 78°C; Η-NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.85(4H.m), 2.58(2H,t), 3.72(2H,s), 4.40(2H,t), 4.83(2H,s), 6.76(lH.s), 7.0-7.4(1 lH.m), 7.6-7.7(lH.m) and 8.46(2H,m); IR 1655, 1621 cm-1. Example 164 - l-(2-Methoxyethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B87 by general method A4. 'H-NMR (CDC13) δ 3.31(3H,s), 3.59(2H,t), 3.71(2H,s), 4.51(2H,s), 7.10(lH,s), 7.2-7.45(5H,m), 8.72(2H,s) and 9.10(lH,s); MS (APCI+) found (M+l)=369; C19H20N4O2S requires 368.
Example 165 - l-(3-Phenylprop-l-yI)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B55 by general method A4. Η-NMR (CDC13) δ
2.08(2H,quintet), 2.65(2H,t), 3.68(2H,s), 3.75(2H,t), 4.49(2H,s), 5.30(2H,s), 6.84(lH,s), 7.10(2H,m), 7.15-7.5(8H,m), 8.69(2H,s) and 9.10(lH,s); MS (APCI+) found (M+l)=429; C25H24N4OS requires 428.
Example 166 - l-(5-Hydroxypent-l-yl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B56 by general method A4. Η-NMR (CDC13) δ 1.3- 1.9(6H,m), 3.64(2H,t), 3.7-3.9(4H.m), 4.50(2H,s), 6.98(lH,m), 7.2-7.5(5H,m), 8.72(2H,s) and 9.10(lH.s); MS (APCI+) found (M+l)=397; C21H24N402S requires 396.
Example 167 - l-(Pyrid-2-ylmethyl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B45 by general method A4. Η-NMR (CDC13) δ 3.73(2H,s), 4.49(2H,s), 5.03(2H.s), 7.1-7.4(8H.m), 7.69(lH.m), 8.57(lH,m), 8.71(2H,s) and 9.09(lH,s); MS (APCI+) found (M+l)=402: C22H19N5OS requires 401. Example 168 - l-(Pyrid-3-ylmethyl)-2-benzylthio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B58 by general method A4, as a buff coloured solid. Η- NMR (CDCI3) δ 3.5 (3H, s), 3.55 (2H, s), 4.51 (2H, s), 4.99 (2H, s), 6.27 (IH, m), 6.26 ( IH, s), 7.01 (IH, s), 7.15-7.50 (8H, m),8.50 (IH, s), 8.62 (IH, m); MS (APCI+) found (M+l) = 431; C24H22N402S requires 430.
Example 169 - l-(Pyrid-4-ylmethyl)-2-benzylthio-5-benzylpyrimidin-4-one
Prepared from intermediate B63 by general method A4, as a brown gum. 'H-NMR (CDCI3) δ 3.78(2H,s), 4.50(2H,s), 4.89(2H,s), 6.64(lH,s), 6.94(2H,d), 7.1-7.5(10H,m) and 8.58(2H,d); MS (El) found M=399; C24H21N3OS requires 399.
Example 170 - l-(2-(Pyrid-2-yl)ethyI)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B65 by general method A4. 'H-NMR (CDC13) δ 3.20(2H,t),
3.55(2H.s), 4.30(2H,t), 4.53(2H,s), 6.75(lH.s). 6.96(lH,m), 7.17(lH,m), 7.25-7.5(5H,m),
7.56(lH,m), 8.4-8.55(3H,m) and 9.10(lH,s),; MS (APCI+) found (M+l)=416;
C23H21N5OS requires 415.
Example 171 - l-(2-(Pyrid-3-yl)ethyI)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B67 by general method A4. Η-NMR (CDC13) δ 3.05(2H,t), 3.60(2H,s), 4.00(2H,t), 4.54(2H,s), 6.57(lH,s), 7.1-7.5(6H,m), 8.43(lH,m), 8.5- 8.65(3H,m) and 9.10(lH,s); MS (APCI+) found (M+l)=416; C23H21N5OS requires 415.
Example 172 - l-(2-(Pyrid-4-yl)ethyl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B68 by general method A4, as a buff coloured solid. Η- NMR (CDC13) δ 3.02 (2H, t), 3.45 (2H, s), 3.52 (3H, s), 4.00 (2H, t), 4.55 (2H, s), 5.95 (IH, m), 6.30 (IH, s), 6.57 (IH, s), 7.02 (2H, m), 7.18 (IH, m), 7.19-7.44 (5H, m), 8.50 (2H, m); MS (APCI+) Found (M+l) = 445; C25H24N402S requires 444.
Example 173 - l-(2-(Pyrid-4-yl)ethyl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B69 by general method A4. 'H-NMR (CDC13) δ 3.03(2H,t), 3.60(2H.s), 4.01(2H,t), 4.54(2H,s), 6.61(lH,s), 7.01(2H,m), 7.25-7.5(5H,m), 8.45-
8.65(4H.m) and 9.1 l( lH.s); MS (APCI+) found (M+l)=416; C23H21N50S requires 415.
Example 174 - l-(2-Phenylethyl)-2-benzylthio-5-((2-methoxypyrid-4- yl)methyl)pyrimidin-4-one
Prepared from Example 88 by general method Cl. Η-NMR (CDC13) δ 3.01(2H,t),
3.57(2H,s), 3.95(5H,m), 4.53(2H,m), 6.27(lH,s), 6.45(lH,s), 6.55(lH.m), 7.0(2H.m), 7.1- 7.5(8H,m) and 8.02(lH,d); MS (APCI+) found M+H=444; C26H25N302S requires 443. Example 175 - l-Benzyl-2-benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4- one
Prepared from intermediate Example 88 by general method Cl, as a colourless stiff gum. 'H-NMR (CDC13) δ 3.67(2H,s), 3.90(3H,s), 4.51(2H,s), 4.93(2H,s), 6.57(lH,s), 6.73(lH,m), 6.81(lH,s), 7.10(lH,m), 7.25-7.45(9H,m) and 8.04(lH,d); MS (El) M=429; C25H23N302S requires 429.
Example 176 - l-(2-Thienylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B73 by general method A4, as a pale yellow crystalline solid. MPt 110 - 112°C; 'H-NMR (CDC13) δ 3.69 (2H, s), 4.54 (2H, s), 5.1 1 (2H, s), 7.02 (3H, m). 7.30-7.42 (6H, m), 8.65 (2H, s). 9.09 (IH, s); MS APCI+) found (M+l) = 407; C21H18N4OS2 requires 406.
Example 177 - l-(2,2-Dimethylprop-l-yl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B74 by general method A4. 'H-NMR (CDC13) δ 0.96(9H,s), 3.62(2H,s). 3.72(2H,s), 4.49(2H,s), 6.91(lH.s), 7.25-7.45(5H,m), 8.70(2H,s) and 9.11(lH,s); MS (APCI+) found (M+l)=381; C21H24N4OS requires 380.
Example 178 - l-(Fur-2-ylmethyI)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B81 by general method A4, as a brown oil. 'H-NMR (CDCI3) δ 3.70 (2H, s), 4.52 (2H, s), 4.91 (2H, s), 6.40 (2H, m), 7.06 (IH, s), 7.26-7.42 (6H, m), 8.70 (2H, s), 9.10 (IH, s); MS APCI+) found (M+l) =391; C21H18N402S requires 390.
Example 179 - l-Methyl-2-benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin- 4-one
Prepared from Example 88 by general method Cl, as a pale cream powder. MPt 119 - 120°C; 'H-NMR (CDC13) δ 3.44(3H,s), 3.69(2H,s), 3.93(3H,s), 4.52(2H,s), 6.62(lH,bs), 6.78(2H,m), 7.2-7.5(5H,m) and 8.10(lH,m); MS (El) M=353; C19H19N302S requires 353.
Example 180 - l-Benzyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B94 by general method A4. Η-NMR (CDC13) δ 1.2-1.8 (12H,m), 2.55(2H,t), 3.25 (2H,t), 3.67 (2H,s), 5.00 (2H,s), 6.8-7.4 (10H,m), 8.7 (2H,s), 9.07 (lH,s); (APCI) M+H=533. C30H33C1N4OS requires 532.
Example 181 - l-(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A4, as a white crystalline solid. Η- NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.56(2H,t), 3.05 (2H,t), 3.29 (2H,t), 3.50(2H,s), 4.02 (2H,t), 6.36(lH,s), 7.0-7.1 (4H,m), 7.2-7.3 (5H,m), 8.47(2H,s) and 9.07(lH.s); (APCI) M+H=547. C31H35ClN4OS requires 546.
Example 182 - l-Methyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B84 by general method A4 as a white crystalline solid. Η- NMR (CDC13) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.56(2H.t), 3.25 (2H,t), 3.50 (3H,st), 3.70(2H,s), 6.94(lH,s), 7.09 (2H,m), 7.23 (2H,m), 8.69(2H,s) and 9.09(lH,s); (APCI) M+H=457. C24H29C1N40S requires 456.
Example 183 - l-Benzyl-2-(8-(4-chlorophenyI)-8-oxooct-l-yl)thio-5-(pyrid-4- yl)pyrimidin-4-one
l-Benzyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-pyrimidin-4-one was prepared from l-benzyl-2-thiouracil and intermediate Al by general method A4, then iodinated with iodine (1.2 equiv) and silver trifluoromethanesulfonate (1 equiv) in chloroform at room temperature overnight, giving l-benzyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- iodopyrimidin-4-one in 27% yield after chromatography. This compound (1 equiv) and 4-pyridylboronic acid (2 equiv) were suspended in dimethoxyethane, 2M aqueous sodium carbonate added, followed by tetrakis(triphenylphosphine)palladium (0.05 equiv). The mixture was refluxed for 16 hours, then the solvent evaporated. Aqueous workup, chromatography and crystallisation from ether gave the title compound as a white crystalline solid. Η-NMR (CDC13) δ 1.3-1.5 (6H,m), 1.6-1.8 (4H,m), 2.94 (2H,t), 3.32 (2H,t), 5.13 (2H,s), 7.27 (2H,d), 7.4 (6H,m), 7.55 (2H,d), 7.90 (2H,d); (APCI) M+H=532. C30H30ClN3O2S requires 531.
Example 184 - l-Benzyl-2-(8-(4-chlorophenyI)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B94 by general method A4. ' H-NMR (CDC13) δ 1.3-1.5
(4H.m), 1.6-1.8 (4H,m)2.93 (2H,t), 3.26 (2H,t), 3.67 (2H,s), 5.01 (2H,s), 6.98 (lH,s), 7.1-
7.2 (2H,m), 7.4-7.5 (5H,m), 7.90 (2H,d), 8.7 (2H,s), 9.07 (lH,s); (APCI) M+H=547.
C30H31ClN4O2S requires 546.
Example 185 - l-(2-Phenylethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A4 as a cream coloured crystalline solid. 'H-NMR (CDC13) δ 1.3-1.5(6H,m), 1.6-1.8(4H,m), 2.94(2H,t), 3.05 (2H,t), 3.30 (2H,t), 3.50(2H,s), 4.03 (2H,t), 6.37(lH,s), 7.05 (2H,m), 7.3 (3H.m), 7.43 (2H,d), 7.89 (2H,d), 8.47 (2H,s), 9.08 (lH,s); (APCI) M+H=561. C31H33C1N402S requires 560.
Example 186 - l-(Fur-2-ylmethyl)-2-(2-phenylethyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B81 by general method A4. Η-NMR (CDC13) δ 3.02 (2H,t), 3.54 (2H,t), 3.69 (2H,s), 4.91 (2H,s), 6.38 (2H,m), 7.06 (lH,s), 7.2-7.35 (5H,m), 7.4 ( lH,m), 8.7 (2H,s), 9.09 (lH,s); (APCI) M+H=405. C22H20N4O2S requires 404.
Example 187 - l-(2-Fluorobenzyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B 131 by general method A4. ' H-NMR (CDC13) δ 3.70 (2H.s), 4.51 (2H,s), 5.01 (2H,s), 7.08 (lH,s), 7.1-7.2 (3H,m), 7.2-7.4 (6H,m), 8.7 (2H,s), 9.09 (lH,s); (APCI) M+H=419. C23H19FN4OS requires 418.
Example 188 - l-(8-PhenyloctyI)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one
Prepared from intermediate B90 by general method A4. ' H-NMR (CDC13) δ 1.2- 1.4(8H,m), 1.5-1.8(4H,m), 2.59(2H,t), 3.6-3.8(4H,m), 4.50(2H,s), 6.93(lH,s), 7.1- 7.5(10H,m), 8.70(2H,s) and 9.10(lH,s); (APCI) M+H=499. C30H34N4OS requires 498.
Example 189 - l-(9-PhenylnonyI)-2-benzylthio-5-(pyrimid-5-ylmethyI)pyrimidin-4- one
Prepared from intermediate B91 by general method A4 as a thick oil. Η-NMR (CDC13) δ 1.2-1.4(10H,m), 1.5-1.85(4H,m), 2.59(2H,t), 3.6-3.8(4H,m), 4.50(2H,s), 6.94(lH,s), 7.1-7.45(lH,m), 8.69(2H,s) and 9.10(lH,s); (APCI) M+H=513. C31H36N4OS requires 512.
Example 190 - l-Benzyl-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B94 by general method A4. ' H-NMR (CDC13) δ 3.68 (2H,s), 4.51 (2H,s), 4.97 (2H,s), 7.00 (lH,s), 7.1 (2H,m), 7.2-7.4 (2H,m), 8.7(2H,s) and 9.08(lH,s); (APCI) M+H=401. C23H20N4OS requires 400.
Example 191 - l-Benzyl-2-benzylthio-5-((l-methylpyrazol-4-yl)methyl)pyrimidin- 4-one
Prepared from Example 105 by general method C3, as a pale brown oil. ' H-NMR (CDC13) δ 3.57 (2H.s), 3.84 (3H,s), 4.52 (2H,s), 4.93 (2H,s), 6.90 (lH,s), 7.1 (2H,s), 7.2- 7.4 (10H,m); (APCI) M+H=403. C23H22N4OS requires 402.
Example 192 - l-Benzyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B94 by general method A4. Η-NMR (CDC13) δ 3.68 (2H,s), 4.48 (2H,s), 4.97 (2H,s), 7.0 (3H,m), 7.1 (2H,m), 7.3-7.4 (5H,m), 8.7 (2H,s), 9.08 (lH,s); (APCI) M+H=419. C23H19FN4OS requires 418.
Example 193 - l-(2,2-Dimethylprop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
no Prepared from intermediate B74 by general method A4 as a oil. Η-NMR (CDC13) δ 0.96(9H,s), 3.61(2H,s), 3.72(2H,s), 4.46(2H,s), 6.85-7. l(3H,m), 7.3-7.45(2H,m), 8.70(2H,s) and 9.1 l(lH,s); (APCI) M+H=399. C21H23FN4OS requires 398.
Example 194 - l-(2-Phenylethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one
Prepared from intermediate B93, by general method A4, as a cream coloured crystalline solid. 'H-NMR (CDC13) δ 3.02 (2H,t), 3.51 (2H,s), 4.00 (2H,t), 4.55 (2H,s), 6.37 (lH,s), 7.0 (2H.m), 7.2-7.4 (8H,m), 8.47 (2H.s), 9.09 (lH,s); (APCI) M+H=415. C24H22N4OS requires 414.
Example 195 - l-(Fur-2-ylmethyl)-2-(4-methylbenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B81 by general method A4. Η-NMR (CDC13) δ 2.33 (3H,s), 3.70 (2H.s), 4.49 (2H,s), 4.90 (2H.s), 6.3-6.4 (2H.m), 6.84 (lH,s), 7.08 (2H,d), 7.33
(2H,d), 7.41 (lH,m), 8.7 (2H,s), 9.10 ( lH,s); (APCI) M+H=405. C22H20N4O2S requires 404.
Example 196 - l-(Fur-2-ylmethyl)-2-(2-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A4. 'H-NMR (CDC13) δ 3.70 (2H,s), 4.56 (2H,s), 4.90 (2H,s), 6.37 (lH.m), 6.41 (lH.m), 7.1 (3H,m), 7.3 (lH,m), 7.41 (lH,m), 7.55 (lH.m), 8.7 (2H,s), 9.10 (lH.s); (APCI) M+H=409. C21H17FN402S requires 408.
I l l Example 197 - l-(Fur-2-ylmethyl)-2-(4-chlorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B81 by general method A4. Η-NMR (CDC13) δ 3.69 (2H,s), 4.48 (2H,s), 4.90 (2H,s), 6.38 (2H,m), 7.06 (lH,m), 7.28 (2H.d), 7.35 (2H,d), 7.42 (lH,m), 8.7 (2H,s), 9.10 (lH,s); (APCI) M+H=425, 2M+H=849. C21H17C1N402S requires 424.
Example 198 - l-(Fur-2-ylmethyl)-2-(3-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B81 by general method A4 . ' H-NMR (CDC13) δ 3.70
(2H,s), 4.51 (2H,s), 4.90 (2H,s), 6.38 (lH,m), 6.41 (lH,m), 7.0 (lH,m), 7.1-7.3 (5H,m),
7.42 (lH,m), 8.7 (2H,s), 9.10 (lH,s); (APCI) M+H=409. C21H17FN402S requires 408.
Example 199 - l-(Fur-2-ylmethyl)-2-(3-chlorobenzyl)thio-5-(pyrirnid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B81 by general method A4, as an orange oil. ' H-NMR (CDC13) δ 3.69 (2H.s), 4.47(2H,s), 4.93 (2H,s), 6.38 (lH,m), 6.41 (lH,m), 7.12 (lH,s), 7.2-7.4 (5H,m). 8.7 (2H,s), 9.08 (lH,s); (APCI) M+H=425. C21H17C1N402S requires 424.
Example 200 - l-Methyl-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B84 by general method A4, as an off-white crystalline solid. 'H-NMR (CDC13) δ 3.49 (3H,s), 3.71 (2H,s), 4.51 (2H,s), 6.96 (lH,s), 7.2-7.5 (5H.m), 8.70 (2H,s), 9.10 (lH,s); (APCI) M+H=325. C17H16N4OS requires 324.
Example 201 - l-((R)-Tetrahydofuran-2-ylmethyl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 133 by general method A4. White solid. ' H-NMR (CDC13) δ 1.37-1.60 (IH, m), 1.81-2.14 (3H, m), 3.53-3.87 (5H, m), 3.99-4.18 (2H, m), 4.50 (IH, s), 7.18(1H, s), 7.28-7.44 (5H, m), 8.72 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 395 C21H22N402S requires 394.
Example 202 - l-((S)-Tetrahydofuran-2-ylmethyl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 132 by general method A4, as a white solid. 'H-NMR (CDCI3) δ 1.37-1.58 (IH, m), 1.8-2.12 (3H, m), 3.55-3.88 (5H, m), 3.98-4.19 (2H, m), 4.5 (2H, s), 7.17 (IH, s) , 7.29-7.44 (5H, m), 8.70 (2H, s), 9.02(1H, s); MS (APCI+) found (M+l) = 395; C21H22N402S requires 394.
Example 203 - l-(4-Fluorobenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B99 by general method A2. as an orange solid. 'H-NMR (CDCI3) δ 3.68 (2H, s), 4.47 (2H, s), 4.94 (2H, s), 6.92-7.20 (7H, m), 7.28-7.41 (2H, m), 8.66 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 437; C23H18F2N4OS requires 436.
Example 204 - l-(4-Bromobenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 115 by general method A2. ' H-NMR (CDC13) δ 3.68 (2H, s), 4.46 (2H, s), 4.91 (2H, s), 7.01 (5H, m), 7.35 (2H, m), 7.50 (2H, m), 8.70 (2H, s), 9.09 (IH, s), MS(APCI+) M+l=497, C23H18BrFN4OS requires 496. MPt 162.2°C (cream solid). MPt. 162.2
Example 205 - l-(2-(6-(4-Fluorophenyl)hex-l-yloxy)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 109 by general method A2 as an oil. Η-NMR (CDC1 ) δ 1.15-1.72 (8H, m), 2.50-2.63 (2H. t), 3.28-3.30 (2H, t), 3.55-3.64 (2H, t), 3.69 (2H, s), 3.89-3.98 (2H, t), 4.47(2H, s), 6.88-7.43 (9H, m), 8.69 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l ) = 551; C30H32F2N4O2S requires 550.
Example 206 - l-(2-Phenoxyethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 101 by general method A2 as a solid. ' H-NMR (CDC13) δ 3.72 (2H, s), 4.10-4.29 (4H, m), 4.47 (2H, s), 6.70-6.80 (2H, d), 6.95-7.39 (7H, m), 8.70 (2H. s), 9.12 (lH.s); MS (ES+) found (M+l) = 467; C24H20F2N4O2S requires 466. Example 207 - l-(3-(5-Phenylpent-l-yloxy)prop-l-yl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 139 by general method A2. Η-NMR (CDC13) δ 1.35 (2H, m), 1.59 (4H, m), 1.95 (2H, m), 2.60 (2H, t), 3.32 (4H, m), 3.68 (2H, s), 3.87 (2H, t), 4.50 (2H. s), 7.01 (IH, s), 7.14-7.38 (10H, m), 8.68(2H, s) 9.08 (IH, s); MS (APCI+) found (M+l) = 515; C30H34N4O2S requires 514.
Example 208 - l-(9-PhenylnonyI)-2-furfurylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B91 by general method A2. 'H-NMR (CDC13) δ 1.28 ( 10H, m), 1.65 (4H, m), 2.60 (2H, t), 3.69 (4H, m), 4.56 (2H, s), 6.30 (IH, m), 6.40 (IH, m),
6.98 (IH, s), 7.14-7.36 (6H, m), 8.69 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) =
503; C29H34N402S requires 502.
Example 209 - l-(9-Phenylnonyl)-2-(thiazol-2-ylmethyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B91 by general method A2. Η-NMR (CDC13) δ 1.28 ( 10H, m), 1.65 (4H, m), 2.60 (2H, t). 3.72 (2H, s), 3.75 (2H, t), 4.85 (2H, s), 6.97 (IH, s), 7.14- 7.30 (6H, m), 7.71 (lH, d). 8.71 (2H, s), 9.1 1 (IH, s); MS (APCI+) found (M+l) = 520; C28H33N50S2 requires 519.
Example 210 - l-(9-Phenylnonyl)-2-(thien-2-ylmethyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B91 by general method A2. 'H-NMR (CDC13) δ 1.28 ( 10H, m), 1.64 (4H, m), 2.60 (2H, t), 3.75 (4H, m), 4.73 (2H, s), 6.94 (2H, m), 7.09 (IH, m), 7.15-7.27 (6H, m), 8.73 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 519; C29H34N4OS2 requires 518.
Example 211 - l-(9-Phenylnonyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B91 by general method A2. 'H-NMR (CDC13) δ 1.28 ( 10H, m), 1.60 (4H, m), 2.59 (2H, t), 3.71 (4H, m), 4.44 (2H, s), 6.95 (lH,s), 7.10-7.27 (8H. m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 549; C31H34F2N4OS requires 548.
Example 212 - l-(2-(2-Pent-l-ylphenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B l 17 by general method A2. Η-NMR (CDC13) δ 0.87 (3H, t), 1.25 (4H, m), 1.45 (2H, m), 2.39 (2H, t), 3.04 (2H, t), 3.50 (2H, s), 3.97 (2H, t), 4.52 (2H, s), 6.31 (IH, s), 6.94-7.21 (8H, m), 7.40 (2H. m), 8.50 (2H, s), 9.09 (IH, s), MS(APCI+) M+l=503, C29H31FN4OS requires 502. MPt 1 12.3°C (colourless solid).
Example 213 - l-(2-(3-Pent-l-ylphenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 1 16 by general method A2. Η-NMR (CDC13) δ 0.89 (3H, m), 1.30 (4H, m), 1.50 (2H, m), 2.52 (2H, t), 2.98 (2H, t), 3.51 (2H, s), 3.98 (2H, t), 4.51 (2H, s), 6.41 (IH, s), 6.80-7.16 (6H, m), 7.41 (2H, m), 8.49 (2H, s), 9.08 (IH, s), MS(APCr) M+l=503. C29H31FN4OS requires 502. MPt 93.2°C (colourless solid). Example 214 - l-(2-(4-Bromophenyl)ethyI)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 114 by general method A2. Η-NMR (CDC13) δ 2.97 (2H, t), 3.59 (2H, s), 3.95 (2H, t), 4.49 (2H, s), 6.50 (IH, s), 6.89-7.05 (4H, m), 7.35-7.44 (4H, m), 8.58 (2H, s), 9.11 (IH, s), MS(APCI+) M+l=511, C24H20BrFN4OS requires 510. MPt 151.6°C (cream solid).
Example 215 - l-(5-Methylfuran-2-ylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B98 by general method A2 as a pale yellow solid. Η-NMR (CDC13) δ 1.64 (3H, s), 3.70 (2H, s), 4.49 (2H, s), 4.83 (2H, s), 5.95 (IH, d), 6.28 (IH, d), 6.94-7.09 (3H, m), 7.33-7.45 (2H, m), 8.69 (2H, s), 9.09 (IH, s), MS (APCI+) found (M+l) = 423; C22H19FN402S requires 422.
Example 216 - l-(2-(2-Chlorophenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 100 by general method A2 as a pale yellow solid. 'H-NMR (CDC13) δ 3.10-3.23 (2H, t), 3.51 (2H, s), 4.00-4.12 (2H, t), 4.51 (2H, t), 6.42 (IH, s), 6.90-7.48 (8H, m), 8.48 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 467; C24H20C1FN4OS requires 466. Example 217 - l-(2-(Thien-2-yl)ethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B97 by general method A2. 'H-NMR (CDC13) δ 3.26 (2H, t), 3.55 (2H, s), 4.02 (2H, t), 4.48 (2H, s), 6.51 (IH, s), 6.67 (IH, m), 6.91 (IH, m), 7.05- 7.27 (4H, m), 8.53(2H, s) 9.09 (IH, s); MS (APCI+) found (M+l) = 457; C22H18F2N4OS2 requires 456.
Example 218 - l-(2-Phenylethyl)-2-(2,3,4-trifluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A3 as a pale yellow foam ' H-NMR (CDC13) δ 3.02 (2H, t), 3.51 (2H,s), 3.99 (2H,t), 4.55 (2H,s), 6.42 (lH,s), 6.8-7.1 (3H,m), 7.2-7.45 (4H.m), 8.48 (2H,s), 9.09 (lH,s); MS (APCI+) found (M+l) = 469; C24H19F3N4OS requires 468.
Example 219 - l-(2-Phenylethyl)-2-(2,3,5-trifluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A3 as a white solid Η-NMR (CDC13) δ 3.02 (2H. t), 3.52 (2H,s), 3.99 (2H.t), 4.51 (2H,s), 6.40 (lH,s), 6.85-7.1 (3H,m), 7.2- 7.35 (3H,m), 7.4-7.55 (IH.m), 8.5 (2H,s), 9.09 (lH,s); MS (APCI+) found (M+l) = 469; C24H19F3N4OS requires 468. Example 220 - l-(2-Phenylethyl)-2-(2,4,6-trifluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A3 as a white solid ' H-NMR (CDC13) δ 3.02 (2H, t), 3.51 (2H,s), 3.99 (2H,t), 4.60 (2H,s), 6.38 (lH,s), 6.6-6.8 (2H,m), 7.0-7.1 (2H,m), 7.2-7.3 (3H,m), 8.48 (2H,s), 9.09 (lH,s); MS (APCI+) found (M+l) = 469; C24H19F3N4OS requires 468.
Example 221 - l-(2-Phenylethyl)-2-(2,4-difluorobenzyI)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2 as a pale yellow solid. Η-NMR (CDC13) δ 2.95-3.08 (2H, t), 3.51 (2H, s), 3.94-4.05 (2H, t), 4.54 (2H, s), 6.39 (IH, s), 6.74-6.91 (2H, m), 6.95-7.06 (2H, m), 7.18-7.34 (3H, m), 7.52-7.67 (IH, m), 8.48 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 451; C24H20F2N4OS requires 450.
Example 222 - l-(2-Phenylethyl)-2-(2-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2. Η-NMR (CDC13) δ 2.95-3.09 (2H, t), 3.49 (2H, s), 3.92-4.06 (2H, t), 4.59 (2H, s), 6.38 (IH, s), 6.94-7.37 (8H, m), 7.50- 7.63 ( IH, t), 8.49 (2H, s), 9.08 ( IH, s); MS (APCI+) found (M+l) = 433; C24H21FN4OS requires 432. Example 223 - l-(2-Phenylethyl)-2-furfurylthio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B93 by general method A2. Η-NMR (CDC13) δ 3.03 (2H, t), 3.51 (2H, s), 4.00 (2H, t), 4.62 (2H, s), 6.41 (3H, m), 7.03 (2H, m), 7.27 (3H, m), 7.38 (IH, m), 8.46 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 405; C22H20N4O2S requires 404.
Example 224 - l-(2-Phenylethyl)-2-(thien-2-ylmethyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2. Η-NMR (CDC13) δ 3.03 (2H, t),
3.51 (2H, s), 3.99 (2H, t), 4.78 (2H, s), 6.36 (IH, s), 6.93-7.02 (3H, m), 7.12 (IH, m),
7.22-7.28 (4H, m), 8.48 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 421;
C22H20N4OS2 requires 420.
Example 225 - l-(2-Phenylethyl)-2-(3,4,5-trifluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A3 as a pale yellow foam. 'H-NMR (CDC13) δ 3.03 (2H, t). 3.52 (2H,s), 4.02 (2H,t), 4.45 (2H,s), 6.46 (lH,s), 6.95-7.2 (4H,m), 7.2-7.4 (3H,m), 8.49 (2H,s), 9.09 (lH,s); MS (APCI+) found (M+l) = 469; C24H19F3N4OS requires 468. Example 226 - l-(2-Phenylethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2. 'H-NMR (CDC13) δ 2.95-3.10 (2H, t), 3.52 (2H, s), 3.95-4.07 (2H, t), 4.49 (2H, s), 6.39 (IH, s), 6.96-7.36 (8H, m), 8.48 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 451; C24H20F2N4OS requires 450.
Example 227 - l-(2-PhenylethyI)-2-(3,5-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2 as a pale yellow solid. ' H-NMR (CDC13) δ 2.97-3.10 (2H, t), 3.52 (2H, s), 3.95-4.16 (2H, t), 4.51 (2H, s), 6.40 (IH, s), 6.66-6.80 (IH, m), 6.89-7.08 (4H, m), 7.18-7.37 (3H, m), 8.49 (2H, s), 9.09 (IH, s); MS (APCr) found (M+l) = 451; C24H20F2N4OS requires 450.
Example 228 - l-(2-Phenylethyl)-2-(3-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2 as a pale yellow solid. Η-NMR (CDCI3) δ 2.95-3.09 (2H, s), 3.52 (2H, s), 3.94-4.07 (2H, t), 4.53 (2H, s), 6.39 (IH, s), 6.90-7.38 (9H, m), 8.48 (2H, s). 9.09 (IH, s); MS (APCI+) found (M+l) = 433; C24H21FN4OS. requires 432. Example 229 - l-(2-Phenylethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2 as a pale yellow solid. Η-NMR (CDCI3) δ 2.98-3.10 (2H, t), 3.49 (2H, s), 3.94-4.06 (2H, s), 4.51 (2H, s), 6.39 (IH, s), 6.94-7.08 (4H, m), 7.20-7.33 (3H, m), 7.36-7.48 (2H, m), 8.48 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 433; C24H21FN4OS requires 432.
Example 230 - l-(2-Phenylethyl)-2-(l-phenylethyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B93 by general method A2 as a pale yellow solid. 'H-NMR (CDCI3) δ 1.82 (2H, t), 2.99 (2H,t), 3.50 (2H,s), 3.85-4.1 (2H,m), 5.35 (lH,q), 6.34 (lH,s), 6.9-7.05 (2H,m), 7.15-7.5 (8H,m), 8.49 (2H,s), 9.09 (lH,s); MS (APCI+) found (M+l) = 429; C25H24N4OS requires 428.
Example 231 - l-(2-(4-Methoxyphenyl)ethyl)-2-(3,4-difluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 134 by general method A2 as a white solid. 'H-NMR (CDCI3) δ 2.91-3.02 (2H, t), 3.59 (2H, s), 3.84 (3H, s), 3.90-4.02 (2H, t), 4.48 (2H, s), 6.42 (IH, s), 6.73-7.31 (7H, m), 8.51 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) : 481 ; C25H22F2N402S requires 480. Example 232 - l-(2-(4-Pent-l-ylphenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 112 by general method A2. 'H-NMR (CDC13) δ 0.88 (3H, t), 1.32 (4H, m), 1.60 (2H, m), 2.60 (2H, m), 2.97 (2H, m), 3.52 (2H, s), 3.97 (2H, t), 4.51 (2H, s),6.46 (IH, s), 6.84-7.1 1 (6H, m), 7.40 (2H, m), 8.50 (2H, s), 9.08 (IH, s); MS(APCr) M+l=503, C29H31FN4OS requires 502. MPt 98.7°C (colourless solid).
Example 233 - l-(Cycloprop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B 105 by general method A2. Η-NMR (CDC13) δ 0.94-1.32 (4H. m), 3.03-3.18 (IH, m), 3.69 (2H, s), 4.42 (2H, s), 6.93-7.07 (2H, t), 7.14 (IH, s), 7.31-7.45 (2H, m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 369; C19H17FN4OS requires 368.
Example 234 - l-(Dodec-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B96 by general method A2 as an oil. Η-NMR (CDC13) δ 0.78-0.85 (3H, t), 1.13-1.70 (20H, m), 3.65-3.80 (4H, m), 4.45 (2H, s), 6.92-7.27 (4H, s), 8.70 (2H, s), 9.1 1 ( IH, s); MS (APCI+) found (M+l) = 515; C28H36F2N4OS requires 514.
Example 235 - l-Ethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one
Prepared from intermediate B89 by general method A2 as a solid. 'H-NMR (CDC13) δ 1.30-1.44 (3H, t). 3.72 (2H, s), 3.75-3.90 (2H, q), 4.47 (2H, s), 6.94-7.17 (3H. m), 7.33- 7.45 (2H, m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 357; C18H17FN4OS requires 356.
Example 236 - l-(l-Methylethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 104 by general method A2 as a solid. Η-NMR (CDC13) δ 1.32-1.45 (6H, d), 3.73 (2H, s), 4.46 (2H, s), 4.49-4.65 (IH, m), 6.94-7.05 (2H, t), 7.17 (IH, s), 7.33-7.45 (2H, m), 8.72 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 371; C19H19FN4OS requires 370.
Example 237 - l-Methyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B84 by general method A2 as a solid. ' H-NMR (CDC13) δ3.49 (3H, s), 3.71 (2H, s), 4.48 (2H, s) 6.93-7.07 (3H, m), 7.32-7.44 (2H, m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 343; C17H15FN4OS requires 342.
Example 238 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B95 by general method A2 as an oil. 'H-NMR (CDC13) δ 0.82-0.98 (3H, t), 1.13-1.80 ( 18H, m), 3.65-3.79 (4H, m), 4.47 (2H, s), 6.90-7.07 (3H, m), 7.31-7.43 (2H, m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 483; C27H35FN4OS requires 482.
Example 239 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5- ylmethyl)pyrimidin-4-one
To a solution of either Example 243 or 244 (0.2g) in dry methylene chloride (4ml) at 4°C was added boron tribromide (IM in methylene chloride, 2ml). The mixture was stirred under argon for 24h and poured into a mixture of ice (50ml) and 0.880 ammonia (15ml) with stirring. Extraction with 5% methano methylene chloride was followed by filtration through kieselguhr and drying the organic layer over sodium sulphate. Removal of the solvent in vacuo gave the desired material as a grey solid (0.15g). Η-NMR (CDC13) δ 0.8-0.95 (3H,m), 1.1-1.4 (16H,m), 1.6-1.85 (2H,m), 3.49 (2H,s), 3.79 (2H,t), 4.45 (2H,s), 6.9-7.1 (2H,m), 7.2-7.45 (3H,m), 8.32 (2H,s); MS (APCI+) found (M+l) = 499; C27H35FN402S requires 498.
Example 240 - l-Benzyl-2-benzylthio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from Example B39 by alkylation with benzyl bromide using general method A4, followed by N-alkylation using general method C2. 'H-NMR (CDC13) δ 3.62 (2H, s), 3.98 (3H, s), 4.51 (2H, s), 4.96 (2H, s), 6.92 (IH, s), 7.10 (IH, m), 7.23-7.40 (9H,m), 8.41 (2H, s); MS (APCI+) found (M+l) = 431; C24H22N402S requires 430.
Example 241 - l-(2-Phenylethyl)-2-(3,4-difluorobenzyl)thio-5-(2-methoxypyrimid- 5-ylmethyl)pyrimidin-4-one
Prepared from Example 107 by general method C3. ' H-NMR (CDC13) δ 3.01 (2H, t), 3.46 (2H, s), 3.99 (2H, t), 4.01 (3H. s), 4.49 (2H, s), 6.33 (IH, s), 6.99-7.29 (8H, m), 8.22 (2H, s); MS ( APCI+) found (M+ 1 ) = 481 ; C25H22F2N402S requires 480.
Example 242 - l-(Furan-2-ylmethyl)-2-(3,4-difluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 107 by general method C3. Η-NMR (CDC13) δ 3.63 (2H, s), 4.00 (3H. s), 4.46 (2H, s), 4.90 (2H, s), 6.38 (2H, m), 7.01 (IH, s), 7.07-7.26 (3H, m), 7.42 (IH, m), 8.44 (2H, s); MS (APCI+) found (M+l) = 457; C22H18F2N403S requires 456. Example 243 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(2-methoxypyrimid-5- ylmethyI)pyrimidin-4-one
Prepared from intermediate B 124 by general method A2. ' H-NMR (CDC13) δ 0.88 (3H, t), 1.25 (16H, m), 1.68 (2H, m), 3.64 (2H, s), 3.71 (2H, t), 4.00 (3H, s), 4.47 (2H, s), 6.87 (IH, s), 7.00 (2H, m), 7.36(2H, m), 8.46(2H, s); MS (APCI+) found (M+l) = 513; C28H37N402S requires 512.
Example 244 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(2-ethoxypyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B92 by general method A3 as an off-white solid. ' H-NMR (CDC13) δ 0.8-0.95 (3H,m), 1.15-1.4 (16H.m), 1.43 (3H,t), 1.55-1.8 (2H,m), 3.68 (2H,s), 3.71 (2H,t), 4.41 (2H,q), 4.47 (2H,s), 6.86 ( lH,s), 6.9-7.1 (2H,m), 7.3-7.45 (2H,m), 8.45 (2H,d); MS (APCI+) found (M+l) = 527; C29H39FN402S requires 526.
Example 245 - l-(Undec-l-yl)-2-(4-fluorobenzyI)thio-5-(2-methylpyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 135 by general method A2. ' H-NMR (CDC13) δ 0.88 (3H, t), 1.25 (16H, m), 1.68 (2H, m). 2.72 (3H, s), 3.68 (2H, s), 3.72 (2H, t), 4.47 (2H, s), 6.89 (IH, s), 6.97 (2H, m), 7.38 (2H, m), 8.58(2H, s): MS (APCI+) found (M+l ) = 497; C28H37N4OS requires 496.
Example 246 - l-(2-Phenylethyl)-2-(4-fluorobenzyl)thio-5-((l-methyl-2-oxo-pyrid- 4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B70 by general method A2. Η-NMR (CDC13) δ 3.01 (2H, t), 3.40 (2H, s), 3.51 (3H, s), 3.97 (2H. t), 4.51 (2H, s), 6.02 (IH, m), 6.24 (IH, s), 6.49 (IH, s), 6.98-7.43 (10H, m); MS (APCI+) M+l=462; C26H24FN302S requires 461. MPt 69- 75°C (cream solid).
Example 247 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-((l-methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one
Prepared from intermediate B 110 by general method A2. ' H-NMR (CDC13) δ 0.88 (3H, t), 1.25 (16H, m), 1.69 (2H, m), 3.50 (3H, s), 3.55 (2H, s), 3.71 (2H, t), 4.78 (2H, s), 6.17 (IH, m), 6.38 (IH, d), 6.84 (IH, s), 6.96 (2H, m), 7.19 (IH, m), 7.39 (2H, m); MS (APCI+) M+l =512, C29H38FN302S requires 511. MPt 78-79°C (colourless solid).
Example 248 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(l-methyl-2-oxopyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 239 by treatment with methyl iodide (1 equiv) and potassium carbonate (2 equiv) in DMF. The misture was stirred at room temperature for 16 hours, then at 50°C for 1 hour. Evaporation of the solvent, aqueous workup and chromatography gave the title compound in 72% yield. Η-NMR (CDC13) δ 0.8-0.95 (3H,m), 1.15-1.4 (16H.m), 1.6-1.85 (2H,m), 3.43 (2H.bs), 3.54 (3H,s), 3.78 (2H,t), 4.46 (2H,s), 6.9-7.1 (2H,m), 7.19 (lH,s), 7.25-7.45 (2H,m), 8.01 (lH,bd), 8.46 (lH,m).
Example 249 - l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(l-benzyl-2-oxopyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 239 analogously to Example 248, using benzyl bromide in place of methyl iodide. 'H-NMR (CDC13) δ 0.8-0.95 (3H,m), 1.15-1.4 (16H,m), 1.6-1.85 (2H.m), 3.39 (2H,s), 3.74 (2H,t), 4.46 (2H,s), 5.08 (2H,s), 6.9-7.1 (3H,m), 7.25-7.45 (7H,m), 7.94 ( lH,d), 8.43 (lH.d); MS (APCI+) found (M+l) = 589; C34H41FN402S requires 588. Example 250 - l-(Undec-l-yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B95 by general method A4. Η-NMR (CDC13) δ 0.88 (3H,t), 1.25 (16H,brs), 1.71 (2H,m), 3.71 (2H,s), 3.74 (2H,m), 4.49 (2H,s), 7.04 (lH,s), 7.26- 7.41 (5H.m), 8.69 (2H,s), 9.09 (lH,s); MS (APCI) found (M+H) = 465; C27H36N4OS requires 464.
Example 251 - l-Methyl-2-(4-fluorobenzyl)thio-5-(2-methoxypyrimid-5-ylmethyl)- pyrimidin-4-one
Prepared from Example 108 by general method C2. ' H-NMR (CDC13) δ 3.47 (3H,s), 3.64 (2H,t), 3.99 (3H,s), 4.47 (2H,s), 6.88 (lH,s), 6.9-7.1 (2H,m), 7.3-7. 5 (2H,m), 8.44 (2H,s); MS (APCI+) found (M+l) = 373; C18H17FN402S requires 372.
Example 252 - l-Methyl-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5- ylmethyl)pyrimidin-4-one
To a solution of Example 251 (5g) in dry methylene chloride was added a solution of boron tribromide IM in dichloromethane (50ml) at 5°C under argon with stirring. After
0.5h, the mixture was allowed to warm to room temperature and was allowed to stir at room temperature for 72h. The mixture was decanted into a mixture of ice (50ml) and 0.880 ammonia (50ml). The solid remaining in the flask was treated with some of the aqueous mixture and 10% methanol in methylene chloride. The entire mixture was filtered through kieselguhr and the organic layer was separated. The aqueous layer was reduced to one quarter volume in vacuo and the solid formed filtered off, washed with water and dried in vacuo to give the desired product (2.2g). Η-NMR (d6 DMSO) δ 3.30 (2H.s), 3.47 (3H,s), 4.41 (2H,s), 7.05-7.25 (2H,m), 7.4-7.55 (2H,m), 7.65 (lH,s), 7.85-8.3 (2H.b): MS (APCI+) found (M+l) = 359; C17H15FN402S requires 358. Example 253 - l-(4-Acetylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)- pyrimidin-4-one
Prepared from intermediate B 136 by general method A4. 'H-NMR (CDC13) δ 2.64(3H,s), 3.79(2H,s), 4.39(2H,s), 6.95(2H,m), 7.05(lH,s), 7.29(2H,m), 7.43(2H,d,j=8.5Hz), 8.08(2H,d,j=8.5), 8.75(2H,s), 9.09(lH,s): MS (APCI) found (M+H ) = 447; C24H19FN402S requires 446.
Example 254 - l-(3-(Non-l-yloxy)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 128 by general method A2. Η-NMR (CDC13) δ 9.08 (IH, s), 8.73 (2H, s), 7.41-7.28 (3H, m), 7.09 (IH, s), 7.03-6.78 (5H, m), 4.36 (2H, s), 3.95 (2H, t), 3.73 (2H, s), 1.78 (2H, quintet), 1.47-1.23 (12H, m), 0.88 (3H, t); MS (APCI+) found (M+l) = 547, C31H35FN402S requires 546.
Example 255 - l-(3-(Dec-l-yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 129 by general method A2. 'H-NMR (CDC13) δ 9.08 (IH, s), 8.73 (2H, s), 7.40-7.27 (4H, m), 7.1 1-7.08 (3H, m), 6.94 (2H, t), 4.35 (2H, s), 3.73 (2H. s), 2.65 (2H, t), 1.67-1.56 (2H. m), 1.30-1.22 (14H, m), 0.88 (3H, t); MS (APCI+) found (M+l) = 545, C32H37FN4OS requires 544.
Example 256 - l-Methyl-2-(4-fluorobenzyl)thio-5-(l-undecyl-2-oxopyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 252 and undecyl iodide by the method of Example 248. Η- NMR (CDC13) δ 0.88 (3H,s), 1.2-1.4 (16H.m), 1.77 (2H,m), 3.43 (2H,s), 3.53 (3H,s), 3.86 (2H,t), 4.47 (2H,s), 6.9-7.1 (2H,m), 7.20 (lH,s), 7.3-7.45 (2H,m), 7.96 (lH,d), 8.44 (lH,d); MS (APCI+) found (M+l) = 513; C28H37FN402S requires 512.
Example 257 - l-Phenyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one
Prepared from intermediate B 121 by general method A2. Η NMR (CDC13) δ: 3.74 (s, 2H), 4.36 (s, 2H), 6.95 (t, 2H), 7.06 (s, IH), 7.30 (m, 4H), 7.55 (m, 3H), 8.72 (s, 2H), 9.10 (s, IH). MS (APCI+) Found (M+l) = 405; C22H17FN4OS requires 404.
Example 258 - l-Phenyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 121 by general method A2. Η NMR (CDC13) δ: 1.35 (m, 6H), 1.65 (m, 4H), 2.91 (t, 2H), 3.14 (t, 2H), 3.76 (s, 2H), 7.04 (s, IH), 7.3 (m, 2H), 7.43 (d, 2H), 7.55 (m, 3H), 7.89 (d, 2H), 8.72 (s, 2H), 9.10 (s, IH). MS (APCI+) Found (M+l) = 533 / 535; C29H29C1N402S requires 533.
Example 259 - l-(4-(Non-l-yloxyphenyl))-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 126 by general method A2. Η-NMR (CDC13) δ 9.07 (IH, s), 8.73 (2H, s), 7.30 (2H, dd). 7.21 (2H, d), 7.13 ( IH, s), 6.95 (2H, d), 6.94 (2H, t), 4.33 (2H, s), 3.97 (2H, t), 3.73 (2H. s). 1.79 (2H, quintet), 1.47-1.23 (12H, m), 0.88 (3H, t); MS (APCI+) found (M+l) = 547, C31H35FN402S requires 546. Example 260 - l-(4-Iodophenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 130 by general method A2. ' H-NMR (CDC13 + CD3OD) δ 9.08 (IH, s), 8.72 (2H, s), 7.85 (2H, d), 7.33-7.26 (2H, m), 7.07 (IH, s), 7.05 (2H, d), 6.98 (2H, t), 4.35 (2H, s), 3.73 (2H, s); MS (APCI+) found (M+l) = 531, C22H16FIN4OS requires 530.
Example 261 - l-(4-(Hex-l-yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 127 by general method A2. Η-NMR (CDC13) δ 9.08 (IH, s), 8.73 (2H, s), 7.33-7.27 (4H, m), 7.19 (2H, d), 7.09 (IH, s), 6.94 (2H, t), 4.35 (2H, s),
3.73 (2H, s), 2.66 (2H, t), 1.62 (2H, quintet), 1.39-1.27 (6H, m), 0.87 (3H, t); MS
(APCI+) found (M+l) = 489, C28H29FN4OS requires 488.
Example 262 - l-(4-(Dec-l-yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 125 by general method A2. Η-NMR (CDC13) δ 9.08 (IH, s), 8.73 (2H, s), 7.33-7.27 (4H, m), 7.19 (2H, d), 7.10 (IH, s), 6.94 (2H, t), 4.35 (2H, s), 3.73 (2H, s), 2.65 (2H, t), 1.67-1.56 (2H, m), 1.34-1.22 (14H, m), 0.88 (3H, t); MS (APCI+) found (M+l) = 545, C32H37FN4OS requires 544.
Example 263 - l-Ethoxycarbonylmethyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B80 and Al by general method A4, as a light brown crystalline solid. MPt 100 - 102°C; Η-NMR (CDC13) δ 1.30 (3H, t), 1.37 (6H, m), 1.70 (4H, m), 2.93 (2H, t), 3.26 (2H, t), 3.71 (2H, s), 4.28 (2H, q), 4.50 (2H, s), 6.90 (IH, s), 7.44 (2H, m), 7.90 (2H, m), 8.71 (2H, s), 9.10 (IH, s); MS APCI+) found (M+l) = 543; C27H31C1N404S requires 542.
Example 264 - l-(3-Ethoxycarbonylprop-l-yl)-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B50 and Al by general method A4, as a brown oil. Η- NMR (CDC13) δ 1.27 (3H, t), 1.38 ( 6H, m), 1.69 (4H, m), 2.05 (2H, m), 2.38 (2H, t), 2.93 (2H, t), 3.25 (2H, t), 3.70 (2H, s), 3.88 (2H, t), 4.12 (2H, q), 7.05 (IH, s), 7.42 (2H, d), 7.91 (2H, d), 8.72 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 571; C29H35C1N404S requires 570.
Example 265 - l-(3-Ethoxycarbonylprop-l-yl)-2-benzylthio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B50 by general method A4, as a brown oil. Η-NMR (CDCI3) δ 1.24 (3H, t), 2.01 (2H, m), 2.35 (2H, m), 3.71 (2H, s), 3.86 (2H, t), 4.12 (2H, q), 4.50 (2H. s), 7.07 (IH, s), 7.27-7.41 (5H, m), 8.72 (2H, s), 9.12 (IH, s); MS (APCI+) found (M+l) = 425; C22H24N403S requires 424.
Example 266 - l-(3-Ethoxycarbonylprop-l-yl)-2-(3,4-difluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B50 by general method A2 as an oil. 'H-NMR (CDC13) δ 1.17-1.30 (3H, m), 1.96-2.12 (2H, m), 2.30-2.41 (2H, t), 3.70 (2H, s), 3.80-3.90 (2H, t), 4.06-4.20 (2H. q), 4.49 (2H, s), 7.01-7.26 (4H, m), 8.72 (2H, s), 9.10 (IH, s); MS (ES+) found (M+l) = 461; C22H22F2N403S requires 460. Example 267 - l-(3-Ethoxycarbonylprop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B50 by general method A2. ' H-NMR (CDC13) δ 1.26 (3H, t), 2.03 (2H, m), 2.35 (2H, t), 3.70 (2H, s), 3.85 ( 2H, t), 4.12 (2H, m), 4.47 (2H, s), 6.71- 7.07 (3H, m), 7.35-7.41 (2H, m), 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) M+l=443, C22H23FN403S requires 442 (orange oil).
Example 268 - l-(5-Ethoxycarbonylpent-l-yl)-2-(3,4-difluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 102 by general method A2 as an oil. Η-NMR (CDC13) δ 1.14-1.87 (9H, m), 2.25-2.37 (2H, m), 3.63-3.82 (4H, m), 4.04-4.19 (2H, q), 4.45 (2H, s), 6.97-7.30 (4H, m), 8.70 (2H, s), 9.10 (IH, s); MS (ES+) found (M+l) = 489; C24H26F2N403S requires 488.
Example 269 - l-(l-(Ethoxycarbonyl)cycloprop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 106 by general method A2 as a foam. 'H-NMR (CDC13) δ 1.08-1.20 (3H, t), 1.38-1.54 ( IH. m), 1.58-1.85 (2H, m), 1.94-2.10 (IH, m), 3.71 (2H, s), 4.04-4.28 (2H, m), 4.35-4.52 (2H, q), 6.90-7.05 (2H, t), 7.08 (IH, s), 7.29-7.42 (2H, m). 8.70 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 441; C22H2,FN403S requires 440.
Example 270 - l-(4-FluorobenzyloxycarbonylmethyI)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B80 by alkaline hydrolysis as in general method D, followed by alkylation with 4-fluorobenzyl bromide by general method A2. ' H-NMR (CDC13) δ 3.71 (2H, s), 4.46 (4H, m), 5.16 (2H, s), 6.87 (IH, s), 6.94-7.06 (4H, m), 7.25-7.35 (4H, m), 8.68 (2H, s), 9.10 (IH. s); MS(APCI+) M+l=495, C25H20F2N4O3S requires 494. MPt 184-186°C (colourless solid). MPt. 184 - 186
Example 271 - l-Ethoxycarbonylmethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B80 by general method A2. 'H-NMR (CDC13) δ 1.26 (3H, t), 3.71 (2H. s), 4.26 (2H, q), 4.46 (2H, s), 4.48 (2H, s), 6.91 (IH, s), 6.98 (2H, m), 7.35 (2H, m), 8.70 (2H, s), 9.09 (IH, s); MS(APCI+) M+l=415, C20H19FN4O3S requires 414. MPt 145.1°C (yellow solid).
Example 272 - l-(l-(Methoxycarbonyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 103 by general method A2 as a solid. 'H-NMR (CDC13) δ 1.68 (3H, d), 3.70 (2H, s), 3.78 (3H, s), 4.38-4.58 (2H, br.q), 4.98-5.10 (IH, q), 6.95- 7.07 (2H, t), 7.19 (IH, s), 7.30-7.42 (2H, m), 8.72 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 429; C20H19FN4O3S requires 428.
Example 273 - l-(trα/ι_-4-(Methoxycarbonyl)cyclohex-l-ylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 137 by general method A2 as a solid. 'H-NMR (CDC13) δ 0.88-1.1 1 (2H, m), 1.30-1.54 (2H, m), 1.60-1.82 (4H, m), 1.94-2.13 (IH, m), 2.14-2.34 ( IH. m), 3.53-3.74 (7H, m), 4.46 (2H, s), 6.90 (IH, s), 6.94-7.08 (2H, t), 7.30-7.44 (2H, m), 8.70 (2H, s), 9.11 (IH, s); MS (APCI+) found (M+l) = 483; C25H27FN403S requires
482. Example 274 - l-(trαns-4-(Methoxycarbonyl)cyclohex-l-yl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 108 by general method A2 as a solid. ' H-NMR (CDC13) δ 1.54-1.97 (6H, m), 2.22-2.39 (2H, d), 2.68-2.79 (IH, br.s), 3.70 (2H, s), 3.73 (3H, s), 4.03-4.25 (IH, m), 4.45 (2H, s), 6.93-7.08 (2H, m), 7.21 (IH, s), 7.30-7.43 (2H, m), 8.71 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 469; C24H25FN403S requires 468.
Example 275 - l-(3-Ethoxycarbonylprop-l-yl)-2-(4-fluorobenzyl)thio-5-((l-methyl- 2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from intermediate B 111 by general method A2. Η-NMR (CDC13) δ 1.25 (3H, t), 2.02 (2H, m), 2.35 (2H, t), 3.50 (3H, s), 3.54 (2H, s), 3.83 (2H, t), 4.12 (2H, q), 4.47 (2H, s), 6.19 (IH, m), 6.37 (IH, s), 6.84-7.41 (6H, m); MS (APCI+) M+l=472, C24H26FN304S requires 471. MPt 109-11 1°C (colourless solid). MPt. 109 - 111
Example 276 - 1 -(Ethoxy carbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 108 by general method C2. Η-NMR (CDC13) δ 1.26 (3H, t), 3.66 (2H, s), 3.99 (3H, s), 4.23 (2H, q), 4.47 (2H, s), 4.48 (2H, s), 6.84 (IH, s), 6.98 (2H, m), 7.34 (2H, m), 8.44 (2H, s); MS (APCI+) found (M+l) = 445; C21H21FN404S requires 444.
Example 277 - l-(4-(Ethoxycarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 107 by general method A2 as a solid. 'H-NMR (CDC13) δ 1.35-1.47 (3H, t), 3.70 (2H, s), 3.93 (IH, s), 4.32-4.52 (3H. m), 5.02 (2H, s), 6.90-7.06 (3H, m), 7.13-7.40 (4H, m), 7.98-8.10 (2H, d), 8.67 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 491; C26H23FN403S requires 490.
Example 278 - l-(4-Methoxycarbonylbenzyl)-2-(8-(4-chlorophenyl)oct-l-yl)thio-5- (pyrid-3-ylmethyl)pyrimidin-4-one
Prepared from Example 70 by general method Cl. ' H-NMR (CDC13) δ 1.2-1.45(8H,m), 1.45-1.75(4H,m), 2.55(2H,t), 3.24(2H,t), 3.73(2H,s), 3.92(3H,s), 5.01(2H,s), 6.81(lH,s), 7.05-7.3(7H,m), 7.61(lH,txd), 8.03(2H,d) and 8.46(2H,bs); MS (El) found M=589; C33H36C1N303S requires 589.
Example 279 - l-(3-Carboxyprop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 267 by general method D. 'H-NMR (d6-DMSO) δ 1.93 (2H, m), 2.29 (2H, t), 3.58 (2H, s), 3.87 (2H, t), 4.40 (2H, s), 7.14 (2H, m), 7.48 (2H, m), 7.81 (IH, s), 8.70 (2H, s), 9.02 (IH, s); MS (APCI-) M-l=413, C20H19FN4O3S requires 414. MPt 188-190°C (colourless solid).
Example 280 - l-Carboxymethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 271 by general method D. Η-NMR (d6-DMSO) δ 3.59 (2H, s), 4.41 (2H, s), 4.67 (2H, s), 7.11 (2H, m), 7.45 (2H, m), 7.72 (IH, s), 8.70 (2H, s), 9.03 (IH, s), 13.55 (IH, bs); MS (APCI-) M-l=385, C18H15FN403S requires 386. MPt 206- 207°C (colourless solid).
Example 281 - l-(3-Carboxyprop-l-yl)-2-(4-fluorobenzyl)thio-5-((l-methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from Example 275 by general method D. 'H-NMR (d6-DMSO) δ 1.90 (2H, m), 2.28 (2H, t), 3.37 (5H, m), 3.86 (2H, t), 4.41 (2H, s), 6.12 (IH, m), 6.18 (IH, s), 7.14 (2H, m), 7.50 (3H, m), 7.73 (IH, s), 12.2 (IH. bm): MS (APCI+) M+l=444, C22H22FN304S requires 443. MPt 245-249°C (colourless solid).
Example 282 - l-(3-Carboxyprop-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 266 by general method D as a white solid. 'H-NMR (DMSO) δ 1.83-2.03 (2H, m), 2.24-2.37 (2H, t), 3.58 (2H, s), 3.81-3.93 (2H, t), 4.41 (2H, s), 7.23- 7.59 (3H, m), 7.81 (IH, s), 8.71 (2H, s), 9.02 (IH, s), 12.13-12.20 (IH, s); MS (APCI-) found (M-1) = 431; C20H18F2N4O3S requires 432.
Example 283 - l-(5-Carboxypent-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 268 by general method D as a white solid. ' H-NMR (DMSO) δ 1.18-1.81 (6H, m), 2.14-2.29 (2H, t), 3.59 (2H, s), 3.76-3.90 (2H, t), 4.41 (2H, s), 7.23- 7.60 (3H, m), 7.85 (IH, s), 8.70 (2H, s), 9.02 (IH, s), 11.92-12.10 (IH, s); MS (APCI-) found (M-1) = 459: C22H22F2N403S requires 460.
Example 284 - l-(4-Carboxybenzyl) -2-(4-fluorobenzyl)thio -5-(pyrimid-5- ylmethyl)-2-thiouracil
Prepared from Example 277 by general method D. l 'lH-NMR (DMSO) δ 3.60 (2H, s), 4.39 (2H, s), 5.21 (2H, s), 7.03-7.19 (2H, t), 7.26-7.49 (4H, m), 7.38-8.02 (3H, m), 8.72 (2H, s), 9.03 (IH, s), 12.92-13.10 (IH, br.s); MS (APCI+) found (M+l) = 463; C24H19FN403S requires 462. Example 285 - l-(4-Carboxycyclohex-l-yl) -2-(4-fluorobenzyl)thio -5-(pyrimid-5- ylmethyl)-2-thiouracil
Prepared from Example 274 by general method D. Η-NMR (DMSO) δ 1.57-1.88 (6H, m), 2.13-2.26 (2H, d), 2.60 (IH, s), 3.62 (2H, s), 3.98-4.10 (IH, m), 4.40 (2H, s), 7.09- 7.19 (2H, t), 7.44-7.53 (2H, m), 8.00 (IH, s), 8.72 (2H, s), 9.00 (IH, s), 12.27 (IH, s); MS (APCI+) found (M+l) = 455; C23H23FN403S requires 454.
Example 286 - l-(3-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 118 by general method A2. Η NMR (CDC13) δ: 1.41 (t, 3H), 3.75 (s, 2H), 4.37 (s, 2H), 4.41 (q, 2H), 6.95 (t, 2H), 7.05 (s, IH), 7.30 (m, 2H), 7.50 (m, IH), 7.60 (t, IH), 7.97 (m, IH), 8.21 (d, IH), 8.72 (s, 2H), 9.10 (s, IH). MS (APCI+) Found (M+l) = 477; C25H21FN403S requires 476. Example 287 - l-(3-EthoxycarbonylphenyI)-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 1 18 by general method A4. Η NMR (CDC13) δ: 1.3 (m, 6H), 1.42 (t, 3H), 1.65 (m. 4H), 2.91 (t, 2H), 3.15 (t, 2H), 3.73 (s, 2H), 4.42 (q, 2H), 7.03 (s, IH), 7.42 (d, 2H), 7.5 (m, IH), 7.62 (t, IH). 7.88 (d, 2H), 7.98 (s, IH), 8.22 (d, IH), 8.72 (s, 2H), 9.09 (s, IH). MS (APCI+) Found (M+l) = 605 / 607; C32H33C1N404S requires 605.
Example 288 - l-(3-CarboxyphenyI)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 286 by general method D as a white solid, m.p 157-160°. Η NMR (DMSO-d6) δ: 3.62 (s, 2H), 4.31 (s, 2H), 7.10 (t, 2H), 7.40 (m, 2H), 7.70 (t, IH), 7.87 (d, IH), 7.94 (s, IH), 8.10 (m, 2H), 8.77 (s, 2H), 9.01 (s, IH), 13.4 (br s, IH). MS (APCI+) Found (M+l) = 449; C23H17FN403S requires 448. Example 289 - l-(3-Carboxyphenyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yI)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 287 by general method D as a white solid, m.p 109-112°. Η NMR (DMSO-d6) δ: 1.3 (m, 6H), 1.65 (m, 4H), 2.9-3.1 (m, 4H), 3.60 (s, 2H), 7.57 (d, 2H), 7.71 (t, IH), 7.8-8.0 (m, 4H), 8.13 (m, 2H), 8.75 (s, 2H), 9.02 (s, IH) 13.35 (br s, IH). MS (APCI+) Found (M+l) = 577 / 579; C30H29ClN4O4S requires 577.
Example 290 - l-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate Bl 19 by general method A2. Η NMR (CDC13) δ: 1.40 (t,
3H), 3.74 (s, 2H), 4.37 (s, 2H). 4.41 (q, 2H), 6.95 (t, 2H), 7.05 (s, IH), 7.30 (m, 2H), 7.40 (d, 2H). 8.20 (d. 2H), 8.72 (s, 2H), 9.1 1 (s, IH). MS (APCI+) Found (M+l) = 477; C25H21FN403S requires 476.
Example 291 - l-(4-Ethoxycarbonylphenyl)-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate Bl 19 by general method A4. Η NMR (CDC13) δ: 1.3 (m, 6H). 1.42 (t, 3H), 1.65 (m, 4H), 2.91 (t, 2H), 3.15 (t, 2H), 3.73 (s, 2H), 4.44 (q, 2H), 7.03 (s, IH), 7.4 (m, 4H), 7.88 (d, 2H), 8.20 (d, 2H), 8.71 (s, 2H), 9.10 (s, IH). MS (APCI+) Found (M+l) = 605 / 607; C32H33C1N404S requires 605. Example 292 - l-(4-Carboxyphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 290 by general method D as a white solid, m.p.258-262° dec. Η NMR (DMSO-d6) δ: 3.63 (s, 2H), 4.31 (s. 2H), 7.10 (t, 2H), 7.40 (m, 2H), 7.74 (d, 2H), 7.95 (s, IH), 8.10 (d, 2H), 8.77 (s, 2H), 9.01 (s, IH), 13.3 (br s, IH). MS (APCI+) Found (M+l) = 449; C23H17FN403S requires 448.
Example 293 - l-(4-Carboxyphenyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 291 by general method D as a white solid, m.p 92-96°. Η NMR (DMSO-d6) δ: 1.3 (m, 6H), 1.6 (m, 4H), 2.9-3.1 (m, 4H), 3.61 (s, 2H), 7.57 (d, 2H), 7.74 (d, 2H), 7.95 (m, 3H), 8.10 (d, 2H), 8.75 (s, 2H), 9.02 (s, IH) 13.35 (br s, IH). MS (APCI+) Found (M+l) = 577 / 579; C30H29ClN4O4S requires 577. Example 294 - l-(5-(Ethoxycarbonyl)fur-2-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from intermediate B 120 by general method A2. Η NMR (CDC13) δ: 1.38 (t, 3H), 3.72 (s, 2H), 4.38 (s, 2H), 4.39 (q, 2H), 6.60 (d, IH), 6.97 (t, 2H), 7.08 (s, IH), 7.20 (d, IH), 7.3 (m, 2H), 8.71 (s, 2H), 9.11 (s, IH). MS (APCI+) Found (M+l) = 467; C23H19FN404S requires 466.
Example 295 - l-(3-Ethoxycarbonyl-4-iodobenzyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. 'H-NMR (250MHz, DMSO) 9.03 (s, IH), 8.82 (s, 2H), 8.00 (m, 2H), 7.57 (s, IH), 7.42 (m, 2H), 7.11 (m, 3H), 5.14 (s, 2H), 4.39 (s, 2H), 3.87 (s, 3H), 3.62 (s, 2H). MS (AP+) 603 (M+H+, 100%).
Example 296 - l-(3-(Hept-l-yloxy)-4-methoxycarbonylbenzyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. ' H-NMR (400MHz, CDC13) 9.00 (s, IH), 8.61 (s, 2H), 7.53 (d, IH), 7.30 (d, IH), 7.28 (d, IH), 7.15 (dd, IH), 6.90 (m, 4H), 4.82 (s, 2H), 4.40 (s, 2H), 3.96 (t, 2H), 3.82 (s, 3H), 3.60 (s, 2H), 1.73 (m, 2H), 1.42 (m, 2H), 1.29 (m, 6H), 0.83 (t, 3H). MS (AP+) 591 (M+H+, 100%).
Example 297 - l-(3-(Hept-l-yloxy)-4-methoxycarbonylbenzyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. ' H-NMR (400MHz, CDC13) 9.00 (s. IH). 8.59 (s, 2H), 7.68 (d, IH), 7.29 (d, IH), 7.28 (d, IH), 6.91 (m. 3H), 6.59 (s, 2H), 4.88 (s, 2H), 4.40 (s, 2H), 3.81 (m, 5H), 3.62 (s, 2H), 1.72 (m, 2H). 1.40 (m. 2H), 1.28 (6H) 0.83 (t, 3H). MS (AP+) 591 (M+H+, 100%).
Example 298 - l-(3-Carboxy-4-(hept-l-yloxy)benzyI)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 296 by general method D as a colourless solid. Η-NMR (250MHz, CDC13) 9.05 (s, IH), 8.75 (s, 2H), 8.65 (br s, IH), 8.02 (d, IH), 7.32 (m, 4H), 6.98 (m, 3H), 4.99 (s, 2H), 4.40 (s. 2H), 4.21 (t, 2H), 3.70 (s, 2H), 1.88 (m, 2H), 1.50- 1.20 (m, 8H), 0.87 (t, 3H). MS (AP+) 577 (M+H+, 100%). Example 299 - l-(3-(Hept-l-yloxy)-4-carboxybenzyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 297 by general method D as a colourless solid. Η-NMR (400MHz, CDC13) 9.04 (s, IH), 8.67 (s, 2H), 8.11 (d, IH), 7.33 (d, IH), 7.31 (d, IH), 7.05 (s, IH), 6.95 (t, 2H), 6.82 (d, IH), 6.68 (s, IH), 4.99 (s, 2H), 4.44 (s, 2H), 4.05 (t, 2H), 3.69 (s, 2H), 1.87 (m, 2H), 1.50-1.25 (m, 8H), 0.87 (t, 3H). MS (AP+) 577 (M+H+, 55%).
Example 300 - l-(3-Methoxycarbonyl-4-hydroxybenzyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. IH-NMR
(250MHz, CDC13) 10.82 (s, IH) 9.03 (s, IH), 8.64 (s, 2H), 7.77 (d, IH), 7.30 (m, 2H), 6.93 (m, 3H), 6.68 (d, IH), 6.53 (dd, IH), 4.88 (s, 2H), 4.41 (s, 2H), 3.91 (s, 3H), 3.64 (s, 2H).
Example 301 - l-(3-Methoxycarbonylbenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. IH-NMR (400MHz. CDCI3) 9.10 (s, IH), 8.71 (s, 2H), 8.07 (d, IH), 7.86 (s, IH), 7.50 (t, IH), 7.30 (m, 3H), 7.07 (s, IH), 7.01 (t, 2H), 5.05 (s, 2H), 4.50 (s, 2H), 3.97 (s, 3H), 3.72 (s, 2H). MS (AP+) 477 (M+H+, 25%).
Example 302 - l-(3-Carboxybenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyI)- pyrimidin-4-one
Prepared from Example 301 by general method D as colourless crystals. IH-NMR (400MHz, DMSO) 13.20 (br s, IH), 9.07 (s, IH), 8.78 (s, 2H), 8.06 (s, IH), 7.95 (d, IH), 7.85 (s, IH), 7.50 (m, 4H), 7.16 (t, 2H), 5.26 (s, 2H), 4.44 (s, 2H), 3.68 (s, 2H).
Example 303 - l-(3,4-Di-(methoxycarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 106 by general method C2 as a yellow solid. IH-NMR (250MHz, CDC13) 9.05 (s, IH), 8.65 (s, 2H), 7.69 (m, IH), 7.44 (s, IH), 7.27 (m, 3H), 6.96 (m, 3H), 4.99 (s, 2H), 4.62 (s, 2H), 4.09 (s, 6H), 3.87 (s, 2H). MS (AP+) 535 (M+H\ 100%).
Example 304 - l-Carboxamidomethyl-2-(8-(4-chlorophenyl)oct-l-yl)thio-5-(pyrid- 3-ylmethyl)pyrimidin-4-one
Prepared from Example 70 by general method Cl, as a buff powder. MPt 147 - 152°C; 'H-NMR (d6 DMSO) δ 1.2-1.5(8H,m), 1.5-1.8(4H,m), 2.54(2H,t), 3.08(2H,t), 3.56(2H,s), 4.53(2H,s),7.1-7.9(9H,m), 8.38(lH,m) and 8.48(lH,bs); MS (El) M=498; C26H31C1N402S requires 498.
Example 305 - l-Dimethylaminocarbonylmethyl-2-(8-(4-chlorophenyl)-8-oxooct-l- yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediates B79 and Al by general method A4, as a light brown crystalline solid. MPt 57 - 59°C; ' H-NMR (CDC13) δ 1.37 (6H, m), 1.69 (4H, m), 2.92 (2H, t), 3.01 (3H, s), 3.16 (3H, s), 3.68 (2H, s). 4.43 (2H, m), 5.06 (2H, s), 7.1 1 (IH, s), 7.42 (2H, m), 7.89 (2H, m), 8.71 (2H, s), 9.11(1H, s).
Example 306 - l-Carboxamidomethyl-2-benzylthio-5-((2-methoxypyrid-4- yl)methyl)pyrimidin-4-one
Prepared from Example 88 by general method Cl, as a cream solid. MPt 126 - 132°C; 'H-NMR (d6 DMSO) δ 3.53(2H,s), 3.81(3H,s), 4.40(2H,s), 4.53), 6.66(lH,s), 6.85(lH,dd), 7.2-7.5(6H,m), 7.63(lH,s), 7.75(lH,bs) and 8.03(lH,d); MS (El) found M=396; C20H20N4O3S requires 396. Example 307 - l-(3-(Octadec-lylaminocarbonyl)prop-l-yI)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) δ 0.88 (3H, m), 1.25 (30H, m), 1.47 (2H, m), 2.05 (2H, m), 2.18 (2H, m), 3.21 (2H, m), 3.69 (2H, s), 3.92 (2H, m), 4.46 (2H, s), 5.42 (IH, m), 6.98 (2H, m), 7.27 (IH, m), 7.37 (2H, m), 8.71 (2H, s), 9.09 (IH, s), MS(APCr) M+l=666, C38H56FN502S requires 665. MPt 115.1°C (colourless solid).
Example 308 - l-(3-(Octadec-9-(Z)-en-lylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzy l)thio-5-(pyrimid-5-ylmethyl)py rimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) δ 0.88 (3H, m), 1.27 (22H, m), 1.47 (2H, m), 1.99-2.20 (8H, m), 3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, m), 4.46 (2H, s), 5.32 (2H, m), 5.42 (IH, m), 6.99 (2H, m), 7.26 (IH, s), 7.37 (2H, m), 8.71 (2H, s), 9.08 (IH, s), MS(APCI+) M+l =664, C38H54FN502S requires 663 (waxy solid).
Example 309 - l-(3-(Octadec-9-(E)-en-lylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) δ 0.88 (3H, t), 1.27 (22H, m), 1.47 (2H, m), 1.99-2.20 (8H, m), 3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, m), 4.46 (2H, s), 5.37 (2H, m), 5.44 (IH, m), 6.99 (2H, m), 7.26 (IH. s), 7.37 (2H, m), 8.71 (2H, s), 9.08 (IH, s), MS(APCr) M+l=664, C38H54FN502S requires 663. MPt 108.4°C (colourless solid). Example 310 - l-(3-(N-Dodec-lyl-N-methylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. 'H-NMR (CDC13) δ 0.88 (3H, m), 1.26 (18H, m), 1.49 (2H, m), 2.02 (2H, m), 2.30 (2H, m), 2.90 (3H, s), 3.17, 3.32 (each IH, m), 3.69 (2H, s), 3.92 (2H, t), 4.46 (2H, s), 6.98 (2H, m), 7.24 (IH, m), 7.35 (2H, m), 8.70 (2H, s), 9.08 (IH, s), MS(APCI+) M+l=596, C33H46FN502S requires 595. MPt 76.9°C (colourless solid).
Example 311 - l-(3-(N-Non-l-yl-N-methylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) δ 0.88 (3H, m), 1.26 (8H, m), 1.48 (2H, m), 2.05 (2H, m), 2.30 (2H, m), 2.90 (3H, s), 3.18, 3.32 (each IH, m), 3.69 (2H, s), 3.91 (2H, t), 4.46 (2H, s), 6.99 (2H, m), 7.25 (IH, m), 7.35 (2H, m), 8.71 (2H, s), 9.08 (IH, s), MS(APCI+) M+l=526, C28H36FN502S requires 525. (coloured oil).
Example 312 - l-(4-(Pent-l-ylaminocarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 284 by general method E as a solid. Η-NMR (CDC13) δ 0.82- 1.05 (3H, t), 1.21-1.48 (3H, m), 1.52-1.77 (3H, m), 3.38-3.54 (2H, q), 3.69 (2H, s), 4.49 (2H, s), 5.01 (2H, s), 6.14-6.27 (IH, br.t), 6.90-7.05 (3H, m), 7.10-7.21 (2H, d), 7.28-7.39 (2H, m), 7.70-7.80 (2H. d), 8.65 (2H, s), 9.07 (IH, s); MS (APCI+) found (M+l) = 532; C29H30FN5O2S requires 531. Example 315 - l-(l-(6-(4-FluorophenyI)hex-l-ylaminocarbonyl)ethyI)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 272 by hydrolysis using general method D, followed by amide coupling using general method E. 'H-NMR (CDC13) δ 1.15-1.72 (1 IH, m), 2.47-2.60 (2H, t), 3.17-3.35 (2H, m), 3.52-3.70 (2H, m), 4.25-4.49 (2H, br.q), 4.74-4.89 (IH, q), 6.53-6.66 (IH, br.t), 6.87-7.16 (6H, m), 7.21-7.40 (2H, m), 7.53 (IH, s), 8.69 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 578; C31H33F2N502S requires 577.
Example 316 - l-(3-(ll-DimethyIaminoundec-l-ylaminocarbonyl)prop-l-yI)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. 'H-NMR (CDC13) δ 1.27 (10H, m), 1.47 (4H, m), 1.99-2.20 (4H, m), 2.30 (6H. m),3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, m), 4.46 (2H, s), 5.49 (IH, bm), 6.99 (2H, m), 7.26 (IH, s), 7.37 (2H, m), 8.71 (2H, s), 9.08 (IH, s), MS(APCI+) M+l=611, C33H47FN602S requires 610 (gum).
Example 317 - l-(3-(3-Ethoxyprop-lylaminocarbonyl)prop-l-yl)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 282 by general method E. Η-NMR (CDC13) δ 1.14-1.35 (5H, m), 1.70-1.88 (2H, m), 2.1 1-2.23 (2H, t), 3.70-3.43 (2H, q), 3.435-3.60 (4H, m), 3.70
(2H, s), 3.87-4.01 (2H, t), 4.44 (2H, s), 6.23-6.38 (IH, br.t), 7.01-7.33 (4H, m), 8.71 (2H, s), 9.09 ( IH ,s); MS (APCI+) found (M+l) = 518: C25H29F2N503S requires 517. Example 318 - l-(3-(5-(Methoxycarbonyl)-5-(benzykloxycarbonylamino)pent- 1 y laminocarbony l)prop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (CDC13) δ 1.2-2.2 (10H, m), 3.19 (2H, m), 3.67 (2H, s), 3.74 (3H, s), 3.85 (2H, t), 4.35 (IH, m), 4.45 (2H, s), 5.09 (2H, s), 5.55 (2H, m), 6.99 (2H, m), 7.22-7.37 (8H, m), 8.71 (2H, s), 9.08 (IH, s), MS(APCI+) M+l =691, C35H39FN606S requires 690 (colourless foam).
Example 319 - l-(3-(5-(Methoxycarbonyl)pent-lylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (CDC13) δ 1.2-1.7 (6H, m), 1.98-2.21 (4H, m), 2.31 (2H, t), 3.22 (2H,m), 3.66 (3H, s), 3.70 (2H, s), 3.92 (2H, t), 4.45 (2H, s), 5.57 (IH, bm), 6.99 (2H, m), 7.26 (IH, s), 7.36 (2H, m), 8.71 (2H, s), 9.08 (IH, s); MS(APCI+) M+1=542, C27H32FN504S requires 541. (oil).
Example 320 - l-(3-(Hex-lylaminocarbonyl)prop-l-yl)-2-(3,4-difluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E as a solid. Η-NMR (CDC13) δ 0.83- 0.98 (3H, t), 1.20-1.59 (8H, m), 1.97-2.28 (4H, m), 3.15-3.29 (2H, q), 3.69 (2H, s), 3.87- 4.01 (2H, t), 4.43 (2H, s), 5.49-5.64 (IH, br.t), 6.99-7.32 (4H, m), 8.71 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 516; C26H30F2N5O2S requires 515. Example 321 - l-(3-(5-(t-Butoxycarbonylamino)pent-lylaminocarbonyl)prop-l-yl)- 2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (CDC13) δ 1.18-1.5 (15H, m), 2.05 (2H, m), 2.19 (2H, m), 3.16 (4H, m), 3.70 (2H, s), 3.92 (2H, t), 4.52 (2H, s), 4.64 (lH,bm), 5.71 (IH, bm), 6.99 (2H, m), 7.28 (IH, s), 7.37 (2H, m), 8.72 (2H, s), 9.08 (IH, s); MS(APCI+) M+l=599, C30H39FN6O4S requires 598. (colourless foam).
Example 322 - l-(3-(6-(t-Butoxycarbonylamino)hex-lylaminocarbonyI)prop-l-yl)- 2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. 'H-NMR (CDC13) δ 1.18-1.5 (17H, m), 2.04 (2H, m), 2.20 (2H, m), 3.15 (4H, m), 3.69 (2H, s), 3.92 (2H, t), 4.45 (2H, s), 4.59 ( IH, bm), 5.80 (IH, bm), 6.96 (2H. s), 7.28 (IH, s), 7.36 (2H, m), 8.71 (2H, s), 9.08 (IH, s); MS(APCI+) M+l=613, C31H41FN604S requires 612. MPt 90-98°C (colourless foam).
Example 323 - l-(3-(Dec-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) δ 0.88 (3H, t), 1.26 (14H, m), 1.47 (2H, m), 1.98-2.20 (4H, m), 3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, t), 4.46 (2H, s), 5.39 (IH, bm), 6.98 (2H, m), 7.24 (IH, s), 7.37 (2H, m), 8.70 (2H, s), 9.08 (IH, s); s); MS(APCI+) M+l=554, C30H40FN5O2S requires 553. MPt 90-98°C (colourless solid). Example 324 - l-(3-(Dec-lylaminocarbonyl)prop-l-yI)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (d6-DMSO) δ 0.85 (3H, m), 1.22 (14H, m), 1.31 (2H, m), 1.87 (2H, m), 2.12 (2H, m), 2.98 (2H, m), 3.35 (3H, s), 3.37 (2H, s), 3.84 (2H, m), 4.41 (2H, s), 6.13 (2H, m), 7.13 (2H, m), 7.51 (3H, m), 7.77 (2H, m); MS (APCI+) M+l=583, C32H43FN403S requires 582. MPt 133.3°C (colourless solid).
Example 325 - l-(3-(Hept-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (CDC13) o 0.88 (3H, t), 1.27 (8H, m), 1.47 (2H, m), 1.98-2.25 (4H, m), 3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, t), 4.52 (2H, s), 5.42 (IH, bm), 6.98 (2H, m), 7.25 (IH, s), 7.37 (2H, m), 8.68 (2H, s), 9.08 (IH, s); MS(APCI+) M+l=512, C27H34FN502S requires 511. MPt 84-89°C (colourless solid). MPt. 84 - 89
Example 326 - l-(3-(Hex-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. 'H-NMR (CDC13) δ 0.89 (3H, m), 1.20-1.55 (8H, m), 1.98-2.20 (4H, m), 3.19 (2H, m), 3.69 (2H, s), 3.92 (2H, t), 4.45 (2H, s), 5.44 (IH, bm), 6.96 (2H, m), 7.25 (IH, s), 7.37 (2H, m), 8.68 (2H, s), 9.08 (IH, s); MS(APCI=)M+1=498, C26H32FN502S requires 497. MPt 106-109°C (colourless solid). Example 327 - l-(3-(Non-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. ' H-NMR (CDC13) δ 0.87 (3H, t), 1.26 (12H, m), 1.47 (2H, m), 1.98-2.25 (4H, m), 3.20 (2H, m), 3.69 (2H, s), 3.91 (2H, t), 4.46 (2H, s), 5.39 (IH, bm), 6.98 (2H, m), 7.24 (IH, s), 7.37 (2H, m), 8.70 (2H, s), 9.08 (IH, s); MS(APCI+) M+l=540, C29H38FN502S requires 539. MPt 92-97°C (colourless solid).
Example 328 - l-(3-(Oct-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. 'H-NMR (CDC13) δ 0.88 (3H, t), 1.27
(10H, m), 1.47 (2H, m), 1.98-2.20 (4H, m), 3.22 (2H, m), 3.69 (2H, s), 3.92 (2H, t), 4.45
(2H, s), 5.43 (IH, bm), 6.98 (2H, m), 7.25 (IH, s), 7.37 (2H, m), 8.70 (2H, s), 9.08 (IH, s); MS(APCP) M+l=526, C28H36FN502S requires 525. MPt 72-83°C (colourless solid).
Example 329 - l-(3-(Pent-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 279 by general method E. Η-NMR (CDC13) 60.90 (3H, m), 1.17-1.61 (6H, m), 1.98-2.26 (4H, m), 3.20 (2H, m), 3.69 (2H, s), 3.92 (2H, t), 4.45 (2H, s), 5.44 (IH, bm), 6.97 (2H, m), 7.25 (IH, s), 7.38 (2H, m), 8.68 (2H, s), 9.08 (IH, s); MS(APCI+) M+l=484, C25H30FN5O2S requires 483. MPt 64-69°C (colourless solid). Example 330 - l-(3-(N-Hex-lyl-N-methylaminocarbonyl)prop-l-yl)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 282 by general method E. ' H-NMR (CDC13) δ 0.78-0.99 (3H, m), 1.19-1.77 (8H, m), 1.95-2.14 (2H, m), 2.25-2.44 (2H, q), 2.92 (3H, d), 3.12-3.27 (IH, t), 3.29-3.42 (IH, t), 3.70 (2H, s), 3.84-4.00 (2H, t), 4.44 (2H, t), 7.01-7.31 (4H, m), 8.71 (2H,s), 9.10 (IH, s); MS (APCI+) found (M+l) = 530; C27H33F2N502S requires 529.
Example 331 - l-(5-(2-mEthoxyethylaminocarbonyl)pent-l-yI)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 283 by general method E. Η-NMR (CDC13) δ 1.22-1.85 (6H, m), 2.13-2.25 (2H, t), 3.29-3.38 (3H, s), 3.39-3.53 (4H, s), 3.68-3.85 (4H, m), 4.44 (2H, s), 5.90-6.04 (IH, br.s), 7.01-7.29 (4H, m), 8.72 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 518; C25H29F2N503S requires 517.
Example 332 - l-(5-(2-Phenylethylaminocarbonyl)pent-l-yl)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 283 by general method E as a foam. Η-NMR (CDC13) δ 1.17- 1.38 (2H, m), 1.56-1.84 (4H, m), 2.04-2.19 (2H, t), 2.77-2.89 (2H, t), 3.41-3.60 (2H, m), 3.64-3.86 (4H, m), 4.43 (2H, s), 5.68-5.85 (IH, m), 7.00-7.38 (9H, m), 8.67 (2H, s), 9.06 (IH, s); MS (APCI+) found (M+l) = 564;C30H31F2N5O2S requires 563.
Example 333 - l-(5-(But-l-ylaminocarbonyl)pent-l-yI)-2-(3,4-difluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 283 by general method E. 'H-NMR (CDC13) δ 0.88-1.00 (3H, t), 1.17-1.76 (10H, m), 2.11-2.22 (2H, t), 3.18-3.30 (2H, q), 3.67-3.88 (4H, m), 4.43 (2H, s), 5.52-5.70 (IH, br.t), 7.00-7.30 (4H, m), 8.71 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 516; C26H31F2N502S requires 515.
Example 334 - l-(5-(N-(2-Phenylethyl)-N-methylaminocarbonyl)pent-l-yl)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 283 by general method E. Η-NMR (CDC13) δ 1.01-1.86 (6H, m), 1.98-2.09 (IH, t), 2.21-2.35 (IH, t), 2.76-2.99 (5H, m), 3.44-3.87 (6H, m), 4.44 (2H, s), 7.00-7.35 (9H, m), 8.71 (2H, d). 9.09 (IH, s); MS (APCI+) found (M+l) = 578; C31H33F2N502S requires 577.
Example 335 - l-(5-(N-But-l-yl-N-methylaminocarbonyl)pent-l-yl)-2-(3,4- difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 283 by general method E. Η-NMR (CDC13) δ 1.20-1.87 (13H, m), 2.24-2.39 (2H. q), 2.88-2.99 (3H, d), 3.18-3.42 (2H, m), 3.68-3.88 (4H, m), 4.44 (2H, s), 7.00-7.29 (4H, m), 8.72 (2H, s), 9.09 (IH, s);MS (APCI+) found (M+l) = 530; C27H33F2N502S requires 529.
Example 336 - l-((R)-l-(Hex-l-ylaminocarbonyl)ethylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6 DMSO) δ 0.8-0.95 (3H, m), 1.15-1.5 (1 lH,m), 2.95-3.2 (2H,m), 3.64 (2H,s), 4.3-4.5 (3H,m), 4.64 (2H,s), 6.95-7.1 (2H,m), 7.3-7.5 (2H,m), 7.71 (lH.d), 8.47 (lH.bd), 8.7 (2H,s), 8.97 (lH,s); MS (APCP) found (M+l) = 541; C27H33FN603S requires 540. Example 337 - l-((S)-l-(Hex-l-ylaminocarbonyl)ethylaminocarbonylmethyI)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (d6 DMSO) δ 0.8-0.95 (3H, m), 1.2-1.55 (HH,m), 3.0-3.25 (2H,m), 3.64 (2H,s), 4.35-4.5 (3H,m), 4.60 (2H,s), 6.90- 7.05 (2H,m), 7.25-7.45 (4H,m), 8.3 (lH,bd), 8.71 (2H,s), 9.01 (lH,s); MS (APCI+) found (M+l) = 541; C27H33FN603S requires 540.
Example 338 - l-((S)-2-(Hex-l-ylaminocarbonyl)pyrrolidin-l-ylcarbonylmethyI)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (CDC13) δ 0.8-0.95 (3H, m), 1.15-1.55 (8H,m), 1.75-2.45 (4H,m), 3.0-3.8 (6H,m), 3.72 (2H,bd), 4.35-4.60 (5H,m), 6.43 (lH,m), 6.90-7.05 (2H,m), 7.26 (lH,s), 7.27-7.45 (2H,m), 8.71 (2H,s), 9.09 (lH,s); MS (APCP) found (M+l) = 567; C29H35FN603S requires 566.
Example 339 - l-(l-Pyrrolidinocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (CDC13) δ 1.87-2.08 (4H, m), 3.44-3.52 (4H, m), 3.72 (2H, s). 4.46 (2H, s), 4.49 (2H, s), 6.95 (3H, m), 7.34 (2H, m), 8.73 (2H, s), 9.10 (IH, s); MS (APCI+) found (M+l) = 440; C22H22FN502S requires 439. Example 340 - l-(3-Butoxyprop-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylrnethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 0.89 (3H, t), 1.32 (2H, m), 1.47 (2H, m), 1.75 (2H, m), 3.32-3.44 (4H, m), 3.51 (2H, t), 3.71 (2H, s), 4.31 (2H, s), 4.47 (2H, s), 6.73 (IH, br. t), 6.98(3H, m), 7,32 (2H, m), 8.71 (2H, s), 9.11 (IH, s); MS (APCI+) found (M+l) = 500; C25H30FN5O3S requires 499.
Example 341 - l-(6-Hydroxyhex-l-yIaminocarbonylmethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (CDCl3/d6 DMSO) δ 1.2-1.6 (8H, m), 3.14 (2H,q), 3.5 (2H,q), 3.67 (2H,s), 3.95 (lH,t) 4.44 (2H,s), 4.52 (2H,s), 6.9-7.1 (2H,m), 7.3-7.5 (2H,m), 7.51(lH,s), 8.04 (lH,bt), 8.73 (2H,s), 9.01 (lH,s); MS (APCI+) found (M+l) = 486; C24H28FN503S requires 485.
Example 342 - l-(6-(4-Fluorophenyl)hex-l-ylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (d6-DMSO) δ 1.20-1.55 (8H, m), 2.51 (2H, m), 3.05 (2H, m), 3.59 (2H, s), 4.38 (2H, s), 4.53 (2H, s), 7.03-7.22 (6H, m), 7.43 (2H, m), 7.69 (IH, s), 8.21 (IH, m), 8.71 (2H, s), 9.02 (IH, s); MS
(APCP) M+l=564, C30H31F2N5O2S requires 563. MPt 170.8°C (cream solid). MPt. 170.8
Example 343 - l-(Tridec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 0.85 (3H, m), 1.20 (20H, m), 1.37 (2H, m), 3.06 (2H, m), 3.59 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.12 (2H, m), 7.44 (2H, m), 7.69 (IH, s), 8.21 (IH, m), 8.70 (2H, s), 9.05 (IH, s); MS (APCP) M+l=568, C31H42FN502S requires 567. MPt 191.5°C (colourless solid).
Example 344 - l-(Tetradec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 0.85 (3H, m), 1.23 (22H. m), 1.36 (2H, m), 3.05 (2H, m), 3.59 (2H, s), 4.38 (2H, s), 4.53 (2H, s), 7.12 (2H, m), 7.44 (2H, m), 7.69 (IH, s), 8.25 (IH, m), 8.70 (2H, s), 9.02 (IH, s); MS (APCP) M+l=582, C^H^FN^S requires 581. MPt 1 1.7°C (colourless solid).
Example 345 - l-(Octadec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (CDC13) δ 0.87 (3H, m), 1.25 (30H, m), 1.47 (2H, m), 3.26 (2H, m), 3.70 (2H, s), 4.37 (2H, s), 4.45 (2H, s), 5.95 (IH, m), 6.99 (3H, m), 7.32 (2H. m), 8.70 (2H, s), 9.09 (IH, s), MS(APCP) M+l=638, C36H52FN502S requires 637. MPt 189.8°C (pale yellow solid).
Example 346 - l-(Octadec-9-(Z)-en-lylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (CDC13) δ 0.88 (3H, s), 1.26 (22H, m), 1.47 (2H, m), 2.01 (4H, m), 3.26 (2H, m), 3.71 (2H, s), 4.35 (2H, s),4.46 (2H, s), 5.33 (2H, m), 5.73 (IH, m), 6.98 (3H, m), 7.34 (2H, m), 8.70 (2H, s), 9.09 (IH, s), MS(APCP) M+l=636, C36H50FN5O2S requires 635. MPt 179.7°C (cream solid). Example 347 - l-(Octadec-9-(E)-en-lylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 0.88 (3H, s), 1.26 (22H, m), 1.47 (2H, m), 1.95 (4H, m), 3.26 (2H, m), 3.70 (2H, s), 4.36 (2H, s), 4.45 (2H, s), 5.38 (2H, m), 5.87 (IH, m), 6.98 (3H, m), 7.32 (2H, m), 8.70 (2H, s), 9.08 (IH, s), MS(APCP) M+l=636, C36H50FN5O2S requires 635. MPt 184.6°C (yellow solid). MPt. 184.6
Example 348 - l-(Dec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 0.85 (3H, m), 1.21 (14H, m), 1.37 (2H, m), 3.06 (2H, m), 3.59 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.12 (2H, m), 7.42 (2H. m), 7.69 (IH, s), 8.26 (IH, m), 8.70 (2H, s), 9.03 (IH, s); MS (APCP) M+l=526, C28H36FN502S requires 525. MPt 187.7°C (colourless solid). MPt. 187.7
Example 349 - l-(Dodec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (d6-DMSO) δ 0.85 (3H, m), 1.23 (18H. m), 1.35 (2H, m), 3.05 (2H, m), 3.59 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.12 (2H, m), 7.43 (2H, m), 7.69 (IH. s), 8.20 (IH, m), 8.71 (2H, s), 9.03 (IH, s); MS (APCP) M+l=554, C30H40FN5O2S requires 553. MPt 191.1°C (colourless solid).
Example 350 - l-(Hept-l-yIaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 0.84 (3H, m), 1.20 (8H, m), 1.37 (2H, m), 3.06 (2H, m), 3.59 (2H, s), 4.38 (2H, s), 4.54 (2H, s), 7.13 (2H, m), 7.42 (2H, m), 7.70 (IH, s), 8.26 (IH, m), 8.70 (2H, s), 9.03 (IH, s); MS (APCP) M+l=484, C25H30FN5O2S requires 483. MPt 189.1°C (colourless solid). MPt. 189.1
Example 351 - l-(Oct-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (CDC13) δ 0.88 (3H, t), 1.25 (10H, m), 1.48 (2H, m), 3.26 (2H, m), 3.70 (2H, s), 4.35 (2H, s), 4.46 (2H, s), 5.81 (IH, m), 6.93-7.03 (3H, m), 7.34 (2H. m), 8.71 (2H, s), 9.08 (IH, s); MS(APCP) M+l=498, C26H32FN502S requires 497. MPt 191-192°C (colourless solid). MPt. 190 - 192
Example 352 - l-(Undec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 0.85 (3H, m),
1.20 (16H, m), 1.37 (2H, m), 3.06 (2H, m), 3.59 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.12
(2H, m), 7.42 (2H, m), 7.69 (IH, s), 8.26 (IH, m), 8.70 (2H, s), 9.03 (IH, s); MS
(APCP) M+l=540. C29H38FN502S requires 539. MPt 190.1°C (colourless solid). MPt. 190.1
Example 353 - l-(2-Hydroxyethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E as a white solid 'H-NMR (d6 DMSO) δ 3.15 (2H.q), 3.4 (2H,q), 3.58 (2H,s), 4.37 (2H,s), 4.57 (2H,s), 4.68 (lH,t), 7.05-7.2
(2H,m), 7.4-7.55 (2H,m), 7.70 (lH,s), 8.33 (lH.bt), 8.70 (2H,s), 9.03 (lH,s); MS (APCP) found (M+l) = 430; C20H20FN5O3S requires 429. Example 354 - l-(2-Methoxyethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E as a white solid Η-NMR (CDCl3/d6 DMSO) δ 3.2-3.45 (7H,m), 3.63 (2H,s), 4.41 (2H,s), 4.59 (2H,s), 6.95-7.1 (2H,m), 7.35- 7.5 (2H,m), 7.69 (lH,s), 8.37 (lH,bt), 8.70 (2H,s), 9.06 (lH,s); MS (APCP) found (M+l) = 444; C21H22FN503S requires 443.
Example 355 - l-(2-Phenylethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (CDC13) δ 2.80 (2H, t), 3.55 (2H,q), 3.66 (2H,s), 4.32 (2H,s), 4.41 (2H,s), 6.08 (lH,bt), 6.9-7.4 (10H,m), 8.66 (2H,s), 9.05 (lH.s); MS (APCP) found (M+l) = 490; C26H24FN502S requires 489.
Example 356 - l-(2-(4-Pent-l-ylphenyl)ethylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (d6-DMSO) δ 0.86 (3H, m), 1.25 (4H. m), 1.51 (2H, m), 2.46 (2H, m), 2.66 (2H, m), 3.24 (2H, m), 3.59 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.0-7.17 (6H, m), 7.46 (2H, m), 7.69 (IH, s), 8.32 (IH, m), 8.71 (2H, s), 9.02 (IH, s); MS (APCP) M+l=560, C31H34FN502S requires 559. MPt 170.6°C (colourless solid).
Example 357 - l-(Hex-l-ylaminocarbonylmethylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. white solid Η-NMR (d6 DMSO) δ 0.8-0.95 (3H, m), 1.2-1.45 (8H,m), 2.95-3.10 (2H.m), 3.58 (2H,s), 3.72 (2H,bd), 4.38 (2H.m), 4.64 (2H,s), 7.05-7.2 (2H,m), 7.40-7.55 (2H,m), 7.70 (lH,s), 7.75-7.9 (lH,m), 8.5-8.6 (lH,m), 8.70 (2H,s), 9.01 (lH,s); MS (APCP) found (M+l) = 527; C26H31FN603S requires 526.
Example 358 - l-(N-(Dodec-l-yI)-N-methylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. 'H-NMR (CDC13) δ 0.88 (3H, m), 1.25 (18H, m), 1.50 (2H, m), 2.98 (3H, d), 3.21, 3.37 each IH, m), 3.73 (2H, s), 4.52 (4H, m), 6.88 (IH, s), 6.99 (2H, m), 7.33 (2H, m), 8.71 (2H, s), 9.10 (IH, s), MS(APCP) M+l=568, C31H42FN502S requires 567. MPt 145.3°C (cream solid).
Example 359 - l-(N-(2-Phenylethyl)-N-methylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E as a solid. 'H-NMR (CDC13) δ 2.78- 2.97 (3H, m), 3.05 (2H, s), 3.42-3.57 (IH, m), 3.58-3.69 (2H, m), 3.73 (2H, s), 4.35-4.53 (3H, m), 6.12 (IH, s), 6.90-7.43 (9H. m), 8.62-8.75 (2H, d), 9.06-9.18 (IH, d); MS (APCP) found (M+l) = 504; C27H26FN502S requires 503.
Example 360 - l-(4-(But-l-ylaminocarbonyl)cyclohex-l-yl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 285 by general method E as a solid. 'H-NMR (CDC13) δ 0.85- 1.04 (3H, t), 1.20-2.50 (13H, m), 3.18-3.33 (2H. q), 3.70 (2H, s), 4.01-4.20 (IH, m), 4.44 (2H, s), 5.47-5.63 (IH, br.t), 6.93-7.07 (2H, t), 7.32-7.43 (2H, m), 7.44 (IH, s), 8.72 (2H, s), 9.08 (IH, s); MS (APCP) found (M+l) = 510; C27H32FN502S requires 509. Example 361 - l-(4-(Hex-l-ylaminocarbonyl)cyclohex-l-yl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 285 by general method E as a solid. Η-NMR (CDC13) δ 0.78- 0.97 (3H, t), 1.20-2.50 (17H, m), 3.17-3.32 (2H, q), 3.70 (2H, s), 4.03-4.20 (IH, m), 4.44 (2H, s), 5.47-5.60 (IH, br.t), 6.92-7.06 (2H, t), 7.30-7.40 (2H, m), 7.44 (IH, s), 8.71 (2H, s), 9.09 (IH, s); MS (APCP) found (M+l) = 538; C29H36FN502S requires 537.
Example 362 - l-(4-(2-Methoxyethylaminocarbonyl)cyclohex-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 285 by general method E as a solid. Η-NMR (CDC13) δ 1.58-
1.90 (4H, m), 2.02-2.30 (4H, m), 2.48 (IH, br.s), 3.36 (3H, s), 3.47 (4H, s), 3.64 (2H, s),
4.03-4.20 (IH, m), 4.44 (2H, s), 5.91 (IH, br.s), 6.92-7.06 (2H, t), 7.31-7.45 (3H, m),
8.72 (2H, s), 9.06 (IH, s); MS (APCP) found (M+l) = 512; C26H30FN5O3S requires 511.
Example 363 - l-(l-(6-(4-Fluorophenyl)hex-l-yl)aminocarbonyl)cycloprop-l-yl)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 269, analogously to Example 315. Η-NMR (CDC13) δ 1.15-1.71 (10H, m), 1.73-1.89 (IH, m), 1.94-2.01 (IH, m), 2.47-2.52 (2H, t), 2.98-3.18 (IH, m), 3.20-3.39 (IH, m), 3.60-3.69 (2H, d), 4.38 (2H, s), 5.64-5.78 (IH, br.t), 6.88-7.01 (4H, m), 7.03-7.20 (3H, m), 7.28-7.40 (2H, m), 8.68 (2H, s), 9.07 (IH, s); MS (APCP) found (M+l) = 590; C32H33F2N502S requires 589. Example 364 - l-(l-(Non-l-ylaminocarbonyl)cycloprop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 269, analogously to Example 315. 'H-NMR (CDC13) δ 0.78-0.98 (3H, t), 1.1 1-1.69 (16H, m), 1.73-1.89 (IH, m), 1.95-2.11 (IH, m), 3.00-3.19 (IH, m), 3.22-3.41 (IH, m), 3.55-3.78 (2H, br.q), 4.40 (2H, s), 5.52-5.65 (IH, br.t), 6.92-7.07 (2H, t), 7.26 (IH, s), 7.29-7.40 (2H, m), 8.69 (2H, s), 9.09 (lH,s); MS (APCP) found (M+l) = 538; C29H36FN502S requires 537.
Example 365 - l-((R)-l-(Non-l-ylaminocarbonyl)ethyI)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 272. analogously to Example 315. Η-NMR (CDC13) δ 0.80-0.94 (3H, t), 1.15-1.37 (12H, m), 1.38-1.54 (2H, m), 1.55-1.66 (3H, d), 3.10-3.36 (2H, m), 3.58-3.80 (2H, br.q), 4.32-4.55 (2H, br.q), 4.72-4.88 (IH, q), 6.08-6.20 (IH, br.t), 6.41- 7.06 (2H, t), 7.29-7.39 (2H, m), 7.50 (IH, s), 8.70 (2H, s), 9.07 (IH, s); MS (APCP) found (M+l) = 526; C28H36FN502S requires 525.
Example 366 - l-(ll-(Dimethylamino)undec-l-ylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (d6-DMSO) δ 1.20 (16H, m), 1.37 (2H, m), 2.15 (6H, s), 2.22 (2H, m), 3.07 (2H, m), 3.59 (2H, s), 4.38 (2H, s), 4.54 (2H, s), 7.13 (2H, m), 7.43 (2H, m), 7.70 (IH, s), 8.26 (IH, m), 8.70 (2H, s), 9.03 (IH, s); MS (APCP) M+l=583, C31H43FN602S requires 582. MPt 152-155°C (colourless solid). MPt. 152 - 155 Example 367 - l-(2-(6-(4-Fluorophenyl)hex-l-yloxy)ethylaminocabonylmethyl)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E ' H-NMR (d6-DMSO) δ 1.26 (4H, m), 1 47 (4H, m), 2.56 (2H, m), 3.23 (2H, m), 3 40 (4H, m), 3.59 (2H, s), 4.38 (2H, s), 4 56 (2H, s), 7.03-7 21 (6H, m), 7 43 (2H, m), 7 69 (IH, s), 8.26 (IH, m), 8 70 (2H, s), 9 03 (lH, s), MS (APCP) M+l =608, C32H35F2N503S requires 607. MPt 155-159°C (colourless solid). MPt 155 - 159
Example 368 - l-(5-(Methoxycarbonyl)-5-(benzyloxycarbonylamino)pent-l- ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one
Prepared from Example 280 by general method E Η-NMR (d6-DMSO) δ 1.35 (4H, m), 1 61 (2H, m), 3.05 (2H, m), 3 61 (5H, m), 3 99 (IH, m), 4.38 (2H, s), 4.52 (2H, s), 5.03 (2H, s), 7 11 (2H, m), 7 34 (5H, m), 7 44 (2H, m), 7.69 (2H, m), 8.24 (IH, m), 8.71 (2H, s), 9 02 (IH, s), MS (APCP) M+l=663, C33H35FN606S requires 662 (colourless solid).
Example 369 - l-(5-(Methoxycarbonyl)pent-l-ylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E 'H-NMR (d6-DMSO) δ 1 19-1 55 (6H, m), 2 24 (2H, m), 3 06 (2H, m), 3.58 (3H, s), 3.60 (2H, s), 4 39 (2H, s), 4 53 (2H, s), 7 12 (2H, m), 7 44 (2H, m), 7 69 (IH, s), 8.26 (IH, m), 8 70 (2H, s), 9 03 (IH, s), MS (APCP) M+l =514, C25H28FN504S requires 513 MPt 166 8°C (colourless solid) MPt. 166 - 172 Example 370 - l-(Non-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. ' H-NMR (d6-DMSO) δ 0.85 (3H, m), 1.21 (12H, bs), 1.35 (2H, m), 3.07 (2H, m), 3.60 (2H, s), 4.39 (2H, s), 4.53 (2H, s), 7.14 (2H, m), 7.45 (2H, m), 7.69 (IH, s), 8.22 (IH, m), 8.68 (2H, s), 9.06 (IH, s); MS (APCP) M+l=512, C27H34FN502S requires 511. MPt 200-202°C (colourless solid).
Example 371 - l-Dimethylaminocarbonylmethyl-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E as a solid. 'H-NMR (DMSO) δ 2.86 (3H, s), 2.97 (3H, s), 3.59 (2H, s), 4.39 (2H, s), 4.86 (2H, s), 7.06-7.20 (2H, t), 7.49-7.52 (2H, m), 7.59 (IH, s), 8.70 (2H, s), 9.04 (IH, s); MS (APCP) found (M+l) = 414; C20H20FN5O2S requires 413.
Example 372 - l-(N-(2-Hydroxyethyl)-N-methylaminocabonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. pale yellow solid 'H-NMR (d6 DMSO) δ 2.86 + 3.02 (2H,2 x s), 3.2 -3.65 (6H,m), 4.39 (2H,s), 4.6-5.05 (3H,m), 7.05- 7.2 (2H,m), 7.35-7.55 (2H.m), 8.70 (2H,s), 9.03 (lH,s); MS (APCP) found (M+l) = 444; C21H22FN503S requires 443.
Example 373 - l-(trαns-4-(4-Fluorobenzylaminocarbonyl)cyclohex-l-ylmethyl)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 273, analogously to Example 315. Η-NMR (CDC13) δ 0.80- 2.15 (10H, m), 3.51-3.65 (2H, d), 3.71 (2H, s), 4.33-4.43 (2H, d), 4.47 (2H, s), 5.64-5.78 (IH. br.t), 6.89 (IH, s), 6.92-7.08 (4H, t), 7.15-7.44 (4H, m), 8.69 (2H, s), 9.10 (IH, s); MS (APCP) found (M+l) = 576; C31H31F2N502S requires 575.
Example 374 - \-{trans -4-(Pent-l-ylaminocarbonyl)cyclohex-l-ylmethyl)-2-(4- fluorobenzyI)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 273, analogously to Example 315. 'H-NMR (CDC13) δθ.81-2.09 (19H, m), 3.16-3.40 (2H, q), 3.52-3.65 (2H, d), 3.71 (2H, s), 4.46 (2H, s), 5.32-5.45 (IH, br.t), 6.89 (IH, s), 6.95-7.08 (2H. t, 7.30-7.45 (2H, m), 8.70 (2H, s), 9.11 (IH, s); MS (APCP) found (M+l) = 538; C29H36FN502S requires 537.
Example 375 - l-(3-(Hex-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5- ((l-methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one
Prepared from Example 281 by general method E. 'H-NMR (CDC13) δ 0.88 (3H, t), 1.28 (6H, m). 1.45 (2H, m). 2.04 (2H, m), 2.20 (2H, m), 3.19 (2H, m), 3.50 (3H, s), 3.54 (2H, s), 3.86 (2H, t), 4.47 (2H, s), 5.69 (lh, bm), 6.21 (IH, m), 6.34 (IH, s), 7.01 (2H, m), 7.09 (IH, s), 7.19 (IH, d), 7.39 (2H, m); MS (APCP) M+l=527, C28H35FN403S requires 526. MPt 134-136°C (colourless solid). MPt. 134 - 136
Example 376 - l-(N-(N'-Hex-l-yl-N'-methylaminocarbonylmethyl)-N-methyl- aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one
Prepared from Example 280 by general method E. ' H-NMR (CDC13) δ 0.88 ( 3H, m), 1.28 (6H. m), 1.4-1.65 (2H, m), 2.92-3.09 (6H, m), 3.17-3.36 (2H, m), 3.70 (2H,s), 4.05- 4.19 (2H, m), 4.48-4.67 (4H, m), 6.97 (2H, m) 7.07 (IH, s), 7.35 (2H, m), 8.71 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 555; C28H35FN603S requires 554.
Example 377 - l-(N-(N'-Hex-l-ylaminocarbonylmethyl)-N-methylaminocarbonyl- methyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 0.87 (3H, m), 1.26
(6H, m), 1.44 (2H, m), 2.98 and 3.14 (3H,2Xs), 3.19 (2H, m), 3.70 (2H, s), 3.87 and 3.97
(2H, 2Xs), 4.46 (2H, m), 4.64 (2H, m), 5.98 and 6.16 (IH, 2Xt), 6.98 (3H, m), 7.33 (2H, m), 8.70 (2H, s), 9.08 (IH, s); MS (APCI+) found (M+l) = 541; C27H33FN603S requires 540.
Example 378 - l-(N-(N'-Hex-l-yl-N'-methylaminocarbonylmethyl)aminocarbonyl- methyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 0.88 (3H, m), 1.28 (6H. m), 1.52 (2H, m), 2.94 (3H, m), 3.18 and 3.38 (2H, 2Xt), 3.72 (2H, s), 4.03 (2H, m), 4.47 (4H, m), 6.98 (3H, m), 7.34 (2H, m), 8.71 (2H, s), 9.09 (IH, s); MS (APCI+) found (M+l) = 541 : C27H33FN603S requires 540.
Example 379 - l-Phenylaminocarbonylmethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 3.62 (2H,s), 4.41 (2H,s), 4.79 (2H,s). 7.0-7.2 (3H.m), 7.25-7.4 (2H,m), 7.4-7.6 (4H,m), 7.76 (lH,bs), 8.72 (2H,s), 9.04 (lH,s); MS (APCI+) found (M+l ) = 462; C24H20FN5O2S requires 461. Example 380 - l-(4-Methoxycarbonylbenzylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (d6-DMSO) δ 3.60 (2H,s), 3.86 (3H,s), 4.38 (2H,s), 4.40 (2H,s), 4.67 (2H,s), 7.05-7.25 (2H,m), 7.3-7.55 (4H,m), 7.74 (lH,s), 7.84 (2H,d), 8.70 (2H,s), 8.93 (lH,t), 9.03 (lH,s); MS (APCI+) found (M+l ) = 532; C27H24FN504S requires 533.
Example 381 - l-(N-Benzylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 3.66(2H,s),
4.41(4H,s), 4.45(2H,d,j=5.7Hz), 6.40(lH,brs), 6.94(lH,t,j=8.6Hz), 7.03(lH,s),
7.23(8H.m), 8.66(2H,s), 9.06(lH,s): MS (APCI) found (M+H ) = 476; C25H22FN502S requires 475.
Example 382 - l-(N,N-Di-(but-l-yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 280 by general method E. Η-NMR (CDC13) δ 0.8-1.05 (6H,m), 1.1-1.75 (8H,m), 3.19 (2H,t), 3.33 (2H,t), 3.72 (2H,s), 4.49 (2H,s), 4.52 (2H,s), 6.85-7.1 (3H,m), 7.3-7.45 (2H,m), 8.70 (lH,s), 9.09 (lH,s); MS (APCI+) found (M+l ) = 498; C28H32FN502S requires 497
Example 383 - l-(N-Methyl-N-(dodec-l-yl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 108 by general method C2. 'H-NMR (CDC13) 0.85 (3H.t), 1.2 (18H,m), 1.5 (2H,m,), 2.92 and 2.95 (3H,2xs). 3.17 and 3.33 (2H,2xm), 3.63 (2H,s), 3.96 (3H,s), 4.45 (2H,s), 4.49 and 4.52 (2H.2xs), 6.79 (lH,s), 6.95 (2H,m), 7.30 (2H,m), 8.42 (2H,s); MS (APCI+) found (M+l) = 598, C^H^FNgO^ requires 597.
Example 384 - l-(N-MethyI-N-(oct-l-yl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 108 by general method C2. 'H-NMR (CDC13) δ 0.8-0.95 (3H,m), 1.1-1.7 (12H,m), 2.95 and 2.99 (3H,2xs), 3.21 and 3.36 (2H, 2xt), 3.66 (2H,s), 3.99 (3H,s), 4.48 (2H,s), 4.51 and 4.55 (2H,d), 6.80 (lH,s), 6.9-7.1 (2H,m), 7.3-7.45 (2H,m), 8.45 (2H,s); MS (APCI+) found (M+l) = 542; C28H36FN503S requires 541.
Example 385 - l-(N-Methyl-N-(oct-l-yl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(2-ethoxypyrimid-5-ylmethyl)pyrimidin-4-one
Isolated as an impurity from one of the batches of Example 384, which had in turn been made from an impure batch of Example 108. Η-NMR (CDC13) δ 0.8-0.95 (3H,t), 1.1-1.7 (12H,m), 1.42 (3H,t), 2.95 and 2.99 (3H,2xs), 3.23 and 3.36 (2H, 2xt), 3.65 (2H,s), 4.39 (2H,q), 4.49 (2H,s), 4.50 and 4.54 (2H,d), 6.77 (lH,s), 6.9-7.1 (2H,m), 7.3-7.4 (2H,m), 8.43 (2H,s); MS (APCI+) found (M+l) = 556; C29H38FN503S requires 555.
Example 386 - l-(N-Methyl-N-(oct-l-yl)aminocarbonylmethyI)-2-(4- fluorobenzyl)thio-5-(2-benzyloxypyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 109 by general method C2. Η-NMR (CDC13) δ 0.75-1.0 (3H,t), 1.05-1.75 (12H.m), 2.95 and 2.98 (3H, 2xs), 3.20 and 3.36 (2H, 2xs), 3.65 (2H,s), 4.4-4.6 (4H.m), 5.42 (2H,s), 6.80 (lH.s), 6.9-7.1 (2H,m), 7.05-7.2 (2H,m), 7.15-7.55 (7H,m), 8.45 (2H,s); MS (APCI-) found (M+l ) = 618; C34H40FN5O3S requires 617. Example 387 - l-(N-Methyl-N-(dodec-l-yl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one
To a stirring solution of Example 383 (7.05 g) in dichloromethane (200 ml) was added in one portion B-bromocatecholborane (10 g). After stirring for 16 h at room temperature, the mixture was poured into water with stirring, diluted with more dichloromethane, shaken, and the phases allowed to separate slowly. The organic layer was purified by flash chromatography (silica, methanol-dichloromethane) and trituration with pet. ether. 'H-NMR (CDC13) δ 0.87 (3H,m), 1.2-1.4 (20,m), 2.88 and 2.96 (3H,2xs), 3.15-3.4 (4H,m), 3.43 (2H,s), 4.41 (2H,m), 4.88 (2H,m), 6.9-7.0 (2H,m), 7.25-7.4 (2H,m), 7.50 (lH,m), 8.15 (2H,b); MS (APCI+) found (M+l) = 584; C31H42FN503S requires 583.
Example 388 - l-(N-Methyl-N-(oct-l-yl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one
Prepared analogously to Example 387. from Example 384. Η-NMR (d6 DMSO) δ 0.8- 0.95 (3H,m), 1.05-1.65 (12,m), 2.81 and 2.94 (3H,2xs), 3.15-3.4 (4H,m), 4.39 (2H,s), 4.83 and 4.85 (2H,2xd), 7.05-7.2 (2H.m), 7.35-7.55 (3H,m), 7.95-8.35 (2H,b); MS (APCI+) found (M+l) = 526; C27H35FN503S requires 525.
Example 389 - l-(3-(N-(Hept-l-yl)-N-methylaminocarbonyl)phenyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 288 by general method E. Η NMR (DMSO-d6) δ: 0.7-1.05 (m, 6H), 1.3 (m, 5H), 1.41 (m. IH), 1.56 (br s, IH), 2.9 (d, 3H), 3.15 (m, IH), 3.4 (m, IH), 3.63 (s, 2H), 4.30 (s, 2H), 7.10 (t, 2H), 7.41 (m, 2H), 7.55 (m, IH), 7.60-7.85 (m, 3H), 7.95 (m, IH), 8.78 (s, 2H), 9.02 (s, IH). MS (APCI+) Found (M+l) = 560; C31H34FN502S requires 559. Example 390 - l-(3-(N-Ethyl-N-methylaminocarboπyl)phenyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 288 by general method E. Η NMR (DMSO-d6) δ: 1.0-1.2 (m, 3H), 2.9 (d, 3H), 3.18 (m, IH), 3.45 (m, IH), 3.62 (s, 2H), 4.31 (s, 2H), 7.10 (t, 2H), 7.40 (m, 2H), 7.60-7.85 (m, 4H), 7.96 (s, IH), 8.78 (s, 2H), 9.01 (s, IH). MS (APCI+) Found (M+l) = 490; C26H24FN502S requires 489.
Example 391 - l-(4-(Prop-l-ylaminocarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 292 by general method E. Η NMR (CDC13) δ: 1.00 (t, 3H), 1.65
(m, 2H), 3.44 (q, 2H), 3.81 (s, 2H), 4.35 (s, 2H), 6.15 (t, IH), 6.95 (t, 2H), 7.20 (s, IH),
7.25 (m, 2H), 7.41 (d, 2H), 7.89 (d, 2H), 8.95 (s, 2H), 9.20 (s, IH). MS (APCI+) Found
(M+l) = 490; C26H24FN502S requires 489.
Example 392 - l-(4-(But-l-ylaminocarbonyl)phenyl)-2-(8-(4-chlorophenyl)-8- oxooct-l-yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 293 by general method E. Η NMR (CDC13) δ: 1.01 (t, 3H), 1.21 (m, 2H), 1.3 (m, 6H), 1.7 (m, 4H), 2.91 (t, 2H), 3.15 (t, 2H), 3.46 (m, 2H), 3.73 (s, 2H), 6.29 (t, IH), 7.03 (s, IH), 7.4 (m, 4H), 7.95 (m, 4H), 8.71 (s, 2H), 9.08 (s, IH). MS (APCI+) Found (M+l) = 618 / 620; C33H36C1N503S requires 618. Example 393 - l-(4-(Hex-l-yloxycarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 292 by general method E as a white solid, m.p. 121-123°. Η NMR (CDC13) δ: 0.89 (t, 3H), 1.35 (m, 4H), 1.65 (m, 4H), 3.46 (q, 2H), 3.74 (s, 2H), 4.36 (s, 2H), 6.11 (t, IH), 6.95 (t, 2H), 7.04 (s, IH), 7.30 (m, 2H), 7.39 (d, 2H), 7.90 (d, 2H), 8.72 (s, 2H), 9.10 (s, IH). MS (APCI+) Found (M+l) = 532; C29H30FN5O2S requires 531.
Example 394 - l-(4-Methylaminocarbonylbenzyl)-2-(4-fluorobenzyl)thio-5- (py rimid-5-ylmethyl)py rimidin-4-one
Carbonyl diimidazole (105mg, 0.65mmol) was added to a suspension of Example 284 (150mg, 0.32mmol) in dichloromethane (10ml) under an atmosphere of argon and the reaction stirred for lh. Methylamine (1.62ml, 2M solution in THF) was added and stirring continued for 2h. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The aqueous phase was extracted with ethyl acetate and the combined organic phase dried (MgS04) and the the solvent removed under reduced pressure. The residue was purified by flash chromatography (10% methanol / ethyl acetate) to afford the desired compound as an off white solid (77mg, 50%).
'H-NMR (CDCI3) 8.90 (s, IH), 8.47 (s, 2H), 7.60 (m, 2H), 7.25-6.65 (m, 6H), 6.28 (s, IH), 4.85 (s, 2H), 4.27 (s, 2H), 3.51 (s, 2H), 2.85 (s, 3H). MS (AP+) 476 (M+H+, 100%).
Example 395 - l-(3-Methylaminocarbonyl-4-(hept-l-yloxy)benzyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared analogously to Example 394, from Example 298, as an off white solid. IH- NMR (CDCI3) 8.98 (s, IH), 8.67 (s. 2H), 8.58 (s, IH), 8.06 (m, IH), 7.28 (m, 2H), 7.06 (m, 2H). 6.89 (m, 2H), 4.87 (s, 2H), 4.38 (s, 2H), 4.05 (t, 2H), 3.58 (s, 2H), 2.93 (s, 3H), 1.81 (m, 2H), 1.45-1.15 (m, 8H). 0.82 (m, 3H). MS (AP+) 590 (M+H+, 100%).
Example 396 - l-(2-(t-Butoxycarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 138 by general method A2. Η-NMR (CDC13) δ 1.41 (9H, s), 3.43 (2H, q, J 6.0Hz), 3.67 (2H, s), 3.97 (2H, s), 4.46 (2H, s), 4.88 (IH, s), 6.99 (2H, m), 7.07 (IH. s), 7.36 (2H, m), 8.70 (2H, s) and 9.09 (IH, s). (APCP) Found (M+l) =
472. C23H26FN503S requires 471. .
Example 397 - l-(2-(Trifluoroacetylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
The compound of Example 396 (200mg) was dissolved in neat TFA (1ml) at room temperature. After 5min. the solution was concentrated to a brown gum and re-evaporated from ethyl acetate. The crude amine salt in ethyl acetate (5ml) was treated with diisopropylethylamine (81mg) and acetyl chloride (50mg) for 24h. The crude reaction mixture was purified by silica gel chromatography to give the title compound as a colourless solid, (72mg, 37%), Η-NMR (CDC13) δ 3.58 (2H, s), 3.77 (2H, m), 4.1 1 (2H, t, J 4.7Hz), 4.37 (2H, s), 6.92-7.02 (3H, m). 7.24-7.31 (2H, m), 8.63 (2H, s), 9.04 (IH, s) and 9.13 (IH, t, J 5.5Hz). (APCI-) Found (M-1) = 466. C20H17F4N5O2S requires 467.
Example 398 - l-(2-(Benzoylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
The compound of Example 396 was treated with trifluoroacetic acid as described in the previous example. A solution of the salt in ethyl acetate was treated with excess IM hydrochloric acid in ether. The corresponding dihydrochloride salt was precipitated, filtered, washed with ether and dried in vacuo to give the crude salt as a white solid. 1- (3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (72mg), 1-hydroxy- benzotriazole hydrate (52mg) and benzoic acid (42mg) in dichloromethane (5ml) at room temperature was treated with the above dihydrochloride (150mg). Diisopropylethylamine (88mg) in DMF (1ml) was added and the solution stirred for 48h. The reaction mixture was diluted with dichloromethane washed with water, brine, dried over anhydrous magnesium sulfate and concentrated. The crude product was purified by silica gel chromatography to give the title compound as a white solid, (84mg, 52%), 'H-NMR (CDC13) 3.52 (2H, s), 3.60 (2H, m), 4.04 (2H, t, J 5.5Hz), 4.36 (2H, s), 7.09 (2H, m), 7.35-7.53 (5H. m), 7.71-7.75 (3H, m), 8.63 (3H, m and s) and 9.02 (IH, s). (APCP) Found (M+l) = 476. C25H22FN502S requires 475.
Example 399 - l-(2-(Hex-l-ylcarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared analogously to Example 398, using heptanoic acid. IH-NMR (CDC13) δ 0.87 (3H, t, J 6.8Hz), 1.26 (6H. br. s), 1.56 (2H, m), 2.14 (2H, t, J 7.9Hz), 3.54 (2H, dd, J 5.8,5.9Hz), 3.66 (2H, s), 4.00 (2H, t, J 5.9Hz), 4.43 (2H, s), 6.19 (IH, t, J 5.8Hz) 7.02 (2H, m), 7.06 (IH, s), 8.70 (2H, s) and 9.08 (IH, s). (APCP) Found (M+l) = 484. C25H30FN5O2S requires 483.
Example 400 - l-(2-(5-Phenylpent-l-ylcarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
a) Prepared analogously to Example 398, using 6-phenylhexanoic acid. IH-NMR
(CDC13) δ 1.33 (2H, m), 1.61 (4H, m), 2.13 (2H, t, J 7.7Hz), 2.59 (2H, t, J 7.7Hz), 3.52 (2H, m), 3.60 (2H, s), 3.97 (2H, t, J 5.8Hz), 4.40 (2H, s), 6.44 (IH, t, J 5.2Hz), 6.99 (2H, t, J 8.6Hz), 7.04 (IH, s), 7.12-8.57 (7H, m), 8.67 (2H, s) and 9.05 (IH, s). (APCP) Found (M+l) = 546. C30H32FN5O2S requires 545. b) Also prepared by reaction of the amine dihydrochloride with 6-phenylhexanoyl chloride in the presence of dusopropylamine. After work up and purification by silica gel chromatography, the title compound was obtained as a colourless solid in 49% yield.
Example 401 - l-(2-(Hept-l-ylcarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared analogously to Example 398, using octanoic acid. IH-NMR (CDC13) δ 0.86
(3H, t, J 6.8Hz), 1.25 (8H, br. s), 1.58 (2H, m), 2.16 (2H, t, J 7.8Hz), 3.55 (2H, m), 3.63
(2H, s), 4.01 (2H, t, J 5.7Hz), 4.40 (2H, s), 6.69 (IH, br. t, J 5.4Hz), 6.98 (2H, t, J 8.5Hz),
7.09 (IH, s), 7.31 (2H, m), 8.69 (2H, s) and 9.07 (IH, s). (APCP) Found (M+l) = 498. C26H32FN502S requires 497.
Example 402 - l-(2-Acetylaminoethyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B76 by general method A4. 'H-NMR (CDC13) δ 1.2- 1.9(10H,m), 2.02(3H,s), 2.92(2H,t), 3.20(2H,t), 3.5-3.8(4H,m), 4.04(2H,m), 7.04(lH,s), 7.43(2H,m), 7.88(2H,m), 8.71(2H.s) and 9.06(lH,s); MS (APCI+) found (M+l)=542; C27H32C1N503S requires 541. Example 403 - l-(4-(tert-Butoxycarbonylamino)but-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 122 by general method A2. Η NMR (CDC13) δ: 1.43 (s, 9H), 1.5 (m, 2H), 1.75 (m, 2H), 3.15 (m, 2H), 3.70 (s, 2H), 3.83 (t, 2H), 4.46 (s, 2H), 4.65 (br s, IH), 7.00 (t, 2H), 7.20 (s, IH), 7.37 (m, 2H), 8.70 (s, 2H), 9.08 (s, IH). MS (APCI+) Found (M+l) = 500; C25H30FN5O3S requires 499.
Example 404 - l-(3-(Ethoxycarbonylamino)prop-l-yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from intermediate B 123 by general method A2. Η NMR (CDC13) δ: 1.23 (t, 3H), 1.93 (m, 2H), 3.20 (q, 2H), 3.71 (s, 2H), 3.86 (t, 2H), 4.10 (m, 2H), 4.46 (s, 2H), 5.25 (br s, IH), 7.00 (t, 2H), 7.30 (s, IH), 7.40 (m, 2H), 8.72 (s, 2H), 9.06 (s, IH). MS (APCI+) Found (M+l) = 458; C22H24FN503S requires 457.
Example 405 - l-(2-(Benzylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 3.39 (2H, s), 3.58 (2H, m), 4.03 (2H, t, J 5.7Hz), 4.31 (2H, s), 4.30 (2H, d, J 5.0Hz), 5.97 (IH, t, J 5.9Hz), 6.26 (IH, t, J 5.6Hz), 6.91-6.99 (3H, m), 7.20-8.58 (7H, m), 8.58 (2H, s) and 9.05 (IH, s). (APCP) Found (M+l) = 505. C26H25FN602S requires 504. Example 406 - l-(2-(Dodec-l-ylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 0.87 (3H, t, J 6.8Hz), 1.27 (18H, v.br s), 1.48 (2H, m), 3.17 (2H, dd, J 6.5,13.0Hz), 3.52 (2H, m), 3.58 (2H, s), 4.03 (2H, t, J 5.0Hz), 4.40 (2H, s), 5.21 (IH, m), 5.70 (IH, m), 6.95 (2H, m), 7.10 (IH, s), 7.30 (2H, m), 8.66 (2H, s) and 9.08 (IH, s). (APCP) Found (M+l) = 583. C31H43FN602S requires 582.
Example 407 - l-(2-(Hept-l-ylaminocarbonylamino)ethyI)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 0.85 (3H, m), 1.26 (8H, m), 1.49 (2H, m), 3.16 (2H, m), 3.51-3.60 (4H, s and m), 4.04 (2H, t, J5.8Hz), 4.39 (2H, s), 5.30 (IH, m), 5.83 (IH, m), 6.94-7.02 (2H, m), 7.07 (IH, s), 7.28-8.60 (2H, m), 8.67 (2H, s) and 9.08 (IH, s). (APCP) Found (M+l) = 513. C26H33FN602S requires 512.
Example 408 - l-(2-(Oct-l-ylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 0.86 (3H, m),
1.24 (10H, m), 1.50 (2H, m), 3.17 (2H, dd, J 6.8,13.0Hz), 3.52 (2H, m), 3.57 (2H, s), 4.04 (2H. t. J 5.5Hz), 4.39 (2H, s), 5.31 (IH, m), 5.85 (IH, m), 7.01 (2H, m), 7.07 (IH, s), 7.30 (2H. m), 7.68 (2H, s) and 9.08 (IH, s). (APCP) Found (M+l) = 527. C27H35FN602S requires 526. Example 409 - l-(2-(2-Thien-2-ylethylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 3.06 (2H, t, J 6.8Hz), 3.52 (6H, m), 4.01 (2H, t, J 5.6Hz), 4.37 (2H, s), 5.47 (IH, t, J 5.7Hz), 5.97 (IH, t, J 5.3Hz), 6.85-7.31 (8H, m), 8.65 (2H, s) and 9.07 (IH, s). (APCP) Found (M+l) = 525. C25H25FN602S2 requires 524.
Example 410 - l-(2-(l,l,3,3-Tetramethylbut-l-ylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 1.01 (9H, s), 1.39 (6H, s), 1.75 (2H, s), 3.51 (2H, m), 3.59 (2H, s), 4.02 (2H, t, J 5.5Hz), 4.39 (2H, s), 5.25 (IH. s), 5.78 (IH, t, J 5.6Hz), 6.98 (2H, m), 7.13 (IH, s), 7.31 (2H, m), 8.67 (2H, s) and 9.08 (IH, s). (APCP) Found (M+l) = 527. C27H35FN602S requires 526.
Example 411 - l-(2-(4-(Butoxycarbonyl)phenylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 0.97 (3H, t, J 7.4Hz), 1 4 (2H, m), 1.73 (2H, m), 3.54 (2H, s), 3.67 (2H, m), 4.13 (2H, m), 4.28 (4H, m), 6.92 (3H, m), 7.18 (2H, m), 7.55 (2H, d, J 8.8Hz), 7.93 (2H, d, J 8.8Hz), 8.62 (2H, s), 8.82 (IH, s) and 9.10 (IH, s). (APCP) Found (M+l) = 591. C30H31FN6O4S requires 590. Example 412 - l-(2-(4-(l-Methylethyl)phenylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 1.20 (6H, d, J 6.9Hz), 2.84 (IH, m), 3.55 (2H, s), 3.60 (2H, m), 4.12 (2H, t, J 4.8Hz), 4.33 (2H, s), 6.48 (IH, m), 6.92 (2H, m), 7.11-7.34 (7H, m), 8.00 (IH, s), 8.63 (2H, s) and 9.10 (IH, s). (APCP) Found (M+l) = 533. C28H29FN602S requires 532.
Example 413 - l-(2-(4-Methylphenylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 2.29 (3H, s), 3.54 (2H, s), 3.60 (2H, m), 4.11 (2H. t J 5.5Hz), 4.32 (2H, s), 6.50 (IH, m), 6.90-7.08 (4H, m), 7.18-7.30 (5H, m), 8.03 (IH, br.s), 8.64 (2H, s) and 9.09 (IH, s). (APCP) Found (M+l) = 505. C26H25FN602S requires 504.
Example 414 - l-(2-(4-Ethoxyphenylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 1.40 (3H, t, J 4.2Hz), 3.57 (4H, v.br.s), 3.97 (2H, q, J 4.2Hz), 4.08 (2H, t, J 5.4Hz), 4.34 (2H, s), 6.13 (IH, br.s), 6.79-6.98 (4H, m), 7.17 (IH, s), 7.23 (4H, m), 7.63 (IH, br.s), 8.66 (2H, s) and 9.09 (IH, s). (APCP) Found (M+l) = 535. C27H27FN603S requires 534. Example 415 - l-(2-(4-Phenoxyphenylaminocarbonylamino)ethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one
Prepared from Example 396 by general method F. IH-NMR (CDC13) δ 3.56 (2H, s), 3.63 (2H, m), 4.13 (2H, m), 6.57 (IH, m), 6.57-8.22 (14H, m), 8.23 (IH, s), 8.65 (2H, s) and 9.05 (IH, s). (APCP) Found (M+l) = 583. C31H27FN603S requires 582.
References
1. EP 645370 (1995)
2. Eur J Med Chem 1989, 24 ( 1), 65
3. Eur J Med Chem 1990, 25 (3), 217 4. Eur J Med Chem 1993, 28 (7-8), 601
5. J Labelled Comp Radiopharm 1987, 24 (4), 431
6. J Med Chem 1995, 38, 3850
7. EP 117345 (1984)
8. EP 68833 (1982) 9. Liebigs Ann Chem 1994, 1849
10. J A er Chem Soc 1950, 72, 3539
11. GB 1 582 527
12. Bull. Soc. Chi. Fr. 1263 (1956); ibid. 1466 (1957)
13. DE 84-3414752 Al 1984 14. Tet Lett 1983, 24 (48), 5309-5312
15. J. Chem. Soc. 1957, 3314.
Biological Data
1. Screen for Lp-PLA2 inhibition.
Enzyme activity was determined by measuring the rate of turnover of the artificial substrate (A) at 37 C in 50mM HEPES (N-2-hydroxyethylpιperazιne-N'-2- ethanesulphonic acid) buffer containing 150mM NaCl, pH 7 4
(A)
Assays were performed in 96 well titre plates
Recombinant LpPLA was purified to homogeneity from baculovirus infected Sf9 cells, using a zinc chelating column, blue sepharose affinity chromatography and an amon exchange column Following purification and ultrafiltration, the enzyme was stored at 6mg/ml at 4°C Assay plates of compound or vehicle plus buffer were set up using automated robotics to a volume of 170μl The reaction was initiated by the addition of 20μl of lOx substrate (A) to give a final substrate concentration of 20μM and 10 μl of diluted enzyme to a final 0 2nM LpPLA2 _ he reaction was followed at 405 nm and 37 °C for 20 minutes using a plate reader with automatic mixing The rate of reaction was measured as the rate of change of absorbance.
Results
The compounds described in the above Examples were tested as hereinbefore described and were found to have IC50 values in the range 0 0001 to 60 uM

Claims

Claims
1. A compounds of formula (I):
(I) in which:
Z is a bond and R* is halogen; or
Z is CR3R4, where R3 and R4 are each hydrogen or C(i_4)alkyl, or R3 and R^ together with the intervening carbon atom form a C(3_6)cycloalkyl ring; and
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents selected from C(i_ιg)alkyl, C(i_ιg)alkoxy, C(i_ιg)alkylfhio, arylC(i_i8)aTkoxy, oxo, hydroxy, halogen, CN, COR5, COOR5, CONR5R6, NR5COR6, S02NR5R6, NR S02 ^, NR R6, mono to perfluoro-C(i_4)alkyl and mono to perfluoro- C(i_4)alkoxy;
X is O or S;
Y is a group of formula -A -A2Ά3- in which A and A3 each represent a bond or a straight chain or branched C(i_ιo)alkylene group and A2 represents a bond or O, S, SO, S02, CO, C=CH2, CH=CH, C≡C, CONH, NHCO, or CR5R6, providing that when A2 is O, S, SO, Sθ2θr CONH, A contains at least two carbon atoms linking the A2 group and the CH2 group in formula (I);
R2 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents selected from the substituents hereinbefore defined for R I , as well as aryl and arylC(i_4)alkyl;
W is a bond and R^ is hydrogen; or
W is S02 or a bond; and
R' is R Ar a hydrocarbyl group which hydrocarbyl group may be optionally interupted within the carbon chain by a group selected from O, COO, OCO, CO, CONR8, NR8CO, NR8CONR9, NR8COO, OCONR8, and NR8, and which hydrocarbyl group may also be optionally substituted by 1 or 2 substituents selected from mono to perfluoro- C(i_4)alkyl, OR8, COOR8, CONR8R9, NR8COR9, NR8CONR9R10, NR8COOR9, OCONR8R9, NR1 !R12 and R1; R5 and R^ are independently hydrogen or C(i_20)alkyl, for instance C(i_4)alkyl (e.g. methyl or ethyl);
R8, R9 and R 10 are independently selected from hydrogen, C(i-20)alkyl (for instance C(i_i5)alkyl), (which may optionally be fluorinated. including up to perfluorinated on the terminal 1 to 3 carbon atoms), C( _20)alkenyl (preferably
C(l2-18)alkenY1)' ary1 ' arylc(l-10)allky1 ' C(l-10)alkoxyC(i_ιo)alkyl, or aryloxyC(i_ιo)alkyl and in which an aryl group may have one or two substituents selected from halogen, C(i_20)alkyl, C(i_20)alkoxy, aryloxy and COOC(i_20)alkyl; and R and R^2 are independently selected from one of the values hereinbefore defined for R8 and R9 or R^ * and R*2 together with the nitrogen atom to which they are attached form a 5- to 7 membered ring optionally containing one or two further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, Cn _4)alkyl, phenyl, or benzyl.
2. A compound as claimed in claim 1 in which Z is CH2.
3. A compound as claimed in claim 1 or 2 in which Rl is an aryl group selected from phenyl, naphthyl, or a 5- or 6- membered, monocyclic heteroaryl group containing 1 or 2 nitro Jbge'-n heteroatoms,
4. A compound as claimed in claim 3 in which Rl is selected from pyridyl, pyrimidyl or pyrazolyl.
5. A compound as claimed in any one of claims 1 to 4 in which X is S.
6. A compound as claimed in any one of claims 1 to 5 in which A^, A2 and A3 each represent a bond or A' and A are straight chain C(i_ιo)alkylene groups and A2 is selected from CO, C=CH2 and O.
7. A compound as claimed in any one of claims 1 to 6 in which R2 is phenyl optionally substituted by 1, 2 or 3 substituents selected from halogen, C(i_4)alkyl, Cπ _4)alkoxy, phenyl and benzyl.
8. A compound as claimed in any one of claims 1 to 7 in which R2YCH2X is a 4-fluorobenzylthio group.
9. A compound as claimed in any one of claims 1 to 8 in which W is a bond.
10. A compound as claimed in any one of claims 1 to 9 in which R^ when a hydrocarbyl group is selected from C(i_20)alky1 ' C(2_20)alkenyl, C(2-20)alkynyl, C(3_6)cycloalkyl, C(3_6)cycloalkylC(i_5)alkyl, or C( _i5)alkoxyC( _ιo)alkyl each of which may be optionally substituted by 1 or 2 substituents selected from mono to perfluoro-C(i_4)alkyl, OR8, COOR8, C0NR8R9, NR8COR9, NR8CONR R10, NR8COOR9, OCONR R9, NRi iR^ and R1.
1 1. A compound as claimed in any one of claims 1 to 10 in which W is a bond and R^ is:
(a) C(i_ιo)alkyl which is substituted by one or two substituents selected from hydroxy, C(i_ιo)alkoxy, COOC(i_ι_)alkyl, CONR8R9, NR8CONR9Rl°, NHCOR8 (in which
R8, R9 and R^ is each independently C(i_20)alkyl), NR! R A phenyl which may be optionally substituted by COOC(i_6)alkyl and heteroaryl;
(b) R is a phenyl or a phenylC(i_g)alkyl group substituted in the phenyl ring by 1 or 2 substituents selected from C(6-i2)alkyl, C(6-i2)alkoxy, COOH, COOC(6_i2)alkyl and C0NHC(6-I2)alkyl; or
(c) R is heteroarylC(i_8)alkyl in which the heteroaryl ring is monocyclic with 5 to 6 members and one or two heteroatoms selected from nitrogen, oxygen and sulphur.
12. A compound as claimed in any one of claims 1 to 11 in which W is a bond and R^ is a group of the formula (CH2)nBRl where n is an integer from 1 to 6, B is selected from
NR14CO, CONR14, NR14CONR15, NRl5COO (in which Rl4 and R15 are independently selected from hydrogen or C( _6)alkyl) and R 3 is C(g_ιg)alkyl (which may optionally be fluorinated, including up to perfluorinated on the terminal 1 to 3 carbon atoms), C(g_ιg)alkenyl, phenyl C(i_6)alkyl and phenylC(i_g)alkoxyC(i_6)alkyl in which phenyl may be optionally substituted by halogen or Cn _6)alkyl.
13. A compound selected from: 2-(8-Phenyloct-l-yl)thio-5-((l-benzyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(8-(4-Fluorophenyl)oct- 1 -yl)thio-5-(( 1 -benzyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4- one;hyl)pyrimidin-4-one;
2-(8-(4-Chlorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
2-(8-(4-Fluorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -benzyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one; 2-(9-Phenylnon-l-yl)thio-5-(( l-benzyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(6-Phenylhex- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(7-Phenylhept- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one; 2-(8-Phenyloct-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(9-Phenylnon- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(6-Benzyloxyhex-l-yl)thio-5-((l-methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(8-(4-Chlorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
2-(8-Phenyloct- 1 -yl)thio-5-(( 1 -butyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one;
2-(8-Phenyloct-l-yl)thio-5-((2,3-dimethylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(6-Benzyloxyhex-l-yl)thio-5-((2,3-dimethylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(8-Phenyloct-l-yl)thio-5-((2,4-dimethylpyrid-5-yl)methyl)pyrimidin-4-one; 2-(5-Phenylpent- 1 -yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(N-(6-(4-Fluorophenyl)hexyl)carboxamidomethyl)thio-5-((2-methylpyrid-5- yl)methyl)pyrimidin-4-one;
2-(6-Benzyloxyhex-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(8-Phenyloct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; 2-(7-Phenylhept- 1 -yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(6-Phenylhex-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(9-Phenylnon-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(6-(4-Chlorobenzyloxy)hex-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(6-(4-Fluorobenzyloxy)hex-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; 2-(8-(4-Methoxyphenyl)-8-oxooct- 1 -yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one;
2-(8-(4-Methoxyphenyl)oct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(8-(4-Fluorophenyl)oct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(8-(4-Fluorophenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one;
2-(8-(4-Chlorophenyl)oct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one;
2-(8-(4-Chlorophenyl)-8-oxooct- l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one;
2-(8-Phenyl-8-oxooct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; 2-(8-(4-Chlorophenyl)-8-hydroxyoct- 1 -yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin- 4-one;
2-(8-(4-Methylphenyl)-8-oxooct-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4- one;
2-(4-Phenylbut-l-yl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; -(8-Phenyloct- 1 -yl)thio-5-(( 1 -oxo-2-methylpyrid-5-yl)methyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrazin-2-ylmethyl)pyrimidin-4-one; -(8-Phenyloct- 1 -yl)thio-5-(pyrid-2-ylmethyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)-8-oxooct- 1 -yl)thio-5-(thiazol-2-ylmethyl)pyrimidin-4-one; -(6-Phenylhex- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-Phenylhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(9-Phenylnon-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(6-Benzyloxyhex- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Fluorophenyl)non-8-en-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(6-(4-Chlorobenzoylamino)hex-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Bromophenyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-(4-Chlorophenoxy)hept- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-Phenoxyhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-Phenylthiohept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-(4-Chlorophenylthio)hept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(6-(3-Chlorophenyl)hex-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-Phenylsulfinylhept- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-(4-Chlorophenylsulfinyl)hept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-Phenylsulfonylhept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(7-(4-Chlorophenylsulfonyl)hept-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(3-Chlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(3,4-Dichlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(2-Thienyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(2-Furyl)-8-oxooct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(2-Pyridyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one;
2-(9-(4-Chlorophenyl)-9-oxonon-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; 2-(8-(3,4-Dichlorophenyl)oct-7-yn- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one;
2-(8-(4-Acetylphenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one;
2-(8-(4-Methylnaphth- 1 -yl)-8-oxooct- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Pyridyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)oct-l-yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(4-(3-Phenylprop- 1 -yloxy)but- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(6-Benzyloxyhex-l-yl)thio-5-(quinolin-3-ylmethyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-(quinolin-3-ylmethyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-((4-methoxypyrid-2-yl)methyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-(2-oxopyrid-4-ylmethyl)pyrimidin-4-one; -(8-Phenyloct- 1 -yl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one; -(6-Benzyloxyhex-l-yl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; -(8-Phenyloct- 1 -yl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one; -(6-Benzyloxyhex-l-yl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one; -(6-Benzyloxyhex-l-yl)thio-5-(fur-3-ylmethyl)pyrimidin-4-one; -(8-Phenyloct-l-yl)thio-5-(fur-3-ylmethyl)pyrimidin-4-one; -Benzylthio-5-(( 1 -methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4-one; -Benzylthio-5-(fur-2-ylmethyl)pyrimidin-4-one; -(3-Chlorobenzyl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one; -(4-Chlorobenzyl)thio-5-(fur-2-ylmethyl)pyrimidin-4-one; -Benzylthio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; -Benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one; -Benzylthio-5-(pyrazin-2-ylmethyl)pyrimidin-4-one; -Benzylthio-5-(thiazol-2-ylmethyl)pyrimidin-4-one; -(4-Chlorobenzyl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -Benzylthio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(3,4-Dichlorobenzyl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -Benzylthio-5-(pyrid-4-ylmethyl)pyrimidin-4-one; -(4-Chlorobenzyl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one; -(3,4-Dichlorobenzyl)thio-5-(pyrid-4-ylmethyl)pyrimidin-4-one;
2-Benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 2-Benzylthio-5-(2-(pyrid-4-yl)ethyl)pyrimidin-4-one;
2-Benzylthio-5-benzylpyrimidin-4-one;
2-(8-Phenyloct- 1 -yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(8-(4-Chlorophenyl)-8-oxooct-l-yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4-one; -(4-Phenylbut-l-yl)oxy-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; -(2-Phenylethyl)thio-5-((2-methylpyrid-5-yl)methyl)pyrimidin-4-one; 2-(2-Phenylethyl)thio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one;
2-Benzylthio-5-(( 1 -methylpyrazol-4-yl)methyl)pyrimidin-4-one;
2-(4-Fluorobenzylthio)-5-((pyrimid-5-yl)methyl)pyrimidin-4-one;
2-(3,4-Difluorobenzylthio)-5-((2-methoxypyrimid-5-yl)methyl)pyrimidin-4-one;
2-(4-Fluorobenzylthio)-5-((2-methoxypyrimid-5-yl)methyl)pyrimidin-4-one; 2-(4-Fluorobenzylthio)-5-((2-benzyloxypyrimid-5-yl)methyl)pyrimidin-4-one;
1 -(4-Hydroxycyclohexyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-yl- methyl)pyrimidin-4-one;
1 -(2-Methoxyethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)- pyrimidin-4-one; 1 -(3-( 1 -Imidazolyl)prop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-yl- methyl)pyrimidin-4-one;
1 -(3-( 1 -Morpholino)prop- 1 -yl)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-(2-Oxo- 1 -pyrrolidino)prop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-Din:ethylaminoprop- 1 -yl)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Hydroxyprop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ; 1 -(3-Hydroxyprop- 1 -yl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-benzylpyrimidin-4-one;
1 -(3-Methoxyprop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Phenylprop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(5-Hydroxypent- 1 -yl)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(Pyrid-2-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethy l)pyrimidin-4-one ;
1 -(Pyrid-2-ylmethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-benzylpyrimidin-4-one; 1 -(Pyrid-3-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid- 4-yl)methyl)pyrimidin-4-one;
1 -(Pyrid-3-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(Pyrid-3-ylmethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-benzylpyrimidin-4-one;
1 -(Pyrid-4-y lmethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
1 -(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid- 4-yl)methyl)pyrimidin-4-one; 1 -(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-benzylpyrimidin-4-one; l-(Pyrid-4-ylmethyl)-2-(8-(4-chlorophenyl)oct-l-yl)thiopyrimidin-4-one;
1 -(2-(Pyrid-2-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-(Pyrid-3-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one;
1 -(2-(Pyrid-3-yl)ethy l)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(2-(Pyrid-4-y l)ethyl)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one;
1 -(2-(Pyrid-4-yl)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
1 -(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct- 1 -y l)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one;
1 -(2-Methy lprop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -Phenylsulfonyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrid-3-ylmethyl)pyrimidin-4- one;
1 -Benzyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
1 -Benzy l-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one; 1 -Benzy l-2-(8-(4-chlorophenyl)oct- 1 -yl)thιo-5-((2-methylpyπd-5-yl)methyl)pyπmιdιn-4- one;
1 -Benzyl-2-(8-phenyloct- 1 -yl)thιo-5-((2-methylpyπd-5-yl)methyl)pyπmιdιn-4-one;
1 -Benzyl-2-(8-phenyloct- 1 -yl)thιo-5-((2-methoxypyπd-4-yl)methyl)pyπmιdιn-4-one; 1 -Benzyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπd-3-ylrnethyl)pyπmιdιn-4-one;
1 -(2-Thιenylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπmιd-5- ylmethyl)pyπmιdιn-4-one,
1 -(2,2-Dιmethylprop- 1 -yl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπmιd-5- ylmethyl)pyπmιdιn-4-one; 1 -(2-( 1 -Pιpeπdιno)ethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyπmιd-5- ylmethyl)pyπrmdιn-4-one;
1 -(2-Hydroxyethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπmιd-5- ylmethyl)pyπmιdιn-4-one,
1 -(2-Hydroxyethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thιo-5-benzylpyπmιdιn-4-one; 1 -Ethyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπmιd-5-ylmethyl)pyπmιdιn-4- one;
1 -(Fur-2-ylmethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyπmιd-5- ylmethyl)pyπmιdιn-4-one;
1 -(Fur-2-ylmethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thιo-5-benzylpyπmιdιn-4-one; 1 -Methyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -y l)thιo-5-bromopyπmιdιn-4-one;
1 -Methyl-2-(8-(4-chlorophenyl)oct- 1 -y l)thιo-5-(( 1 -methyl-2-oxo-pyπd-4- yl)methyl)pyπmιdιn-4-one;
1 -Methyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -y l)thιo-5-(( 1 -methyl-2-oxo-pyπd-4- yl)methyl)pyπmιdιn-4-one, l-Methyl-2-(8-(4-chlorophenyl)oct-l-yl)thιo-5-(pyπd-3-ylmethyl)pyπmιdιn-4-one;
1 -Methyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thιo-5-(pyπmιd-5-ylmethyl)pyπmιdιn-4- one;
1 -Methyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thιo-5-benzylpyπmιdιn-4-one;
1 -Phenyl-2-(8-(4-chloropheny l)oct- 1 -y l)thιo-5-(( 1 -methyl-2-oxo-pyπd-4- yl)methyl)pyπmιdιn-4-one;
1 -Methylsulfonyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thιo-5-(pyπd-3-y lmethyl)pyπmιdιn-4- one;
1 -Benzyl-2-(8-phenyloct- 1 -yl)oxy-5-(pyπd-3-ylmethyl)pyπmιdιn-4-one; l-(2-Methoxyethyl)-2-benzylthιo-5-(pyπmιd-5-ylmethyl)pyπmιdιn-4-one; l-(3-Phenylprop-l-yl)-2-benzylthιo-5-(pyπmιd-5-ylmethyl)pyπmιdιn-4-one, 1 -(5-Hydroxypent- 1 -yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Pyrid-2-ylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(Pyrid-3-ylmethyl)-2-benzylthio-5-(( 1 -methyl-2-oxo-pyrid-4-yl)methyl)pyrimidin-4- one; 1 -(Pyrid-4-ylmethyl)-2-benzylthio-5-benzylpyrimidin-4-one; l-(2-(Pyrid-2-yl)ethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(Pyrid-3-yl)ethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(Pyrid-4-yl)ethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(Pyrid-4-yl)ethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(2-Phenylethyl)-2-benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one; l-Benzyl-2-benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one; l-(2-Thienylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2,2-Dimethylprop-l-yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -Methy l-2-benzylthio-5-((2-methoxypy rid-4-y l)methy l)pyrimidin-4-one ;
1 -Benzyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-Phenylethyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one;
1 -Methyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -Benzyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrid-4-yl)pyrimidin-4-one;
1 -Benzy l-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one;
1 -(2-Phenylethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(2-phenylethyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Fluorobenzyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(8-Phenyloctyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(9-Phenylnonyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-Benzyl-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -Benzy l-2-benzylthio-5-(( 1 -methy lpyrazol-4-yl)methyl)pyrimidin-4-one; l-Benzyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2.2-Dimethylprop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(2-Phenylethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(4-methylbenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(2-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(4-chlorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(3-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Fur-2-ylmethyl)-2-(3-chlorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
l-Methyl-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-((R)-Tetrahydofuran-2-ylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-((S)-Tetrahydofuran-2-ylmethyl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(4-Fluorobenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(4-Bromobenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-(6-(4-Fluorophenyl)hex- 1 -yloxy)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-Phenoxyethyl)-2-(3.4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-(5-Phenylpent- 1 -yloxy )prop- 1 -yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(9-Phenylnonyl)-2-furfurylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(9-Phenylnonyl)-2-(thiazol-2-ylmethyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(9-Phenylnonyl)-2-(thien-2-ylmethyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(9-Phenylnonyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-(2-Pent- 1 -ylphenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one;
1 -(2-(3-Pent- 1 -y lphenyl)ethyl)-2-(4-fluorobenzy l)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(2-(4-Bromophenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(5-Methylfuran-2-ylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(2-(2-Chlorophenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(2-(Thien-2-yl)ethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(2-Phenylethyl)-2-(2,3,4-trifluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(2,3,5-trifluorobenzyl)thio-5-(pyrimid-5-ylmethyl)ρyrimidin-4-one; l-(2-Phenylethyl)-2-(2,4,6-trifluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(2,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(2-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-furfurylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(thien-2-ylmethyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(3,4,5-trifluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(3,5-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(3-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-Pheny lethyl)-2-( 1 -phenylethyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(4-Methoxyphenyl)ethyl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- y lmethyl)pyrimidin-4-one ; 1 -(2-(4-Pent- 1 -ylphenyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one;
1 -(Cycloprop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Dodec-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-Ethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -( 1 -Methylethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-Methyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Undec-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one; l-Benzyl-2-benzylthio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-Phenylethyl)-2-(3,4-difluorobenzyl)thio-5-(2-methoxypyrimid-5- ylmethyl)pyrimidin-4-one; l-(Furan-2-ylmethyl)-2-(3,4-difluorobenzyl)thio-5-(2-methoxypyrimid-5- y lmethy l)py rimidin-4-one ;
1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4- one;
1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-(2-ethoxypyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-(2-methylpyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(2-Pheny lethyl)-2-(4-fluorobenzyl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- y l)methy l)pyrimidin-4-one ;
1 -(Undec- 1 -y l)-2-(4-fluorobenzyl)thio-5-(( 1 -methyl-2-oxo-pyrid-4-y l)methyl)pyrimidin- 4-one; 1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-( 1 -methyl-2-oxopyrimid-5-ylmethyl)pyrimidin- 4-one;
1 -(Undec- 1 -yl)-2-(4-fluorobenzyl)thio-5-( 1 -benzyl-2-oxopyrimid-5-ylmethyl)pyrimidin- 4-one;
1 -(Undec- 1 -yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -Methyl-2-(4-fluorobenzyl)thio-5-(2-methoxypyrimid-5-ylmethyl)pyrimidin-4-one; l-Methyl-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one; l-(4-Acetylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-(Non- 1 -yloxy)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-y lmethyl)pyrimidin-4- one; 1 -(3-(Dec- 1 -yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -Methyl-2-(4-fluorobenzyl)thio-5-( 1 -undecyl-2-oxopyrimid-5-ylmethyl)pyrimidin-4- one; l-Phenyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -Phenyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one;
1 -(4-(Non- 1 -yloxyphenyl))-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(4-Iodophenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(4-(Hex- 1 -yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(4-(Dec- 1 -yl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -Ethoxycarbonylmethyl-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Ethoxycarbonylprop- 1 -y l)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(3-Ethoxycarbonylprop- 1 -yl)-2-benzylthio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-Ethoxycarbonylprop- l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- y lmethy l)py rimidin-4-one ;
1 -(3-Ethoxycarbonylprop- l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(5-Ethoxycarbonylpent-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -( 1 -(Ethoxycarbonyl)cycloprop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(4-Fluorobenzyloxycarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-Ethoxycarbonylmethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -( 1 -(Methoxycarbonyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one 1 -(trøns-4-(Methoxycarbonyl)cyclohex- 1 -ylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ; l-(tran_-4-(Methoxycarbonyl)cyclohex-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Ethoxycarbonylprop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one; l-(Ethoxycarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-methoxypyrimid-5- ylmethyl)pyrimidin-4-one; l-(4-(Ethoxycarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; 1 -(4-Methoxycarbonylbenzyl)-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrid-3-ylmethyl)- pyrimidin-4-one;
1 -(3-Carboxyprop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-Carboxymethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-Carboxyprop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(( 1 -methyl-2-oxo-pyrid-4- yl)methyl)pyrimidin-4-one;
1 -(3-Carboxyprop- 1 -yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(5-Carboxypent-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(4-Carboxybenzyl) -2-(4-fluorobenzyl)thio -5-(pyrimid-5-ylmethyl)-2-thiouracil;
1 -(4-Carboxycyclohex- 1 -yl) -2-(4-fluorobenzyl)thio -5-(pyrimid-5-ylmethyl)-2- thiouracil; l-(3-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; l-(3-Ethoxycarbonylphenyl)-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one: l-(3-Carboxyphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-Carboxyphenyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(4-Ethoxycarbonylphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one;
1 -(4-Ethoxycarbonylphenyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- y lmethyl)pyrimidin-4-one ' l-(4-Carboxyphenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(4-Carboxyphenyl)-2-(8-(4-chloropheny l)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(5-(Ethoxycarbonyl)fur-2-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(3-Ethoxycarbonyl-4-iodobenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ; 1 -(3-(Hept- 1 -yloxy)-4-methoxycarbonylbenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ;
1 -(3-(Hept- 1 -yloxy )-4-methoxycarbonylbenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Carboxy-4-(hept- 1 -yloxy )benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one;
1 -(3-(Hept- 1 -yloxy )-4-carboxybenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
l-(3-Methoxycarbonyl-4-hydroxybenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(3-Methoxycarbonylbenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(3-Carboxybenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(3,4-Di-(methoxycarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -Carboxamidomethyl-2-(8-(4-chlorophenyl)oct- 1 -yl)thio-5-(pyrid-3- ylmethyl)pyrimidin-4-one; l-Dimethylaminocarbonylmethyl-2-(8-(4-chlorophenyl)-8-oxooct-l-yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-Carboxamidomethyl-2-benzylthio-5-((2-methoxypyrid-4-yl)methyl)pyrimidin-4-one; l-(3-(Octadec-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethyl)pyrimidin-4-one ;
1 -(3-(Octadec-9-(Z)-en- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one; 1 -(3-(Octadec-9-(E)-en- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one;
1 -(3-(N-Dodec- 1 yl-N-methy laminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-(N-Non- 1 -yl-N-methylaminocarbonyl)prop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one;
1 -(4-(Pent- 1 -ylaminocarbonyl)benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)py rimidin-4-one ;
1 -( 1 -(6-(4-Fluorophenyl)hex- 1 -ylaminocarbonyl)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(3-( 11 -Dimethylaminoundec- 1 -ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(3-(3-Ethoxyprop-lylaminocarbonyl)prop-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one; l-(3-(5-(Methoxycarbonyl)-5-(benzykloxycarbonylamino)pent-l ylaminocarbony l)prop-l- yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-(5-(Methoxycarbonyl)pent- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(3-(Hex-lylaminocarbonyl)prop-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(3-(5-(t-Butoxycarbonylamino)pent- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-(3-(6-(t-Butoxycarbonylamino)hex-lylaminocarbonyl)prop-l-yl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(3-(Dec- 1 ylaminocarbony l)prop- 1 -y l)-2-(4-fluorobenzy l)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(3-(Dec-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-(Hept- 1 ylaminocarbony l)prop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(3-(Hex-lylaminocarbonyl)prop-l-yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(3-(Non- 1 ylaminocarbony l)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ;
1 -(3-(Oct- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ; 1 -(3-(Pent- 1 ylaminocarbonyl)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(3-(N-Hex-lyl-N-methylaminocarbonyl)prop-l-yl)-2-(3,4-difluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(5-(2-mEthoxyethylaminocarbonyl)pent-l-yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(5-(2-Phenylethy laminocarbonyl)pent- 1 -yl)-2-(3 ,4-difluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ;
1 -(5-(But- 1 -ylaminocarbonyl)pent- 1 -yl)-2-(3,4-difluorobenzyl)thio-5-(pyrimid-5- y lmethyl)pyrimidin-4-one ; l-(5-(N-(2-Phenylethyl)-N-methylaminocarbonyl)pent-l-yl)-2-(3,4-difluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(5-(N-But- 1 -yl-N-methylaminocarbonyl)pent- 1 -yl)-2-(3,4-difluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -((R)- 1 -(Hex- 1 -ylaminocarbonyl)ethy laminocarbonylmethyl)-2-(4-fluorobenzy l)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -((S )- 1 -(Hex- 1 -ylaminocarbonyl)ethy laminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-((S)-2-(Hex-l-ylaminocarbonyl)pyrrolidin-l-ylcarbonylmethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -( 1 -Pyrrolidinocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Butoxyprop- 1 -ylaminocarbonylmethy l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(6-Hydroxyhex- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(6-(4-Fluorophenyl)hex- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one;
1 -(Tridec- 1 -y laminocarbonylmethy l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(Tetradec-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(Octadec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(Octadec-9-(Z)-en-lylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethyl)pyrimidin-4-one ; 1 -(Octadec-9-(E)-en- lylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(Dec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(Dodec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one
1 -(Hept- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(Oct- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(Undec- 1 -ylaminocarbony lmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-Hydroxyethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-Methoxyethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-Phenylethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-(4-Pent- 1 -y lphenyl)ethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one; 1 -(Hex- 1 -ylaminocarbonylmethylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-(Dodec- 1 -yl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(N-(2-Phenylethyl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one;
1 -(4-(But- 1 -y laminocarbonyl)cyclohex- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(4-(Hex- 1 -ylaminocarbony l)cyclohex- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(4-(2-Methoxyethylaminocarbonyl)cyclohex- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one; 1 -( 1 -(6-(4-Fluoropheny l)hex- 1 -yl)aminocarbonyl)cycloprop- 1 -yl)-2-(4-fluorobenzy l)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -( 1 -(Non- 1 -ylaminocarbonyl)cycloprop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -((R)- 1 -(Non- 1 -ylaminocarbonyl)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -( 11 -(Dimethylamino)undec- 1 -ylaminocarbony lmethy l)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-(6-(4-Fluorophenyl)hex- 1 -yloxy)ethylaminocabonylmethyl)-2-(4-fluorobenzyl)fhio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(5-(Methoxycarbonyl)-5-(benzyloxycarbonylamino)pent- 1 -ylaminocarbonylmethyl)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(5-(Methoxycarbonyl)pent- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(Non-l-ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-Dimethylaminocarbonylmethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(N-(2-Hydroxyethyl)-N-methylaminocabonylmethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(trαras -4-(4-Fluorobenzylaminocarbony l)cyclohex- 1 -ylmethyl)-2-(4-fluorobenzyl)thio- 5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(trans-4-(Pent- 1 -ylaminocarbony l)cyclohex- 1 -ylmethy l)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(3-(Hex- 1 ylaminocarbony l)prop- 1 -y l)-2-(4-fluorobenzyl)thio-5-(( 1 -methyl-2-oxo- pyrid-4-yl)methyl)pyrimidin-4-one;
1 -(N-(N ' -Hex- 1 -yl-N' -methylaminocarbonylmethyl)-N-methylaminocarbonylmethyl)-2- (4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-(N' -Hex- 1 -ylaminocarbonylmethyl)-N-methylaminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-(N' -Hex- 1 -yl-N' -methylaminocarbonylmethyl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; l-Phenylaminocarbonylmethyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin- 4-one; l-(4-Methoxycarbonylbenzylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(N-Benzylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(N,N-Di-(but- 1 -yl)aminocarbonylmethy l)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(N-Methyl-N-(dodec- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-Methyl-N-(oct- 1 -yl)aminocarbony lmethy l)-2-(4-fluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-Methyl-N-(oct- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- ethoxypyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-Methyl-N-(oct- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- benzyloxypyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(N-Methyl-N-(dodec- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2- oxopyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(N-Methyl-N-(oct- 1 -yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid- 5-ylmethyl)pyrimidin-4-one;
1 -(3-(N-(Hept- 1 -yl)-N-methylaminocarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid- 5-ylmethyl)pyrimidin-4-one; l-(3-(N-Ethyl-N-methylaminocarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(4-(Prop- 1 -ylaminocarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(4-(But- 1 -ylaminocarbonyl)phenyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(4-(Hex- 1 -yloxycarbonyl)phenyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(4-Methylaminocarbonylbenzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-Methylaminocarbonyl-4-(hept- 1 -yloxy)benzyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-(t-Butoxycarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy 1 )pyrimidin-4-one; l-(2-(Trifluoroacetylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-(Benzoylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4- one; 1 -(2-(Hex- 1 -ylcarbony lamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-(5-Phenylpent- 1 -ylcarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-(Hept- 1 -ylcarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2- Acetylaminoethyl)-2-(8-(4-chlorophenyl)-8-oxooct- 1 -yl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(4-(tert-Butoxycarbonylamino)but- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(3-(Ethoxycarbonylamino)prop- 1 -yl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-(Benzylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-(Dodec- 1 -ylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- y lmethy l)pyrimidin-4-one ;
1 -(2-(Hept- 1 -ylaminocarbony lamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; 1 -(2-(Oct- 1 -ylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-(2-Thien-2-ylethylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one;
1 -(2-( 1 , 1 ,3.3-Tetramethylbut- 1 -ylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(4-(Butoxycarbonyl)phenylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one;
1 -(2-(4-( 1 -Methylethyl)pheny laminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5- (pyrimid-5-ylmethyl)pyrimidin-4-one; l-(2-(4-Methylphenylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(2-(4-Ethoxyphenylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; and l-(2-(4-Phenoxyphenylaminocarbonylamino)ethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one.
14. A compound selected from: 2-(4-Fluorobenzylthio)-5-((pyrimid-5-yl)methyl)pyrimidin-4-one; l-Methyl-2-(4-fluorobenzyl)thio-5-(pyrimid-5-ylmethyl)pyrimidin-4-one; 1 -(Tetradec- 1 -ylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; l-(N-(Dodec-l-yl)-N-methylaminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(pyrimid-5- ylmethyl)pyrimidin-4-one; and
1 -(N-Methyl-N-(dodec- 1 -ylaminocarbony lmethyl)-2-(4-fluorobenzyl)thio-5-(2- methoxypyrimid-5-ylmethyl)pyrimidin-4-one.
15. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 and a pharmaceutically acceptable carrier.
16. A compound of formula (I) as claimed in claim 1 for use in therapy.
17. A compound of formula (I) as claimed in claim 1 for use in the treatment of atherosclerosis.
18. A method of treating a disease state associated with activity of the enzyme Lp-PLA, which method involves treating a patient in need thereof with a therapeutically effective amount of a compound of formula (I) as claimed in claim 1.
19. A process for preparing a compound of formula (I) which process comprises:
(a) treating a compound of formula (IIA):
H
(HA) in which R^ and Z are as hereinbefore defined; with a compound of formula (III):
R2YCH L1
(III) in which Y and R2 are as hereinbefore defined and L A a leaving group e.g. bromine or iodine: to give a compound of formula (IA):
(IA) in which Z, Y, R and R2 are as hereinbefore defined and X is S; or
(b) treating a compound of formula (IV):
H
(IV) in which Z and R^ are as hereinbefore defined and L2 is a leaving group, e.g. halogen such as chlorine or bromine, alkylthio such as methylthio,or -NHNO2, with a compound of formula (V):
R2YCH2XH " (V)
in which X, Y and R2 are as hereinbefore defined; advantageously at an elevated temperature, in a solvent such as pyridine. to give a compound of formula (IA); and thereafter, and if so desired;
treating a compound of formula (IA) form (a) or (b) above with a compound of formula (VI):
R7WLl (VI) in which L^, W and R7 are as hereinbefore defined; to give a compound of formula (IB):
(IB) in which X, Y, Z, R^ and R2 are as hereinbefore defined and WR7 is as hereinbefore defined, other than -H;
(c) treating a compound of formula (IIB):
O
HN R1
W.
\
R7
(IIB) in which W is a bond, Z and Rl are as hereinbefore defined and R7 are as hereinbefore defined, other then H, with a compound of formula (III) as hereinbefore defined, to obtain a compound of formula (IB); and, thereafter and if so desired;
treating a compound of formula (IA) or (IB) in which X is S with a compound of formula (V):
R2YCH2OH
(VII) in which Y and R2 are as hereinbefore defined; to give a corresponding compound of formula (I) in which X is O; or
(d) for a compound of formula (I) in which Z is a bond and R^ represents halogen, treating a compound of formula (VIII):
(VIII) in which W, Y, R2, and R7 are as hereinbefore defined; with a halogenating agent, preferably with bromine to form a compound of formula (I) in which Z is a bond and R* is bromine, the reaction being advantageously effected in a solvent such as dichloromethane.
EP98954482A 1997-11-06 1998-10-23 Pyrimidinone compounds and pharmaceutical compositions containing them Expired - Lifetime EP1028955B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9723358 1997-11-06
GBGB9723358.9A GB9723358D0 (en) 1997-11-06 1997-11-06 Novel compounds
GBGB9723352.2A GB9723352D0 (en) 1997-11-06 1997-11-06 Novel compounds
GB9723352 1997-11-06
PCT/EP1998/006988 WO1999024420A1 (en) 1997-11-06 1998-10-23 Pyrimidinone compounds and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
EP1028955A1 true EP1028955A1 (en) 2000-08-23
EP1028955B1 EP1028955B1 (en) 2003-07-16

Family

ID=26312554

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98954482A Expired - Lifetime EP1028955B1 (en) 1997-11-06 1998-10-23 Pyrimidinone compounds and pharmaceutical compositions containing them

Country Status (9)

Country Link
US (2) US6417192B1 (en)
EP (1) EP1028955B1 (en)
JP (1) JP2001522844A (en)
AR (1) AR016666A1 (en)
AU (1) AU1157599A (en)
CA (1) CA2309177A1 (en)
DE (1) DE69816471T2 (en)
ES (1) ES2203988T3 (en)
WO (1) WO1999024420A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105377B1 (en) * 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) * 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
AU766003B2 (en) 1999-05-01 2003-10-09 Smithkline Beecham Plc Pyrimidinone compounds
GB9910378D0 (en) * 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
AU3546601A (en) 2000-02-16 2001-08-27 Smithkline Beecham Plc Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
MX2009012197A (en) 2007-05-11 2010-01-15 Univ Pennsylvania Methods of treatment of skin ulcers.
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
TW201209043A (en) * 2010-05-17 2012-03-01 Glaxo Group Ltd Novel processes
JP2013544854A (en) 2010-12-06 2013-12-19 グラクソ グループ リミテッド Compound
MX2013006342A (en) * 2010-12-06 2013-08-26 Glaxo Group Ltd Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2.
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
US20140171431A1 (en) * 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2736908A1 (en) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclic pyrimidone compounds
SG11201505520WA (en) 2013-01-25 2015-08-28 Glaxosmithkline Ip Dev Ltd 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
EP2948456A4 (en) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Bicyclic pyrimidone compounds as inhibitors of lp-pla2
CN105008365B (en) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 Compound
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
BR112017022654A2 (en) * 2015-04-24 2018-07-10 Shionogi & Co., Ltd. 6-membered heterocyclic derivative and pharmaceutical composition comprising the same
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
JP6692113B2 (en) * 2016-10-21 2020-05-13 塩野義製薬株式会社 Pharmaceutical composition containing 6-membered heterocyclic derivative
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
CN107382726A (en) * 2017-08-02 2017-11-24 东南大学成贤学院 A kind of preparation method of (E) 2 (methoxymethylene) 4 aryl N-butyl
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
WO2022012798A1 (en) 2020-07-15 2022-01-20 Merck Patent Gmbh Optically active devices
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154834A (en) * 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
GB1582527A (en) 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
DE2739193A1 (en) * 1977-08-31 1979-03-08 Bayer Ag INDAN-5-YL-N-ALKYL-CARBAMIC ACID ESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PLANT PROTECTANT
JPS6050191B2 (en) * 1978-04-07 1985-11-07 三共株式会社 5↓-Fluorouracil derivative
US4352933A (en) 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
DE3803063A1 (en) * 1988-01-29 1989-08-10 Schering Ag THIOHURINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE NEUTRON CAPTURE THERAPY OF MALIGNEN MELANOMAS
HU203736B (en) 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9924420A1 *

Also Published As

Publication number Publication date
ES2203988T3 (en) 2004-04-16
DE69816471D1 (en) 2003-08-21
US6417192B1 (en) 2002-07-09
DE69816471T2 (en) 2004-05-27
WO1999024420A1 (en) 1999-05-20
JP2001522844A (en) 2001-11-20
AU1157599A (en) 1999-05-31
US20020120139A1 (en) 2002-08-29
EP1028955B1 (en) 2003-07-16
CA2309177A1 (en) 1999-05-20
AR016666A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
EP1028955B1 (en) Pyrimidinone compounds and pharmaceutical compositions containing them
AU766003B2 (en) Pyrimidinone compounds
US5436233A (en) 4-aminoquinazoline derivatives
KR100223135B1 (en) Cyclic imino derivatives, process for their preparation and drugs containing them
US6559155B1 (en) Pyrimidinone derivatives for the treatment of atherosclerosis
WO2000066566A1 (en) Pyrimidine compounds
BG107034A (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
US20050153964A1 (en) Novel compounds
KR20010094748A (en) Aromatic heterocyclic compounds as antiinflammatory agents
WO2000068208A1 (en) Pyrimidinones derivatives for the treatment of atherosclerosis
JP2005513020A (en) New compounds
EP0869943A1 (en) Monocyclic beta-lactame derivatives for treatment of atherosclerosis
WO2003015786A1 (en) 2, 5-substituted 1-(aminocarbonylalkyl) -pyrimidin-4-one derivatives with lp-pla2 inhinitory activity for the treatment of atherosclerosis
US5025016A (en) Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these compounds, and method of treatment
JP2926335B2 (en) Pharmaceutical composition
JP2000143637A (en) Pyrimidine derivative and manufacture of the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000515

17Q First examination report despatched

Effective date: 20011002

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE ES FR GB IT LI NL

DAX Request for extension of the european patent (deleted)
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030716

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69816471

Country of ref document: DE

Date of ref document: 20030821

Kind code of ref document: P

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030915

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20031003

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20031022

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20031031

Year of fee payment: 6

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20031203

Year of fee payment: 6

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2203988

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041031

BERE Be: lapsed

Owner name: *SMITHKLINE BEECHAM P.L.C.

Effective date: 20041031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050503

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050630

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051023

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20041025

BERE Be: lapsed

Owner name: *SMITHKLINE BEECHAM P.L.C.

Effective date: 20041031